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i 
ABSTRACT 
 
 
Breast carcinoma is the most frequent type of cancer affecting women. Among 
the recently described molecular and phenotypic classes of breast cancer, 
human epidermal growth factor receptor 2 (HER2)-positive tumours are 
associated with a poor prognosis. HER2 status is currently assessed in routine 
breast cancer reporting using immunohistochemistry (IHC) in addition to in 
situ hybridisation (ISH) in borderline cases. The ability of HER2 gene status to 
predict response to targeted therapy (Trastuzumab) is well documented. 
However, prognostic information provided by IHC expression categories and 
prognostic value added by using ISH in borderline cases remains 
unclear.  HER2 plays an important role in cancer progression being targeted to 
provide predictive and prognostic information. Moreover, HER2 is related to 
cancer resistance against a variety of therapies; however, trastuzumab has 
proved successful in treatment of this subgroup. Nevertheless, patients may 
acquire resistance to this drug after a period of treatment, which indicates that 
other molecular mechanisms might influence success of this therapy. 
Dimerisation between members of the HER family may contribute to 
resistance against treatments due to different combinations that trigger different 
downstream pathways. This is promoted by ligands, which are expressed as 
transmembrane precursor protein molecules and have a conserved epidermal 
growth factor-like domain. Through resistance to trastuzumab, other drugs are 
being developed to interact in different domains of HER2 protein. The study of 
interaction between receptors/ligands will characterise specifically their 
signalling pathway and understand which strategy to acquire. 
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The main aim of this thesis was to assesses the status of HER2 protein (IHC), 
HER2 gene (chromogenic ISH) and HER heterodimers (in situ proximity 
ligation assay (PLA)), including HER2/EGFR, HER2/HER3 and HER2/HER4, 
in two BC series prepared in tissue microarray format; a series of consecutive 
primary operable BC cases (n = 1858) including HER2+ trastuzumab naïve 
cases (TrN, n = 221), the second series of HER2+ trastuzumab adjuvant treated 
cases (TrT, n = 143). Therefore determining the biological characterisation of 
these biomarkers by associating against clinicopathological parameters, 
survival outcome and understand the trastuzumab therapy value.  
 
There was excellent overall concordance between HercepTest negative (scores 
0/1+) and positive (3+) with CISH positive/negative (defined as HER2/Chr17 
FRS\QXPEHUUDWLRRI 2; p < 0.001). Kaplan-Meier analysis for breast cancer 
specific survival (BCSS) and disease free interval (DFI) revealed statistically 
significant differences between HER2 positive and negative cases detected by 
HercepTest and CISH (p < 0.001).  Interestingly, it was identified that 
HercepTest 2+ non-amplified cases were not significantly different with those 
amplified 2+ or 3+ cases with respect to their behaviour (BCSS and DFI). 
 
The results revealed an inverse association between the HER 
heterodimerisation status and hormone receptor status (p < 0.001), and a 
significantly worse outcome amongst cases revealing high levels of all 
heterodimers (p < 0.001). Among ER+ cases, the heterodimers high levels 
were significantly associated with worse prognosis (p < 0.001) overall. 
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However amongst the two HER2+ populations dimerisation status did not 
show an association with patient outcome. 
 
The overall concordance between HercepTest and CISH analysis for HER2 
status was excellent. All HercepTest 2+ cases identified were observed to have 
poor outcomes similar to those HercepTest 3+ cases regardless of gene 
amplification status. In the current clinical environment cases exhibiting IHC 
2+ and non-amplified gene HER2 status will not be offered targeted HER2 
therapy but do exhibit aggressive clinical behavioural characteristics. Even 
though those patients with high levels of the HER2 truncated form, p95HER2, 
have shown poor outcome, this biomarker does not reveal any extra findings 
comparing with the HER2 expression results. Beside HER2, EGFR is the only 
monomer that reveals prognostic value amongst the breast cancer patients. 
Tumours exhibiting high levels of HER heterodimerisation have an adverse 
prognosis, however in the context of HER2+ breast cancer no association with 
clinical outcome was observed regardless of use of trastuzumab treatment. 
HER2/HER3 heterodimerisation status assessed in multivariate analyses has 
shown that this protein-protein interaction is associated with a poor prognostic 
outcome, which needs further investigation and assessment of clinical utility to 
use in the future in breast cancer treatment decision. Further quantification 
analysis of dimer/ligand complex using PLA of other HER family members 
may be useful to identify subset of patients associated with distinct outcome, 
response to treatment and relationships with HER signalling related 
biomarkers. 
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1. CHAPTER 1: Introduction 
 
1.1 Cancer 
 
Throughout history cancer has been present in human nature. Egyptians first 
described the disease, even though the word cancer was not used, in 
approximately 3000BC. Several manuscripts were found revealing some cases 
of tumours, including breast, and was described as a non-treatable disease.  
Carcinos, which refers to the Latin word µcrab¶ or in ancient Greek µcancer¶, 
was the term firstly described by Hippocrates (460-370 BC) as an ulcer-
forming tumour.  
 
Nowadays, in developing countries cancer is the second most common cause 
of death and the first in developed countries. Different factors as smoking, 
pollution, sedentary lifestyle and western food style together with population 
aging have been described as the mains factors for the rise of this disease1. In 
2008 it was estimated there were nearly 12.7 million cancer cases worldwide, 
and 7.6 million deaths caused by cancer2. Males have been affected more by 
lung cancer with 17% of the total new cancer cases and 23% of the total cancer 
deaths. In developing countries lung cancer affects 11% of women. Though 
this dLVHDVH PRVWO\DIIHFWV WKH ZRUOG¶V developed countries for both genders, 
the cancer mortality percentage is comparable with developing countries. This 
fact might be related to an earlier diagnostic stage and access to the latest and 
innovative treatments in the developed countries. Additionally, preventive 
measures like tobacco control or vaccination to avoid cervical and liver 
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carcinomas and promotion of physical exercise together with healthier diet 
behaviours are being applied in these countries3.  
 
Of the 26 different types of cancer, breast carcinoma is the most common in 
women with approximately 1.38 million new cases worldwide, which 
corresponds to 23% of the total cases and 14% of cancer death3. During the last 
decade of the twentieth century cervical cancer was the most common type of 
cancer in developing countries, however in 2008 breast cancer became more 
common amongst women with 50% of the breast cancer cases and 60% of the 
deaths worldwide3.   
 
Breast carcinomas are heterogeneous with a variable prognosis depending on 
different histological characteristics and molecular characteristics, which 
influence patient prognosis and tumour behaviour4. The central interest was 
always to evaluate and differentiate breast cancer patients to understand the 
different prognosis. In order to score the breast carcinomas, tumour size, 
tumour stage and histological grade are the three main variables used to 
calculate the Nottingham Prognostic Index (NPI)5. NPI offered a more 
completed scoring method to predict the survival time amongst the patients 
carrying this disease6. This system has been amongst others currently used to 
decide which adjuvant treatments are appropriate7,8. However this histologic 
scientific method, based on Scarff-Bloom Richardson system, was questioned 
due to supposed inconsistency9. For breast cancer prognosis, the method 
developed by Bloom and Richardson involves microscopic analysis of tubule 
formation, mitosis frequency and nuclear pleomorphism10. Even though NPI 
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was seriously questioned, different studies were performed and validated this 
approach11,12 and has been adopted by all Europe13 and USA14. In the last two 
decades of the last Century, breast cancer research focussed on biomarkers 
documentation and understanding. Techniques such as immunohistochemistry 
made possible this mode of research by using highly specific antibodies to 
react against certain antigens, such as hormone receptors (HR), epidermal 
growth factor receptors (EGFR), tumour suppressor genes, angiogenic and 
adhesion factors, matrix metalloproteinases amongst others, some revealing 
prognostic applicability15.  
 
The vast quantity of genes that are involved in cancer cell differentiation, 
development, and death made it possible to understand the complexity and 
heterogeneity of the cellular and molecular structures.  Scientific studies took 
place to understand these genetic discrepancies. The use of cDNA microarrays 
related the tumour genes and their phenotypic distinctions providing a great 
potential to a more descriptive taxonomy of carcinomas16,17. Molecular biology 
establishment made possible a new approach for cancer research, without 
which it would not be possible to describe the mechanisms involved in cancer 
cells biology. Understanding the mode of cancer cells development is 
constantly being improved by different discoveries developed on molecular 
biology and genetics field. Nowadays the approach for cancer, either for 
diagnostic or research purposes, using molecular tumour morphology analysis 
is made possible by the characterisation of at least four breast cancer groups 
allowing treatment discrimination. The cancer cases were separated into two 
main groups and well defined. One group revealing low or absent expression of 
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Oestrogen receptor (ER) and the second group involving ER gene high 
expression. Two distinct subgroups are described amongst the ER positive 
cases, Luminal A with the highest expression for ER as well as GATA-3 and 
Progesterone receptor (PgR) and Luminal B that reveal low to moderate 
expression of ER, PgR and might reveal high expression of Ki67. Patients 
expressing ER revealed better outcome, especially Luminal A. The two 
subgroups that do not express ER are the basal-like tumours or also named as 
triple-negative, which do not express ER, PgR or human epidermal growth 
factor receptor 2 (HER2) but high expression of cytokeratins (CK) revealing 
the worse prognosis, and the HER2 subgroup revealing no expression of ER or 
PgR but high expression of several genes localised in the amplicon HER2, 
which includes HER2 and GRB7. The outcome for this subgroup is amongst 
the worst  in breast cancer17.   
 
New genomic analysis technologies applied on the study of human genome and 
more particular tumour tissues, like comparative genomic hybridisation 
(CGH), made it possible to divulge mutated regions of the chromosomes 
specifically present in breast carcinomas18 including oncogenes as HER2 
amongst others19. Lately by genome analysis of 2000 breast cancer tumours, 
revealed a cluster of 10 discriminative groups with distinct genetic features. 
Furthermore each group was specifically correlated with a different prognosis 
even though further studies are required to start implementing this taxonomy in 
clinical treatments discrimination20.  
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1.2 General introduction to HER family: Type 1 Tyrosine 
Kinase Growth Receptors 
 
1.2.1 Epidermal Growth Factor Receptor Family 
Human epidermal growth factor receptor (EGFR or HER) family is composed 
of four different types: HER1 (EGFR or c-erbB-1), HER2 (neu, p185 or c-
erbB-2), HER3 (c-erbB-3) and HER4 (c-erbB-4) (Figure 1.1)21. These four 
molecules compile type I group of 20 families of Receptor Tyrosine Kinases 
(RTKs) and regulate several cellular metabolic reactions22,23. This RTK family 
has an important role in cell proliferation, differentiation, adhesion, survival 
and migration. The organisation of these molecules permits a contact from side 
to side of the plasma membrane. Furthermore, this communication encourages 
gene expression, provoking a reaction by the cell to external stimulus 
performing intracellular docking sites for signalling complexes. These 
complexes are then released into the cytoplasm for activation of several signal 
transduction cascades24. RTKs can function as controllers of cellular progress, 
however they may influence the development and improvement of different 
types of carcinomas25 being present in 30% of the epithelial cancers26. The 
entire group of 20 RTK families share some structural relationships consisting 
of extracellular and intracellular segments connected by a transmembrane 
fragment27, showing high functional and structural identities28. Amongst the 
HER family, the similarity of these molecules ranges from 53%, involving 
EGFR and HER3, up to 64% between EGFR and HER2. More specifically the 
most conserved sequence is located on the tyrosine kinase domain with a range 
of 59-81% of identity and the C-terminal sequence showing a poor similarity 
of between 12-30%29.  
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HER proteins are composed of a highly conserved ectodomain (ECD) or 
extracellular binding region where the ligand fragment interacts and directs 
molecular structure alteration, promoting receptor dimerisation, enhancing 
kinase activity30. Four domains named L1, S1 (CR1), L2 and S2 (CR2), also 
known by domain I, II, III and IV, respectively, compose the ECD31. Domains 
I and III interact with the respective ligand32. Additionally the domains II and 
IV, which the whole HER group shares, are composed by two high reactive 
cysteine-rich domains25 and interact to each other and with the cell 
membrane27. The transmembrane hydrophobic segment is composed of 20-30 
amino acids molecules33, with special attention for five residues included in the 
-helices that is critical on dimerisation reaction34.  It has critical role in 
dimerisation where a mutation on valine amino acid is enough to result in a 
dramatic transformation35, i.e., originating a dimer with constant activation36. 
Forces of van der Waals37 and hydrogen bonds38 are also significantly involved 
in the dimerisation reaction comprising the -helices.  An intracellular tyrosine 
kinase domain compose the remain structure of the entire complex27. This last 
domain exhibits an extended C-terminal tail with high levels of conservation 
comprising the ATP-linking position for receptor autophosphorylation and 
phosphorylation of respective substrates25. This fragment of the receptor 
structure is the most conserved possessing a motif GlyX GlyX XGlyX (15-20) 
lys, which is the linkage location for ATP39. Finally the carboxy terminal tail 
(including in the intracellular domain), possesses tyrosine residues that are the 
phosphorylation spots, which react under ligand-monomer/monomer 
interactions40.  However, within the HER family it is possible to register some 
exceptions, such as HER3 not possessing intramembranous kinase activity and 
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HER2 missing a ligand binding site24. However these receptors may cooperate 
with each other to form active heterodimers and trigger downstream pathways 
that can lead to cell development41. 
 
Within the RTK group, the HER family is the only able to achieve dimerisation 
triggering their own stimulation. The general RTK families drive dimerisation 
by a kinase transphosphorylation through a covalent stimulation that will 
trigger certain downstream pathways until exhaustion of the phosphatases. 
Nonetheless HER monomers are activated in a allosteric manner, which the 
kinase domain from the first monomer interacts with the kinase domain of the 
second monomer triggering downstream pathways with no need for additional 
phosphorylation reactions42. This approach builds a whole reaction system that 
increases the activation specificity of the downstream signalling. Consequently 
the great variety of arrangements that the HER family possess to form dimers, 
either homodimers or heterodimers, will deliver a diversity of distinctive 
purpose43.  
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Figure 1.1± The four members of HER family is represented showing some differences and 
similarities amongst them. HER2 (2) is the only member of this family that does not possess 
any ligand-binding site on its ectodomain. On the other hand, HER3 (3) show some lack of 
tyrosine kinase (TKI) region located onto the internal domain. EGFR (1) and HER4 (4), 
contain both, ligand link site and TKI. The receptor tyrosine kinase domain is a conserved 
region present in all family members, except HER3, which is dependent of the other members 
to form a dimer and trigger downstream pathways.   
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1.2.1.1    HER2 Receptor 
HER2 is the member amongst its RTK family more intensively studied in 
breast cancer and other solid cancers due to it being a crucial systematic tool in 
a clinical perspective for prognostic analysis and treatment target.  
 
Firstly identified by Schechter et al 198444, HER2 is a transmembrane 185kDa 
protein44 and its gene is located on chromosome 17q2145. The HER2 protein 
frequency in breast epithelial cells can be between 20,000-50,000 per cell 
however carcinoma cells might express in excess of 2,000,000 receptors per 
cell46. Overexpression of HER2 is also associated with poor prognosis in 
ovarian47, stomach48 and uterus carcinoma with worse prognosis amongst the 
uterine serous papillary carcinoma49. Also a mutation at codon 655 of the 
HER2 gene modifies the structure of the receptor transmembrane domain 
resulting in an active form, promoting development of HER2 homodimers50. 
Cells that either possess this mutation on the HER2 gene or overexpress HER2 
protein have a high possibility to show HER2 homodimerisation resulting in 
continuous uncontrolled growth and division, and apoptosis avoidance21. This 
is further supported by the fact that this genetic mutation is associated with a 
higher risk of breast carcinoma51.  
 
Approximately 10%-34% of breast tumours possess cells that show 
amplification of HER2 and overexpression of HER2, which is associated with 
reduced overall survival21,52-54. It is also involved in driving malignant growth 
of breast cancer cells, i.e., HER2 protein is greatly linked with metastatic 
occurrences55 and with an aggressive phenotype56. Additionally approximately 
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40% of the inflammatory breast carcinomas might reveal HER2 
overexpression57. A residual number of cases (1-2%) show HER2 protein 
overexpression without gene amplification58. This occurrence may take place 
due to modification in system of control of gene expression59. Amplification of 
HER2 results in an overexpression of the protein that might affect the activity 
of this receptor characterised either by ligand-independent dimerisation, where 
HER2 reacts by itself, or it dimerises with any other receptor of the same 
family60. HER2 does not include an ectodomain where a ligand can connect, 
but is able to act as a co-receptor with high affinity for receptors of the same 
family, thus forming heterodimers25.  Within RTKs Type I group, HER2 is the 
most favourable molecule to interact with the others due to extend 
ligand/heterodimer linkage and therefore prolonging activation of the mitogen-
activated protein kinase (MAPK) pathway21,61,62 relating these cases with high 
biological activity. Additionally HER2 does not interact with any ligand, as its 
conformation arm is constantly predisposed to exist in a competent form and 
ready to connect with any of the other monomers from the same family63.  
 
HER2 overexpression can make available some mitogenic and anti-apoptotic 
signals64, more specifically it can promote different signalling reactions 
downstream, such as proliferation when RAS-MAPK pathway is activated, 
inhibition of apoptosis by phosphatidylinositol 3-kinase (PI3K)/Akt pathway24 
and promotion of angiogenic reaction by production of vascular endothelial 
growth factor (VEGF)65. More specifically it encourages PI3K/Akt signalling 
cascade promoting cell cycle and survival66 due to high presence of cyclin D1 
(Cdk1) and inhibition of p27. Cdk1 is a critical cyclin-dependent kinase in 
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G1/S phase shift, being a regulator of cell cycle. This cyclin was distinguished 
as it is upregulated in HER2 overexpressing cells and moreover showing 
reduced activity when HER2 expression is blocked, decreasing tumour growth 
due to cells being detained in G1 stage67. The molecule p27, which inhibits 
Cdk2 gene that is related to cell cycle progression, is arrested by high levels c-
Myc and D-cyclins when cells show a HER2 overexpression68,69. Therefore 
HER2 overexpression can affect cell cycle by arresting Cdk2 activity and 
promoting p21 phosphorylation70. PI3K/Akt pathway, stimulated by HER2 
overexpression, can inhibit cell apoptosis by interaction of p21 phosphorylated 
with apoptosis-signal-regulating kinase 1 (ASK1), blocking its activity25,71. 
Additionally HER2 overexpressing breast cancer cells showed an association 
with high levels of Ki67 expression. This might explain the high proliferative 
phenotype of these types of cancer cells and a link between HER2 gene and 
MKI67 gene upregulation72. Others have reported this relationship using 
immunohistochemistry assays revealing an association of Ki67 and HER2 
protein intensities73,74.  
 
1.2.1.2    HER2 Gene 
HER2 positive (HER2+) breast carcinomas do not follow a linear approach due 
to a range of abnormalities present in the genome. Moreover, not only HER2 is 
amplified others, including MYC, FGFR1, ZNF217 or CCND1 might be 
present at high levels of amplification75. Therefore it is possible to think that 
HER2+ breast cancers are biologically heterogeneous.  This is exemplified by 
the population of HER2+ tumours can be separated by positive or negative ER 
expression76. 
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Through the DNA microarray technique, Bertucci et al attempted to distinguish 
gene amplifications between HER2+ and HER2- cohorts to demonstrate any 
discrepancies. Considering the HER2+ cases, an additional 29 genes were 
identified to be overexpressed. The origin of these overexpressions might not 
be the same for all genes, being either a co-amplification due to close 
proximity to HER2, or regulation of these genes by identical factors that 
stimulate HER2 expression, or even genes regulated by HER2 itself. On a 
distance lower than one megabase from HER2 gene, on chromosome 17,q12, 
six genes were identified including GRB772,77, which is also involved in 
gastric78, oesophageal79, testicular80 and breast carcinoma81. The aberrant 
expression of these genes might explain the different outcomes to trastuzumab 
treatments. GRB7 is involved in cell migration dependent on integrins77 and 
PPARBP that is involved in downregulation of p53 and consequently a 
decrease in apoptosis82. However genes localised in different regions of the 
same chromosome might be affected by HER2 amplification indirectly, i.e., 
these genes activated only by HER2 overexpression and not by HER2 
amplification itself such as CD41, CD61, CD31 and MAP2K672. Furthermore 
genes, such as CDH15 (M-Cadherin) and GATA4, not present on chromosome 
17 might be amplified in HER2 positive cancer cells72. On the other hand, 
genes located in close proximity to HER2 and therefore co-amplified, might 
not overexpress their respective proteins due to possess different members on 
their transcription mechanism such as its promoters or repressors72. This 
indicates that even though a gene is amplified, is not the only factor to incite 
overexpression.  
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1.3 Limitations of the current classification system 
 
In the last years significant important innovations were achieved not only to 
prevent breast but in diagnosis and therapy progress. Also research made 
significant progresses on detection of potential biomarkers and genetic 
abnormalities to characterise new types of breast cancers20. Nowadays the 
major difficulty is to understand whether a patient will benefit from a specific 
treatment strategy or not. In breast cancer treatment only a small number of 
targets are accessible, like trastuzumab and endocrine therapies that are used 
depending on which receptor is identified as the target83. Though, different 
groups have questioned HER2 classification methods. HER2 gene 
amplification analysis is not accurate and the selection of patients might not be 
correct. 
 
Chromosome 17 polysomy (p17) is characterised by a minimum of one or 
more copies of the chromosome than observed in normal diploid cells. 
Polysomy is associated with only moderate overexpression of HER2 which 
suggests a diminutive control of this polysomy on HER2 gene expression in 
breast cancer development84. This polysomy control is null in HER2-negative 
cases85. It is also possible to frequently observe a high copy number of 
chromosome 17 centromere (CEP17) in the lack of HER2 gene amplification86. 
Those cases holding p17 and treated only with chemotherapy revealed a higher 
benefit when compared with breast cancer patients with no p17. However both 
groups possess similar disease free interval (DFI) (3-5 years) when submitted 
to trastuzumab, which might reveal that p17 does not predict if patients either 
benefit or not from this antibody therapy87. Patients that exhibit p17 are not 
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candidates for adjuvant trastuzumab therapy except those showing strong 
HER2 overexpression 88,89. By the use of microarray-based CGH technique 
Marchio et al was able to suggest that p17 is an extremely uncommon incident 
in breast carcinoma cases, showing that only one case proved to be polysomic 
by CGH among 18 fluorescent in situ hybridisation (FISH) polysomic cases.  
Moreover CGH results showed two among 12 samples with FISH polysomy 
revealing HER2 amplification ratio lower than 2. Therefore although these 
patients might benefit from trastuzumab therapy they are denied to such 
treatment90.  On the other hand, patients that possess HER2 amplification are 
denied to trastuzumab treatment because of high number of CEP17 due to gain 
or amplification of this centromere and consequently a ratio HER2/CEP17 < 
291. It might be more precise placing into consideration only the mean number 
of HER2 signals ignoring the number of CEP1790. Being suggested that above 
6 HER2 signals as the mean cut-off to be considered to characterise a patient as 
HER2 gene amplified and be able to benefit from trastuzumab or alternative 
HER2 mark therapy90.  
 
Studies developed to this point are more directed to gene amplification or 
protein levels of each HER receptor. However some protein analysis relate 
HER3 expression with poor survival outcome92,93, others relate its expression 
with good prognosis94,95. Still not very clear if analysis of DNA, mRNA or 
protein levels of these receptors is the best way to assess in order to define the 
patients outcome96,97. Some studies even suggest the evaluation of co-
expression of different members of HER family98,99. However the study of not 
only coexpression but the interaction of these receptors, like dimerisation, 
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stimulated by different ligands might be a way to assess this complex problem 
and provide some answers. Interaction amongst this family is so complex and 
diverse that cancer cells expansion might be more dependent on this variability 
of processes than with each receptor individually. 
 
1.4 HER2 and hormone receptors 
 
1.4.1 Crosstalk - ER, PgR and HER2  
Nearly 65% of primary breast carcinomas possess positive levels of ER and 
tamoxifen was the first permitted drug to be applied in treatments where ER is 
the target. This drug competes with oestrogen to bind with ER and therefore 
represses the high transcriptional action of ER. Subsequently ER positive 
breast cancer cells lose their proliferative phenotype, which is successful in 
approximately 60% of the ER positive tumours100. Aromatase inhibitors and 
other anti-steroidal drugs are also effective against ER positive carcinomas101.  
Some ER positive cases however demonstrate resistance to endocrine therapy 
and others develop resistance after a certain period of time on therapy102. The 
mechanisms of resistance are not entirely understood. Nonetheless crosstalk 
between the ER/HER family are involved in mechanisms of resistance in 
patients with breast carcinoma when submitted to endocrine treatments103-105.  
 
Dimerisation between HER family members triggers several downstream 
pathways as a consequence of phosphorylation of kinases, resulting in anti-
apoptotic encouragement and enhancement of cell proliferation or even cell 
migration106-108. PI3K/Akt or MAPK might be involved in the activation of 
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these responses; however they can be also implicated in the activation of ER or 
even its co-regulators. This way ER is able to develop its cellular outcomes, 
which means higher stimulation on tumour development and endocrine 
treatment resistance in those cells showing high expression of HER2 and 
ER105,109-111.  
 
ER expression is primarily located in the nucleus, where it acts as a 
transcriptional regulator for several genes. Its structure is composed of a ligand 
linkage site, transcription activator sites and a DNA binding site in order to 
cooperate with promoters of the target genes112,113. The target genes 
transcription include the recruitment of AIB1 (SRC3), an ER coactivator114. On 
the other hand the structure of ER is highly reactive with tamoxifen, which 
stimulates the enrolment of corepressors and therefore the transcription of the 
target genes becomes compromised105,115. Depending on the tissue involved, 
tamoxifen can possess both antagonist and agonist roles, which might indicate 
that in different tissues different corepressors and coactivators are involved. In 
case of those cells holding high levels of coactivators, as AIB1 or SRC1, 
tamoxifen acts as an agonist115.  
 
ER can act as a coactivator of proteins such as cyclin D1, involved on cell 
cycle, insulin-like growth factor receptor (IGFR), PgR, transforming growth 
factor alpha (TGF- ) and 9(*) 7KLV PRGH RI ³WDFWLF´ from ER on cell 
biology is named as ER genomic mediated mechanism116. Additionally ER 
might be located in the cytoplasm of breast tumour cells and in the membrane, 
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where it is able to react with Src, EGFR and HER2, known as ER non-genomic 
mediated mechanism (Figure 1.2)105,117,118. 
 
When tamoxifen is applied in cancer cells expressing high levels of ER, AIB1 
and HER2, it works as an agonist resulting in tumour development. However if 
this tumour suffers estrogen deficiency this development is compromised. 
Therefore aromatase inhibitors, which deprive the cell of oestrogen, indicate to 
posses a more efficient effect on ER/HER2 positive cancer cells119,120. 
Moreover, crosstalk between ER and HER has been demonstrated via the 
EGFR/HER2 downstream pathways, MAPK, is compromised if the 
concentration of ER drops significantly, but is enhanced in case of tamoxifen 
or oestrogen levels increase105.   
 
Supporting Tyrosine Kinase Inhibitors (TKIs), such as gefinitib, on cancer 
cells expressing ER, HER2 and AIB1, prevents the phosphorylation of the 
HERs changing the effects mediated by oestrogen and tamoxifen. Hence is 
possible to understand that the HERs are able to influence the outcome of 
oestrogen and tamoxifen due to a crosstalk occurrence105. Also MAPK when 
activated is able to phosphorylate AIB1, which enhances the agonist effect of 
tamoxifen. Therefore the overexpression of HER2 and dimerisation with 
EGFR stimulates downstream pathway MAPK with tumour development as a 
consequence of the presence of tamoxifen109. A different study using 
MCF7/HER2-18 cells (expressing ER, AIB1 and HER2) revealed high levels 
of AIB1 activity when submitted to heregulin, oestrogen or tamoxifen. 
However if gefinitib is applied, this AIB1 phosphorylation is prevented, 
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confirming crosstalk amongst ER and HER2 occurs121. When submitted to both 
gefinitib and tamoxifen, AIB1 activation is repressed, the antagonist effect of 
tamoxifen is observed and moreover the tumour cells development inhibited105. 
 
 
 
 
 
 
Figure 1.2 ± The crosstalk HER2/ER and its effects on breast cancer cells biology, 
understanding at the same time the significance of respective transduction pathways. Also 
different certain drug elements used in cancer therapy are represented in this diagram, 
including trastuzumab (Trast), aromatase inhibitors (AI) and tyrosine kinase inhibitors (TKI). 
Two ER main pathways are represented, the non-genomic ER mediated reaction ± intervened 
by the hormone oestrogen (E) ± and the nuclear-genomic ER mediated reaction.  
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1.5 HER2 breast cancer therapy 
 
 
1.5.1 Trastuzumab (Herceptintm; Genentech; South San Francisco, Ca) 
Though the expression of HER2 is inversely associated with ER/PgR status122, 
those tumours revealing both ER and HER2 positivity tend to be resistant to 
tamoxifen therapy120 and moreover when tamoxifen is applied alone results in 
a negative effect on patients prognosis123. Adjuvant C chemotherapy cocktail 
that combines Cyclophosphamide, Adriamycin and Fluorouracil (CAF), 
showed that this adverse effect is not observed comparing with only 
tamoxifen124. Additionally, aromatase inhibitors, like letrozole, possess a 
greater reaction than tamoxifen in both ER+/EGFR+ and ER+/HER2+119.  
Regimes including anthracycline revealed a correlation of improved therapy 
frequency and HER2 positivity125. When Cyclophosphamide containing 
regimens (CMF)126 and taxanes127 are used  as adjuvant chemotherapy on 
HER2 positive carcinomas it revealed lack of effectiveness. However later 
studies contradict this statement when concerning the taxane as adjuvant 
therapy128. Finally those HER2+ cases submitted to paclitaxel following 
adjuvant chemotherapy exhibit promising results independently of ER status129.  
Regarding all these studies, it is possible to understand that HER2 has 
prognostic value even though for some chemotherapy administrations it 
remains ineffective. Therefore HER2 targeted therapy is the most effective 
strategy or in combination with the most effective chemotherapy and/or in 
combination with endocrine therapy.   
 
HER2 positive breast tumours commonly exhibit numerous genomic 
abnormalities, however this type of carcinoma is strictly conditioned on HER2 
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expression and its downstream pathways to develop and survive.  Therefore 
targeting this receptor is an appropriate strategy in order to treat patients with 
HER2+ cancer. Numerous strategies are currently in development not only to 
react with HER2 itself in several of its domains, either extra or intracellular, 
but also some of its downstream pathways elements. 
 
Trastuzumab is already approved by US Food and Drug Administration (FDA), 
and is applied in those HER2 overexpressing breast cancer patients; it acts on 
the HER2 domain IV avoiding the formation of a heterodimer or homodimer56.  
This drug was initially developed from a mouse monoclonal antibody, which 
reacts with HER2. This receptor is not itself a tumour specific antigen, but 
when expressed 10 to 100 times above normal level it becomes a target of 
trastuzumab. This attribute is useful when the purpose is to target only cancer 
cells and therefore this discrimination may contribute for success of 
trastuzumab in cancer treatments. The mouse constant region does not react as 
an antigen to provoke a reaction by human immune system. Additionally the 
use of this mouse antibody in humans would cause an anaphylactic shock 
therefore the constant region from the anti-mouse antibody (HAMA) was 
³KXPDQLVHG´ UHVXOWLQJ LQ D FKLPHULFDO PROHFXOH - anti-HER2 MoAb (Figure 
1.3)56. From clinical trials, it is conclusive that trastuzumab has a significant 
effect on patients that diagnosed with tumours showing high intensity staining 
of HER2 protein (HercHS7HVWRUDKLJKJHQHDPSOLILFDWLRQXVLQJ),6+
method130 or chromogenic in situ hybridisation (CISH)131 (scoring system 
explained in methods chapter). However, patients showing moderate protein 
expression (HercepTest 2+) do not show a response to treatment if no gene 
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amplification was additionally present132. These cases revealing weak 
overexpression are not necessarily correlated with HER2 gene amplification 
but with p1784. When compared with chemotherapy alone or use of 
trastuzumab plus chemotherapy, the disease-free survival and the overall 
survival of HER2+ patients can increase 20%133.  
 
 
 
 
Figure 1.3 ± Humanised monoclonal antibody. Anticancer monoclonal antibodies (MoAbs) 
produced in mice invoke an immune response in human patients due to antigenic constant 
regions of the heavy and light chains (black) (A). Therefore, the mouse MoAb was humanised 
by designing non-immunogenic heavy and light chains resulting in a chimeric antibody (B). 
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1.5.2 Trastuzumab role in breast cancer treatment 
The role of this therapeutic antibody could be separated into two main 
mechanisms as stimulation of the immunologic structure mediating an anti-
tumour reaction or inhibition of HER family downstream pathways. However 
the mechanism of action of trastuzumab is still not completely understood, but 
it has been suggested that internalisation of the complex trastuzumab/HER2 
and degradation of the respective receptor occurs134,135. Trastuzumab/HER2 
interaction is characterised by internalisation and denaturation of the 
receptor135,136. Other groups suggest that the PI3K/Akt pathway is triggered by 
HER2/HER3 heterodimer, which is affected, and downregulated by 
trastuzumab in cells with HER2 overexpression137,138. 
 
1.5.2.1 Immune system  
When trastuzumab is given to patients, the immune system is activated by 
recruiting the effector cells responsible for detection of the antibodies and as a 
consequence results in a cytotoxic response139. Trastuzumab promotes 
apoptosis of cancer cells by antibody-dependent cellular cytotoxicity 
(ADCC)140 and the immune system responds to this stimulus provoked by 
trastuzumab. Hence the natural killer (NK) cells may develop the key role for 
this cytotoxic reaction. These white blood cells possess an Fc gamma receptor 
which interacts with the Fc domain on trastuzumab, resulting in NK-mediated 
cell lysis141. However in cancer patients in an advanced stage with an immune 
system immunosuppressed, the levels of cytotoxicity reactions are very 
low142,143.  
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A modification of trastuzumab is showing promising results in vitro on 
enhancing ADCC when compared against the original and patented therapeutic 
antibody. The transformation of the ordinary trastuzumab molecule consists on 
elimination of the fucose (defucosylation) from the oligosaccharides linked to 
the heavy chain of Asn297144. These results were confirmed by in vivo where 
an improved median progression free survival is observed in preclinical models 
of HER2+ breast carcinomas145. The use of vaccines targeting the HER2 
ectodomain is a promising strategy as these will decrease significantly any 
functional autoimmune reaction and destruction of the normal tissue will be 
limited146. 
 
1.5.2.2 Inhibition of angiogenesis 
Several pro-angiogenic factors are expressed in breast carcinomas to promote 
development of new blood vessels to provide more nutrients and oxygen that 
consequently encourage tumour growth. However, Izumi Y et al demonstrated 
that trastuzumab can act as an anti-angiogenic drug147. The vessel development 
becomes compromised and therefore rapid expansion of the tumour does not 
take place. In addition the evolution to metastasis is reduced due to a lower 
migration by endothelial cells. When combined with chemotherapy, 
trastuzumab is even more effective in preventing angiogenesis148.  Moreover, it 
has a double effect reducing the expression of pro-angiogenic factors VEGF149, 
TGF 150, Angiopoietin-1 (Ang-1)151 and Plasminogen-Activator Inhibitor-1 
(PAI-1)152, and enhancing anti-angiogenic factors as Thrombospondin-1 (TSP-
1)153.  
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1.5.2.3 Induction of cell cycle arrest and apoptosis 
The tumour volume of HER2+ breast tumours can decrease enormously when 
submitted to trastuzumab therapy due to enhancement of apoptosis cells154. It 
induces apoptosis and cell cycle arrest due to dramatically reducing the 
mitogenic signalling downstream pathways including PI3k and MAPK155,156. 
The cycle arrest of the cells treated with trastuzumab occurs through G1 stage 
of the cell cycle156 and the levels of p27KIP1 also increase inhibiting cell cycle 
development157. The expression of gene p27KIP1 produces a cell cycle inhibitor 
functional protein, which interacts with different classes of cyclin dependent 
kinase (Cdk) molecules inhibiting the termination of the cell cycle (Figure 
1.4)158.  
 
in vitro studies performed with only trastuzumab suggest that the levels of 
apoptosis are barely affected159,160. However when this antibody is combined 
with some chemotherapy agents these levels of apoptosis increase and the cell 
growth inhibition can vary among 20%-90%161.  
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Figure 1.4 ± The mechanism suggested of trastuzumab against HER2 membranal protein. By 
linkage of the monoclonal antibody on HER2 monomer the whole complex HER2/HER3 
dimer/PI3K is interrupted and consequently the levels of p27 increase due to its decrease of 
degradation. By increase of the P27 levels, cell cycle arrest takes place.  
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1.5.2.4 Other mechanisms of action 
Although it remains unclear, trastuzumab appears to downregulate HER2 by 
promoting its internalisation and denaturation155,156. However it trastuzumab 
does not have any influence on HER2 endocytosis but when recycled the 
complex trastuzumab/HER2 receptor, an inactive complex, returns to cell 
surface162,163. Also trastuzumab in combination with chemotherapy can block 
DNA repair as demonstrated through a study using HER2 overexpressing 
breast cancer cell lines BT-474 and SK-BR-3, which suffer high incidence of 
DNA breaks in a different approach of other cell lines164. Finally, a study 
performed with the same breast cancer cell lines by Molina et al165 suggested 
that trastuzumab may obstruct the HER2 (p185) ectodomain cleavage avoiding 
development of  the HER2 active form - p95 HER2, a truncated membrane bound 
fragment related with occurrence of lymph node metastasis166. 
 
One active effect by trastuzumab was reported to be the inhibition of 
HER3/HER2 and HER3/p85 dimerisation that consequently downgraded the 
levels of PI3K and Akt pressure for cell survival159. Ritter CA et al confirmed 
this when the appliance of gefinitib reduced the levels of p85 and HER3 
association inhibiting the activation of Akt167. Moreover there is dependency of 
PI3K pathway on HER3 phosphorylation.  
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1.6 Mechanism of resistance to trastuzumab 
 
1.6.1 Overview 
Although trastuzumab is used for therapies against HER2 metastatic breast 
cancer cases, employment of this drug on its own demonstrated to be 
successful in only up to 35% of these cases168. However when combined with 
first-line chemotherapy, the success of therapy can range 50%-84%169,170. The 
efficacy of trastuzumab when applied either as a single agent or in combination 
with chemotherapy can be temporary due this development of resistance. This 
suggests that other mechanisms are involved in cancer development, which are 
independent of this therapy171. Those cases submitted to trastuzumab alone or 
chemotherapy alone revealed a disease progression to progression of 4.6 ± 8.3 
months against 7.4 ± 14.2 months for those receiving chemotherapy plus 
trastuzumab and a median survival time of 20.3 ± 22.2 months against 25.1 ± 
32.2 months, respectively169.  
 
The unsuccessful results may be caused by failure of trastuzumab to block the 
dimerisation when high levels of ligands are present172. It is not clear what 
contributes for trastuzumab resistance, however some additional mechanisms 
may be involved and influence the final therapy results.  
 
1.6.1.1 Truncated HER2 (p95 HER2) 
Since trastuzumab links to the ectodomain of HER2 receptor, it was proposed 
the possible mechanism of resistance involving p95HER2. This molecule does 
not possess the external domain and therefore trastuzumab does not attach to 
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p95HER2 and promote its degradation. Moreover a proteolytic cleavage of the 
ectodomain results in a generation of a phosphorylated tyrosine kinase HER2 
p95HER2 165,166. This molecule constantly activated might trigger downstream 
pathways improving the influence of the cancer cells and moreover higher 
presence of this molecule in node positive cases comparing with the negative 
cases173. Within HER2 overexpression breast cancer cell lines the presence of 
heregulin, p95HER2 promotes HER3 transphosphorylation which is not inhibited 
by trastuzumab, however with lapatinib the transphosphorylation reaction is 
repressed174. Confirming this, breast cancer cells transfected with either HER2 
or p95HER2, showed sensitivity to trastuzumab and lapatinib in those transfected 
with HER2, however the cells transfected with p95HER2 were resistant to 
trastuzumab but not to lapatinib175. Some mechanisms of resistance are 
associated with p95HER2 as the expansion of downstream pathways activated 
from other members of HER family and consequently PI3K activation, or also 
IGFR might also over react176. The incidence of PI3K over activation can reach 
70% of these breast carcinomas177, reducing the efficacy of trastuzumab and 
lapatinib176,178. The heterodimer HER2/HER3 is a PI3K activator, however the 
dimer resulting from p95HER2 is more operative when compared with the full 
length HER2179. It was additionally reported that TGF  levels increase too as a 
consequence of p95HER2 presence179.  
 
1.6.1.2 PI3K/Akt pathway & PTEN expression 
In order to achieve a phosphorylated Akt the membrane associated 
phosphatidylinositol 4,5 ± biphosphate (PtdIns(4,5)P2 or PIP2) is converted, by 
result of HER2/HER3 heterodimerisation, into Phosphatidylinositol 3,4,5 ± 
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triphosphate (PIP3)180.  The PI3k/Akt pathway, highly present in HER2 
overexpressing cancer cells, stimulates inhibition of cell cycle arrest and/or an 
anti-apoptotic incident159. In contrast Phosphatase and tensin homolog (PTEN) 
is an important anti-tumour gene that is highly correlated with trastuzumab. Its 
protein is the phosphatase with the important role of converting the reactive 
PIP3 to PIP2, being a natural antagonist of PI3K activation180. Furthermore, 
cancer cells expressing small amounts of PTEN exhibit high activity of PI3K 
and therefore develop resistance to trastuzumab. The use of PI3K inhibitors is a 
possible strategy in order to achieve higher sensitivity to trastuzumab181. It was 
shown that those cell lines showing HER2 positivity and no PTEN expression 
develop some resistance to trastuzumab, however the combination of 
trastuzumab with a PI3K inhibitor (LY294002) the cells did not survive178. The 
molecular mechanisms of trastuzumab identified comprise the inhibition of 
PI3k and Akt pathways due to HER2 ectodomain being blocked and the 
impossibility of cleavage159,165. PTEN is a tumour suppressor gene on 
chromosome 10 that, either through mutations or haploinsufficiency, is not 
expressed in standard levels within half of breast cancer cases182,183. As a 
phosphatase it reacts with PI3, dephosphorylating it on position D3 with the 
purpose of recruiting Akt184. PTEN influences PI3k to promote the production 
of PI3 and Akt activity185, inducing apoptosis and cell cycle arrest. 
 
On the other hand, the tyrosine kinase Src, possesses an important role as a 
pro-oncogenic factor and when associated with HER2 it becomes reactive and 
inactivates the main role of PTEN 181,186. Therefore when trastuzumab interacts 
with HER2 in the same domain as Src, PTEN can perform its tumour 
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suppressive functions, which contributes for trastuzumab anti-cancer 
progression 181. When the interaction of this oncogene with HER2 is blocked 
by trastuzumab, PTEN can contribute against the uncontrolled and high-
proliferated cancer cells. The lack of PTEN results in resistance to trastuzumab 
in HER2 overexpressing patients resulting in poor prognosis. Absence or low 
expression of PTEN is a great indicator of trastuzumab resistance 181. 
 
1.6.1.3 EGFR involved in trastuzumab resistance  
EGFR might confer a trastuzumab resistance phenotype when it is expressed in 
high levels in HER2+ cell lines187. Furthermore this resistance is conducted by 
either the presence of EGFR/EGFR homodimers or EGFR/HER2 heterodimers, 
which both trigger several downstream pathways including MAPK and 
AKT187. The levels of HER2/EGFR reduced the trastuzumab therapeutic 
effects and it is in part responsible for the trastuzumab resistance acquired by 
tumour cells167. Moreover expression of HER ligands like EGF, TGF , 
betacellulin, and heregulin has also been associated with trastuzumab 
resistance172,188,189. Cells directed to overexpress TGF  developed high levels 
of resistance to trastuzumab. Therefore TGF  might be significantly involved 
in trastuzumab resistance due to its levels being increased dramatically 
comparing pre- and post-therapy periods in breast cancer patients190.  
 
Long periods of exposure to trastuzumab encourage EGFR expression creating 
resistance to this monoclonal antibody however further anti-EGFR agents, such 
as gefinitib or cetuximab further increase sensitivity191. However lapatinib 
showed to be more effective due to obstruction of cell proliferation despite 
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EGFR expression, demonstrating independency of lapatinib on EGFR range192. 
Moreover lapatinib demonstrated to be more effective in antagonising Akt 
activation. MAPK phosphorylation is not significantly affected by lapatinib, 
which suggests this pathway is a compensation for the lack of Akt 
phosphorylation187,193. Additionally two studies have implied that the presence 
of lapatinib enhances HER2 levels while trastuzumab has an opposite effect194. 
Therefore trastuzumab resistance might be partly explained by EGFR/EGFR 
homodimerisation, which is present in high levels when cell lines were 
submitted to trastuzumab, which indicates a direct association between EGFR 
phosphorylation and trastuzumab resistance187. 
 
HER2/EGFR heterodimer levels are affected in different ways by the presence 
of lapatinib, increasing with low levels of lapatinib, however showing an 
opposite effect for high concentrations of this drug187,193.  
 
1.6.1.4 IGF-1R involved in Trastuzumab Resistance 
The main PI3K upstream triggering involves another RTK, which is not part of 
the HER family ± Insulin-like growth factor (IGF-1R), however might be 
associated with some of the HER family reactions.  Cells that overexpress both 
HER2 and IGF-1R reveal high levels of resistance against trastuzumab. Even 
though addition of insulin-like factor binding protein-3 (a-IR3) supplementing 
the trastuzumab treatment, it significantly reduces the resistance of these 
specific cell lines (MCF-7/HER2-18). Also IGF-1R is able to trigger 
downstream pathways increasing the concentrations of SKP2, which interacts 
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with p27, reducing its levels and consequently leading to cell cycle 
progression195,196.   
 
1.6.1.6 HER3 involved in treatment resistance 
HER3 being completely dependent on any other member of HER family, the 
cancer therapies were not significantly directed on HER3 role but on the same 
family members. There is some evidence that some HER2+ tumours associate 
HER3 as the responsible for trastuzumab resistance197. However, trastuzumab 
does not disturb HER2/HER3 downstream cascades in HER2 amplified breast 
cancers175,198. Moreover the use of tyrosine kinase inhibitors as an alternative 
approach shows that is not effective as desired due to short time ability on 
restriction of the catalytic activity of the receptors199-201. Notwithstanding that 
the therapeutic strategies are driven towards HER2 overexpression, these 
inhibitors block HER2/HER3 dimerisation action for just a few hours and thus 
is unsuccessful on suppression of HER3 activation and with a final 
consequence on maintain PI3K/Akt downstream pathway operational, 
promoting proliferation and survival202.  
 
HER2/HER3 heterodimerisation activity may be inhibited in order to inactivate 
HER2 metabolic role. However this requires high concentrations of TKIs that 
would not be supportable in vivo203. HER3 plays a critical role in protection of 
HER2/HER3 dimerisation function against TKIs action due to a high range of 
different mechanisms that are able to regulate HER3 expression and signalling. 
In fact HER3 levels are increased as a compensatory response in HER2 
amplified breast cancer cells with the presence of TKIs202. More precisely the 
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increase in HER3 levels is stimulated by the dramatic decrease of Akt 
signalling203. HER3 signalling is stimulated by different mechanisms to 
increase of its expression, translation expansion, which involves proliferation 
of the raptor complex of mTor204. Additionally the half-life can be extended by 
HER3 avoiding dephosphorylation through alteration of HER family anti-
regulators such as NRDP1 or LRIG1205. Finally, HER3 expression can be 
affected by microRNA, e.g. miR205, which reduces HER3 activity and 
reinstates the initial sensitivity to TKIs in HER2 positive cancer cells 206 . 
 
1.7 Trastuzumab toxicity and alternative therapies 
 
1.7.1 Overview 
Exceptionally, rare cases of heart disease have been reported where 
trastuzumab is used in cancer treatments. This type of reaction, although rare, 
has a higher frequency when trastuzumab is used in combination with other 
therapeutic compounds such as paclitaxel or docetaxel132,207,208. These cardiac 
effects are not understood, but it is thought to cause dilated cardiomyopathy209-
212
. HER-2 is highly expressed in cardiac cells to avoid apoptosis and 
consequently increase cell survival to avoid cardiac dysfunction213. It promotes 
V\QWKHVLV RI VHYHUDO SURWHLQV VXFK DV QXFOHDU IDFWRU ț% 1)-ț% ZKLFK LV
involved in control of proteins during cells stress and activator-protein-1 (AP-
1) that controls proteins responsible for the progress of cardiac hypertrophy214. 
Other secondary effects can emerge when trastuzumab is used for cancer 
treatment such as myelosuppression, nausea, emesis and hypersensitivity, 
however these reactions can be prevented using antihistamines, anti-
inflammatory drugs and corticosteroids215.   
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1.7.1.1 Trastuzumab-DM1 (TDM1) 
New strategies to improve trastuzumab effectiveness are being addressed by 
linking a cytotoxic agent in order to intensify and discriminate the target cells 
increasing their cytotoxicity. Thus, this new molecular complex composed by 
trastuzumab, the cytotoxic element and a connector forms trastuzumab-DM1 
(T-DM1)216. T-DM1 is an antagonist of tubulin polymerisation originated from 
maytansine and MCC linker, which links trastuzumab to DM1, composes the 
connector. Some studies already showed some effectiveness of this molecule in 
HER2+ cell lines resistant to trastuzumab alone217. This complex is chemically 
very stable and shows positive results with the addition of low toxicity levels 
amongst the patients during phase I study218. The action resides on its 
cytotoxicity role only when it is internalised by the cell once the linkage 
against HER2 occurs. In case this reaction does not occur, T-DM1 will stay 
inactive and therefore not affect the whole system216.  The higher concentration 
level for this drug tolerated by patients is limited to 3.6mg/kg every 3 weeks. 
However tiredness, sickness, anaemia and high levels of liver enzymes 
occurred in patients submitted to T-DM1219. 
 
1.7.1.2 Pertuzumab 
A new generation of monoclonal antibodies developed to inhibit HER 
dimerisation are currently being developed. Pertuzumab, like trastuzumab, 
blocks the interaction between HERs family members, preventing 
heterodimerisation of HER2 with HER3 or EGFR 220, even though 
HER2/HER3 heterodimer is the main target221. However the difference 
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between pertuzumab and trastuzumab is regarding the locale of interaction in 
the HER2 ectodomain. While trastuzumab binds on epitope in domain IV, 
pertuzumab reacts with domains I, II and III222,223. It is possible to conclude 
that this drug could be valuable in trastuzumab resistant cases and use of 
pertuzumab in combination with trastuzumab could be a good strategy due to 
their different target epitopes on HER2 ectodomain. However it has been 
reported that pertuzumab does not have an additional benefit224. Even though 
in the presence of high levels of heregulin, the heterodimer HER2/HER3 is not 
disturbed by trastuzumab, however pertuzumab is capable to disrupt this 
heterodimer in similar conditions225.  
 
Trastuzumab and pertuzumab act on the extra-membrane domain of the 
receptor preventing ligand interaction or cleavage of this domain creating the 
oncoprotein p95HER2. Therefore an alternative strategy may reside on use of 
small molecules that compete for ATP preventing phosphorylation and 
consequently activation of TK domains in the cytoplasm. Thus, the main 
objective of the treatments is the use of antibodies that interact directly with the 
external domain of the receptors, although small interfering molecules could be 
used to disrupt the PI3k pathway226.  Among these small molecules gefitinib, 
erlotinib and lapatinib are used in this type of therapy171. Several studies 
demonstrated that lapatinib presented successful results where trastuzumab did 
not have any effect, being suggested to use it with trastuzumab treatment227. 
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1.7.1.3 Small Molecules or tyrosine kinase inhibitors (TKIs) 
As referred above, the consequence of ligand/receptor linkage is the formation 
of either HER homodimer or heterodimers developing an allosteric activation 
of certain tyrosine residues24, which triggers several downstream pathways 
responsible for survival as PI3K or proliferation via MAPK228,229.  
 
Other strategies targeting HER2+ breast cancer are being developed 
particularly surrounding the use of tyrosine kinase inhibitors (TKIs). These 
molecules compete against ATP to bind on HER family catalytic site, reducing 
downstream pathways activation230. Amongst the group of TKIs there are 
irreversible inhibitors, e.g. canertinib (Pfizer, Groton, USA)231 and reversible 
inhibitors, e.g. lapatinib (GlaxoSmithKline, King of Prussia, USA)230. 
Although these inhibitors are HER family specific, the majority possess an 
unselective approach. Amongst a high number of these agents that have been 
tested to inhibit tyrosine kinases, lapatinib is the most specific small molecule 
against EGFR and HER2 and extra two kinases STK10 and SLK. The small 
molecule EKB-569 reacts against 56 kinases amongst 113 examined, which 
included non-HER family targets232. Carnetinib reacted positively against 36 
kinases even though reported to be a specific inhibitor of EGFR, HER2 and 
HER4232. Although these small molecule inhibitors reveal promise, the lack of 
specificity may cause high levels of toxicity. Additionally in some HER2 
positive breast carcinomas is not appropriate to target all the HER family. This 
argument is supported by those reporting HER4 correlates with better survival 
outcome and therefore should not be inhibited233. Unlike monoclonal 
antibodies such as trastuzumab, TKIs only reduces levels of phosphorylation 
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but do not limit the number of HER2 receptors in tumour cells174,230. Lapatinib 
disturbs both HER2 and EGFR phosphorylation a month after the first 
application234. Additionally the levels of pErk1/2, pAkt and cyclin D 
decreased, promoting cancer cell apoptosis234. Another factor that plays an 
iPSRUWDQW UROH RQ SDWLHQW¶V SURJQRVLV LV VXUYLYLQ ZKLFK LV DQ LQKLELWRU RI
apoptosis and downregulated when HER2 amplified breast cancer patients are 
submitted to lapatinib235.      
 
Trastuzumab therapies might result in some toxicity including in the cardio 
system, however lapatinib demonstrated to involve lower risks on this level236. 
Other small molecules, provoke a stronger EGFR signalling inhibition, the 
frequency of toxicity increased considerably being characterised by diarrhoea 
and skin rash237,238. 
 
Lapatinib has been demonstrated to be the most promising small molecule to 
be applied in HER2+ breast cancer therapy where a partial reaction is observed 
when submitted to lapatinib238.  
 
Currently, several strategies are being addressed to increase the levels of 
therapy success, which include the combination of lapatinib with trastuzumab, 
aromatases inhibitors, anti-oestrogens and taxanes. These combinations might 
reveal some advantages due to complementation of each other. HER2 positive 
breast cancer patients when submitted to trastuzumab possess better survival 
outcome, however the frequency of metastases localised in central nervous 
system is high239. The reason is due to the high molecular weight of 
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trastuzumab, which is unable to pass the blood brain barrier and therefore is 
not able to act on metastatic cells. Small molecules are able to permeate this 
barrier and act on brain metastasis239. Additionally lapatinib may complement 
trastuzumab therapy against the mechanisms of resistance originated during 
trastuzumab monotherapy. IGF-1R is linked to trastuzumab resistance amongst 
the HER2+ breast cancers, however it does not affect lapatinib influence 
improving the patients outcome240. The lack of PTEN also reveals as a 
mechanism of resistance for trastuzumab241, as lapatinib is not dependent on 
PTEN, and is therefore not affected by this factor242. Since p95HER2 does not 
possess an ectodomain, trastuzumab is not able to interact in order to disrupt 
p95HER2 uncontrollable action. Therefore lapatinib offers an alternative way to 
increase the chances of control p95HER2 reacting via intracellular domain174. 
In a clinical trial, some patients were submitted to either trastuzumab/lapatinib 
or lapatinib alone. The combination of both drugs revealed a significant 
improvement on the risk of disease progression and better survival 
prognosis243. 
 
Finally the combination of TKIs with other current therapies might be able to 
increase the levels of success amongst the HER2 amplified breast cancers. The 
combination of trastuzumab and lapatinib showed to be more effective against 
cancer cell lines which survivin activity was inhibited, when compared with 
the use of any of the drugs singly244.  
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1.8 Transmembrane precursor proteins molecules 
 
1.8.1 Overview  
All members of HER family, apart from HER2, are activated by a group of 
ligands, expressed as transmembrane precursor proteins, which possess a 
conserved epidermal growth factor (EGF)-like domain or neuregulins. This 
domain is composed by six cysteine residues localised on a region of 40 amino 
acids245. The cysteine residues form disulphide bonds in order to confine the 
secondary structure into a three loop conformation, which will be vital for their 
activity and respective specificities 246. Expressed by 11 different genes229 the 
HER ligands group includes EGF, betacellulin (BTC), TGF , heparin-binding 
EGF-like growth factor (HB-EGF), epiregulin (EPR), amphiregulin (AREG), 
epigen (EPI) and a subfamily of four neuregulins (NRG), which after splicing 
reaction originates six different proteins (NRG 1 ȕ ȕDQG229,247-
249
. All HER family members with exception for HER2 possess on their 
ectodomain four subdomains that assume an auto-inhibition form through 
deficiency of ligands63,250.   Each HER member has specific ligands that they 
interact with which in turns encourages dimerisation130. Some of these ligands 
only interact with EGFR such as EGF, TGF  and AREG229. Other ligands 
specifically interact either with EGFR or HER4 including HB-EGF, BTC and 
EPR251. NRG 1 and 2 cooperate with both HER3 and HER4, but NRG3 and 
NRG4 only bind to HER4 (Figure 1.5)229. Even though HER4 interacts directly 
with its respective ligands, recent studies suggested that HER4 when existing 
as a heterodimer might be able to interact with ligands such as EGF, TGF , 
HB-EGF and EPR248,252. 
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An interesting study by Révillion et al247 revealed high levels of ligand 
expression in 85% of breast carcinoma cases independently of HER2 
eminence. Moreover the same group demonstrated that a co-expression occurs 
between receptors and ligands indicating autocrine or paracrine pathways 
triggered by ligands on breast cancer cells. 
 
 
 
 
 
Figure 1.5 ± Interaction specificity with Ligands. EGFR interacts with specific ligands as EGF 
(Epidermal Growth Factor), TGF  (Transforming Growth Factor-ǹOSKD), Epigen (EPG) and 
AREG (Amphiregulin), which do not bind to any other receptor of HER family. Nevertheless 
this receptor shares some ligands interaction specificity with HER4, HB-EGF (Heparin-
Binding EGF-like Growth Factor) and EPR (Epiregulin). On the other hand HER4 and HER3 
interact with both NRG1 (Neuregulin) and NRG2, but NGR3 and NGR4 only create a linkage 
with HER4. BTC (Betacellulin) is the only ligand able to interact with EGFR, HER3 and 
HER4 (misrepresented in the diagram for HER3). 
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1.8.1.1 Epidermal Growth Factor (EGF)   
EGF and TGF  were firstly identified due to their effects on inhibition of acid 
gastric inhibition253 DQGD³VDUFRPDJURZWKIDFWRU´254 respectively. EGF when 
introduced in neonatal mice, affects eyelid opening tooth eruption255 and 
neurobehavioral progress256. The protein is expressed by a gene of 110kb 
located on chromosome 4q25257 and consists of a 1217 amino acid precursor, 
which is glycosylated and secreted by adjacent cells258. EGF is expressed in a 
wide range of normal tissues and is highly correlated with promotion of cell 
proliferation. EGF overexpression occurs in several types of cancer such as 
breast, liver or pancreas29. In vitro, proliferation and differentiation of 
mammary epithelial cells is highly controlled by EGF performing an important 
role as a mitogenic factor in both normal and malignant cells259. EGF, like 
other growth factors, encourages phosphorylation of tyrosine kinase domain 
and autokinase action of p185C-erB-2 that is linked to poor prognostic breast 
cancers260. EGF expression is expressed in approximately 15% - 30% of 
invasive carcinomas261,262, revealing a negative association with ER expression 
but not with tumour size, differentiation or even metastasis development even 
though it is linked with poor outcome261. Additionally overexpression of HER2 
increases linkage affinity between EGF and heregulins to their respective 
receptors due to a reduction of their rates of ligand dissociation263. Moreover 
the reduction or suppression of HER2 diminishes the ligand/receptor 
connection and for that reason the HER family downstream pathways are not 
triggered61. 
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1.8.1.2 Transforming Growth Factor-alpha (TGF ) 
TGF  is composed of a 50 amino acid peptide achieving a total weight of 
5.6kDa with an identical secondary structure when compared to EGF including 
three sulphide bonds264. However it shows only 30-40% of homology to EGF 
in the tertiary conformation but has a similar affinity for EGFR265 interacting 
ZLWK ERWK WKH VXEGRPDLQV , DQG ,,, RI WKH UHFHSWRU¶V HFWRGRPDLQ266,267. 
Furthermore EGF and TGF  expression are highly associated with EGFR 
expression, however when co-expression of EGFR and HER3 occurs, TGF  is 
the ligand with higher affinity247. TGF  is highly expressed throughout 
gestation and lactation in breast epithelial cells. Likewise in tumour cells, high 
expression is associated with high tumour grade, recurrence and aggressive 
outcome268 and is detected in 40% - 70% of cancer cases269,270. 
 
1.8.1.3 Heparin-Binding EGF-like Growth Factor (HB-EGF) 
Amongst the EGF-like family, HB-EGF was the first to be identified in 
secretions of macrophages-like cells. Its transmembrane precursor is composed 
by 208 amino acids including a weight of 14 to 20 kDa271. In order to 
accomplish soluble HB-EGF activation of metalloproteinases has to take 
place272. In fibroblast and smooth muscle cells, HB-EGF holds a higher 
mitogenic and chemotactic influence when compared with EGF and TGF 273. 
This ligand is able to interact with EGFR271 promoting cell proliferation and 
motility and with HER4 the interaction results only in cell motility274. Its role 
is significantly important in gastric275, bladder276 and prostate carcinomas277. 
Although HB-EGF expression is highly expressed in breast cancer cells, one 
study has demonstrated that the levels of expression is reduced dramatically in 
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those patients with a worse prognosis, large tumour size, elevated cell 
proliferation and high tumour grade278. It can also promote apoptosis 
avoidance, when anti-cancer treatments are employed or even the immune 
system attempt to execute destruction of the cell279. Moreover this ligand can 
promote regulation of p21, which inhibits cell cycle280. 
 
1.8.1.4 Betacellulin (BTC) 
BTC is distinguished from other ligands by its unique capacity to trigger 
heterodimerisation of all the HERs281. Its human precursor is composed of 178 
amino acids, which is reduced to 80 amino acids with a weight of 32kDa as the 
active molecule. Similarly to all EGF group, BTC possesses a standard EGF-
like domain composed of six cysteine residues282. BTC interacts with EGFR 
however the affinity is ten times lower comparing with the connection of the 
receptor with EGF, and an additional similarity involves the activation of the 
heterodimer HER2/HER3 in certain cell lines283. mRNA analysis revealed a 
high expression of BTC in pancreatic tissue, heart and lung of mice284. In 
breast, BTC can stimulate cell growth285. Moreover it promotes differentiation 
of breast epithelial cells to express neutral lipid including droplets284. 
 
1.8.1.5 Amphiregulin (AREG) 
AREG 10.2 kb gene is located on chromosome 4q13, which originates a 
precursor with molecular weight of 34 ± 36 kDa286. It only interacts with 
EGFR287 and shows a different behaviour when compared with the other 
ligands due to performing two different functions; either improving some 
normal or cancer cell lines growth or inhibiting this process in other cancer 
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cells288. Similarly to BTC the interaction with EGFR, which is exclusive for 
AREG, is characterised by a lower affinity when compared with EGF288 or 
even TGF 289. However this ligand is highly connected to growth of normal 
and breast cancer cell lines and some breast primary breast cancer cases, 
showing superior expression in invasive breast carcinoma287,290. Moreover, 
when AREG expression is suppressed the development of breast tumour is 
affected and reduction of angiogenesis is also observed291,292. Certain 
correlations of AREG with other biomarkers and clinicopathological 
parameters remain ambiguous due to discrepancy of observations between 
different studies. Some studies did not observe any correlation between AREG 
and ER status, tumour stage, grade and size293, others found an association with 
ER levels290.  
 
1.8.1.6 Epiregulin (EPR) 
EPR is a protein mainly expressed by macrophages, placenta and tumour 
epithelial cells294. This protein, with low affinity against the HERs, retains 46 
amino acids residues and a molecular weight of 5.4kDa with high levels of 
similarity with other EGF ligands reaching up to 50%294. The gene responsible 
for EPR expression is located on chromosome 4q13295. Amongst breast cancer 
cell lines this ligand links directly with EGFR and HER4 only296. Interestingly 
EPR promotes inhibition of some tumour cells growth but promotes cell 
growth amongst fibroblasts294.  
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1.8.1.7 Epigen (EPG) 
Epigen was the last EGF-like ligand to be documented297, with a molecular 
weight of 14.7kDa is expressed by its gene localised on chromosome 
4q13.3298,299. The EGF-like ligand family is characterised into two different 
groups, the low affinity group including EPG, EPR and AREG and the high 
affinity group composed by EGF, TGF  and HB-EGF297. However the low 
affinity group does not possess high influence and is less like to be affected by 
antagonist mechanisms. If EPG possesses low affinity against its main 
receptor, the same group reveals an association with high mitogenic features by 
evading the physiological machinery due to a faint phosphorylation. This way 
interaction levels with c-Cbl, an ubiquitin enzyme, drops dramatically avoiding 
downregulation of the growth complex.  Finally this ligand was described as 
possessing specificity to EGFR but also a fragile ability to activate HER3 and 
HER4297.  
 
1.8.1.8 Neuregulins (NRGS) 
Neuregulins are a diverse family of ligands, expressed by four genes (NRG 1 - 
4), which has been highly described due to be present in a high number of 
cancer tumours. The first of the group to be detected was NRG1 and using the 
same primers it was possible to detect the second member NRG2300. NRG3300 
and NRG4301 were detected by the use of bioinformatics techniques when the 
NCBI database was scrutinised. NRG1 gene is located on chromosome 8p12, 
which expression can undergo splicing resulting in 15 different isoforms. 
However, NRG  DQGȕDUHWKHPDLQLVRIRUPVLQYROYHGVSHFLILFDOO\LQUHFHSWRU
recognition by their c-terminal248. NRG2 gene also expresses two isoforms 
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NRG2  DQG15*ȕZKLFKSRVVHVVDGLVWLQFWLYHSURSHUW\RIUHFRJQLVLQJDQG
activate HER3 and HER4302. NRG3 gene is located in chromosome 10q22 
expressing a protein with EGF-like domain 39% similar to NRG1 and the 
cytoplasmic domain only 12% similar to NRG1 suggesting that NRG3 is not a 
slice isoform of NRG1300. NRG4 is encoded by a gene located on chromosome 
15q24298 and the closest similarity is with NRG3 with 42% of their EGF-like 
domain, which explains their common and only growth factor target HER4301.  
 
In breast, they have an important function in development of breast 
glands303,304, however they are also expressed in several tissues where they 
have different functions being involved in improvement of vascular endothelial 
cells305, pancreas, muscles306 and nervous system where different NRG act in 
different areas of this structure307. NRG2 is expressed in neurone system by 
Schwann cells presenting in high concentrations in synaptic spots308. During 
normal development of breast, all four NRGs are expressed with NRG3 having 
the most important role309 and shows the highest expression levels when EGFR 
and HER4 are co-expressed247. Furthermore levels of NRGs are increased in 
invasive breast cancer304. Although the cause remains unknown, the genes 
responsible for synthesis of NGR1 and NGR3 proteins experience 
rearrangement in breast cancer cells310. These molecules have an important role 
in breast cell cycle and survival, controlling differentiation of cells, growth and 
proliferation. NRG1 is also involved on proliferation of several tissues311 and 
consequently may have an important function in interaction of ligands and 
receptors. NRG1 also interacts with HER3 and HER4 stimulating 
materialisation of the heterodimers alongside HER2. However the mechanisms 
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involved in this complex reaction(s) remain unclear312. The different members 
of NRG family are present at high concentrations in different incidence, where 
KLJKOHYHOVRI15*ȕDUHIRXQGLQODUJHEUHDVWWXPRXUV!PPDQGDORQJ
with NRG4, in high-grade tumours. On the contrary, NGR3 is associated with 
low grade-tumours311. Due to NRG family possess a strong mitotic outcome 
have been receiving high interest as potential therapeutic targets, more 
specifically targeting the inhibition of their signalling313. An autocrine 
activation of HER3 by NRG revealed development of resistance to gefitinib 
therapy226.  Additionally high levels of NRG1 promote resistance to 
trastuzumab in MCF-7 cell lines314. Patients submitted to trastuzumab and 
revealing low levels of HER2 but high expression of NRG1 possess a better 
outcome, suggesting that this group of patients might benefit from this therapy 
even though the low expression of HER2314.  
 
1.8.1.9 Other Ligands  
Neuroglycan C315 has more recently been identified as a member of the NRG 
family. Tomoregulin 1 and 2316 have also been suggested as possible ligands 
that interact with HER family, however further studies need to conducted in 
order to confirm this.  
 
The EGF domain is amongst one of the most common recognised in the human 
genome existing in more than 3000 genes (www.sanger.ac.uk). Therefore it is 
reasonable to surmise that more ligands and possibly new HER family splicing 
forms may be identified in the future, revealing an even higher variation on 
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possible combinations and more and diverse biological effects might be 
understood currently (Figure 1.6). 
 
 
 
 
Figure 1.6 ± Possible dimer combinations amongst the HER family.  
(From: http://www.kent.ac.uk/bio/gullick/?tab=research) 
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1.9 HER family dimerisation 
 
1.9.1 Overview 
A ligand-ectodomain interaction encourages dimerisation, which is 
characterised by contact either of two HER proteins from the same family ± 
heterodimerisation ± or of two identical molecules ± homodimerisation. The 
nature of EGFR, HER3 and HER4, molecular conformation is unable to 
interact with any other RTK. The dimerisation arm remains in an auto-
repressed conformation due to an intramolecular linkage inside a protein 
situated in domain IV of the ectodomain (ECD). However when the ligand 
connects to one of these glycoproteins, the dimerisation arm located in domain 
II of the ECD, converts into a competent conformation (Figure 1.7)32. Even 
though an interaction with a ligand is not enough to provoke the reaction41. 
This is the primary approach to incite interaction between two monomers, 
however it is not unique. The kinase region localised on HER molecule tail 
(except for HER3) is activated by a transphosphorylation reaction. Two lobes, 
C and N, which cooperate to generate the active conformation, compose this 
domain. The activation of kinase occurs when the C-lobe of the first kinase 
contacts the N-lobe of the second one, which becomes allosterically activated 
(Figure 1.8)42. Multiple pathways are triggered as a consequence of dimerisation 
of the HER family, as phospholipase CȖ (PLCȖ), signal transducer and 
activation of transcription (STATs), Ras/MAP kinase (MAPK) and PI3K317, 
with the last two being well documented to be associated in cell survival and 
proliferation, by activation of several transcription factors and Cdk1 and 
decreasing the levels of active p27 with consequent cell cycle arrest is 
evaded70,106. 
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In cancer cells, mutations of the kinase domain on HER2 triggers EGFR 
resistance to some inhibitors318. The structure of the dimers can manipulate 
downstream pathways where some arrangements are present in aggressive 
carcinomas, like HER2/EGFR, EGFR/HER3 and HER2/HER3283,319. However 
the heterodimerisation of HER2/EGFR is reported to be present in the most 
aggressive carcinomas and worst prognosis confirmed by cancer shortest 
disease free survival and cancer specific survival320. Even though the 
differences amongst these heterodimers, they are more stable321 and produce 
downstream pathways which are more effective263 when compared with other 
heterodimers not including HER2. 
 
After the biological reaction, the interacting ligand receptor is broken by an 
endocytic reaction, inactivating receptors. The unphosphorylated HER 
molecules are then either degraded or recycled to return onto the cell 
membrane322. Ubiquitin ligases can react with kinase domain playing the role 
of negative regulators. Furthermore the molecule RALT also known as 
Mitogen-inducible gene 6 (Mig6), is a protein that has the ability of binding to 
HER family molecules in their kinase domain slowing down the kinase 
activity323. Expression knockout of this protein may influence the cell cycle 
and promotes cancer development324,325.  
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Figure 1.7 ± The ectodomain and endoplasmic domain of a member of HER family. The 
ectodomain has four substructures that together are the competent form due to a ligand 
molecule interaction with substructures I and III. Also the substructure II is where the 
interaction with another receptor takes place due to the localisation of the motif arm and where 
pertuzumab interacts with the receptor during treatments. The last substructure, IV, is the target 
from trastuzumab avoiding competent conformation of the ectodomain.  The endoplasmic 
domain includes the N-lobe and C-lobe of the tyrosine kinase involved in the dimerisation 
process, at cytoplasmic level, which will trigger several downstream pathways by 
phosphorylation reaction.  
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Figure 1.8 ± Induced HER Dimerisation. Ligand/Receptor connection that triggers 
dimerisation reaction that takes place in the internal domain showing the N-lobe of one 
monomer reacting with the C-lobe of the second monomer. Phosphorylation of the tyrosine 
sites takes place to activate downstream pathways.  
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1.10 Hypothesis 
 
Accurate quantification of protein expression and other biological 
characteristics, such as HER heterodimerisation, could be important to 
elucidate and predict patient outcome, particularly with HER targeted 
therapies. The action of these molecules are controlled by a complex system 
that includes structures modifications or connections with other molecules such 
as ligands; the subsequent heterodimer arrangements will trigger different 
pathways and consequently different outcomes30,31. It is therefore hypothesised 
that the different HER heterodimers might possess distinct associations with 
relevant biomarkers including hormone receptors and moreover how it 
influences survival outcome amongst the patients. If any of these heterodimers 
is associated with trastuzumab resistance development and in which period of 
time after the first treatment this resistance is developed. Three techniques are 
going to be utilised for a more complete understanding of the heterodimers 
biochemistry, which includes Immunohistochemistry, chromogenic in situ 
hybridisation and a novel technology named in situ Proximity Ligation Assay. 
Classes of biomarkers never identified before discriminated amongst breast 
cancers can be characterised. An innovative and more robust classification 
system of breast carcinoma is possible to be developed and discrimination of 
patients can be more reliable, with reduce number of relapses or even death 
occurrence originated by wrong diagnosis and therapy decision.  
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1.11 Aims 
 
Therefore the aims of this study are four fold: 
 
1) To accurately establish HER2 status of a large historical series of breast 
cancers, by comparing correlation between protein overexpression and 
gene amplification (determined by CISH) in order to determine and 
understand their specific contributions to patient outcome.   
   
2) Perform quantification of HER2 as a monomer, and heterodimers 
(HER2/HER3, HER2/EGFR and HER2/HER4) in both Unselected 
HER2+ breast cancer series.  
 
3) Determine the biological characterisation of these heterodimers in both 
Unselected and HER2+ breast cancer series by correlating to 
FOLQLFRSDWKRORJLFDO SDUDPHWHUV SDWLHQW¶V VXUYLYDO RXWFRPH DQG
trastuzumab therapy effectiveness. 
 
4) Understand how and if p95HER2 demonstrates any different outcome 
from the wild-type HER2 molecule and the correlation between them. 
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2. CHAPTER 2: Patients and Methods 
 
2.1   Patient samples  
 
2.1.1 Unselected Series 
The first patient series comprised 1858 unselected primary operable invasive 
breast carcinoma cases between 1986-1998, from the well-characterised 
Nottingham-Tenovus Primary Breast Carcinoma Series (Unselected Series). 
The entire series was evaluated for clinicopathological variables as age, 
menopausalcc status, tumour type326, histological grade327, tumour size, tumour 
recurrence, presence of distance metastasis, lymph node status, vascular 
invasion and Nottingham Prognostic Index (NPI)328. The NPI was obtained 
using the formula: 0.2 x tumour size (cm) + grade (1-3) + lymph node stage (1-
3). Patients were assessed in three prognostLFJURXSV 3.4 ± good prognosis, 
3.41-5.4 ± moderate prognosis and > 5.4 ± poor prognosis. The treatment 
strategy was established on tumour characteristics including NPI and hormone 
UHFHSWRU VWDWXV 7KH SDWLHQWV H[KLELWLQJ DQ 13, VFRUH   GLG QRW UHFHive 
adjuvant therapy, those patients with NPI score > 3.4 received, Tamoxifen if 
ER positive (n = 1272, 73.2%) (± Zoladex if premenopausal), or classical 
cyclophosphamide, methotrexate and 5-fluorouracil if ER negative (n = 465, 
26.8%) and fit enough to tolerate chemotherapy329. 
 
Table 2.1 summarises the clinicopathological parameters. A total of 1256 
(67.6%) were 50 years old or over and 601 (32.4%) were under 50 years old. 
The age range was 18-72 years, mean age situated on 54 years and the median 
Chapter 2: Methodology 
56 
55 years. Histopathological description of the disease varied, which is 
illustrated with 354 (19.1%) tumours grade I, 616 (33.3%) grade II and 880 
(47.6%) grade III. Tumour size ranged between 0.1 cm and a maximum size of 
15.0 cm. A total of 1367 (73.9%) of patients tumours were 1.5cm or larger and 
484 (26.1%) under 1.5cm. Additionally 1187 (64.1%) revealed tumour stage 
N0, 505 (27.3%) stage N1 and 159 (8.6%) stage N2. 
 
Follow-up data was collected for the first time at 3 months after surgery, 
followed by an interval of 6 months and then each 12 months (median 160 
months; range 1-224 months). Throughout this time, relapse occurred in 718 
(39.6%) cases, distant metastasis in 559 (30.3%) cases and 483 (31.7%) 
patients died from breast cancer. Local recurrence, defined as an additional 
malignancy occurring in the same mammary tissue, and regional recurrence, 
defined as an extra malignant incidence in lateral axillary lymph nodes, 
occurred in 216 (11.9%) and 178 (9.8%) patients, respectively. 
Characterisation, including immunoreactivity, marking and categorising of ER, 
progesterone receptor (PgR), p53, breast cancer 1 (BRCA1), basal phenotype 
(BP) and Triple Negative Phenotype (TN) were previously determined in this 
series330-333. 
 
2.1.2 HER2+ Series 
 
2.1.2.1 HER2+ adjuvant trastuzumab series 
The HER2+ adjuvant trastuzumab series consisted of 143 primary operable 
breast tumours from patients presenting between 2003 and 2010 who received 
adjuvant trastuzumab. A total of 79 (56.4%) patients were aged over or equal 
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to 50 years, and 61 (43.6%) were less than 50 years old. The age of patients at 
presentation ranged between 31 and 79 years old (median and mean of 52 
years). At primary diagnosis 3 (2.1%) tumours were grade 1, 37 (25.9%) grade 
2, and 103 (72.0%) cases were grade 3. A total of 120 (83.9%) patients had 
tumours 1.5cm or larger, (ranging from 0.1 cm and 8 cm). Relapse occurred in 
23 (16.1%) cases, distant metastasis in 17 (12.1%) cases, and 10 (7.0%) 
patients died from breast cancer. Local recurrence occurred in 7 (4.9%) of 
cases and regional recurrence in 1 (0.8%) case.  
 
2.1.2.2 HER2+ trastuzumab naïve series 
The HER2+ trastuzumab naïve series (n = 224) is composed by all HER2 
positive cases part of Unselected Series. A total of 142 (63.4%) of patients 
were 50 years old or over and 82 (36.6%) less than 50 years old, with an age 
range between 27 and 71 years old and median of 53.  This series primarily 
consisted of grade III tumours (186, 83.0%) of cases the remaining being either 
grade II (33, 14.8%) or grade I (5, 2.2%). The tumour size ranged between 0.5 
cm and 8.0 cm, including 186 (83.0%) of patients having tumours larger than 
1.5 cm. The tumour lymph node (LN) stage N3 was present in 34 (15.2%) 
cases, N2 in 67 (30.0%) patients and the majority 122 (54.8%) acquired LN 
stage 1. Finally relapse occurred in 113 (51.1%) of patients, distant metastases 
occurred in 102 (45.5%) cases and 97 (49.7%) patients died from breast cancer. 
Local and regional recurrence occurred in 31 (14.0%) and 28 (12.7%) of the 
patients, respectively.  
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2.1.2.3 HER2+ Series 
Combining the HER2+ adjuvant trastuzumab and HER2+ trastuzumab naïve 
series resulted in the HER2+ Series, which included 367 patients. 
Clinicopathological parameters for this series are summarised in Table 2.1 
patients.   
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Table 2.1 ± Clinicopathological characteristics of the Unselected series (n = 1858), HER2+ 
trastuzumab naïve series (n = 224), HER2+ adjuvant trastuzumab series (n = 143) and 
HER2+ Series (n = 367). 
Characteristics Unselected Series HER2+ (Trastuzumab Naïve) HER2+ (Adjuvant Trastuzumab) HER2+ (Naïve + Adjuvant) 
 N Patients (%) N Patients (%) N Patients (%) N Patients (%) 
Age at Diagnosis (Years) 
    
 <50  601 (32.4) 82 (36.6) 61 (43.6) 143 (39.3) 
  1256 (67.6) 142 (63.4) 79 (56.4) 221 (60.7) 
     
Menopausal 
    
Pre 700 (37.7) 92 (41.1) 26 (18.6) 118 (32.4) 
Post 1154 (62.3) 132 (58.9) 114 (81.4) 246 (67.6) 
     
Death 
    
No 1043 (68.3) 98 (50.3) 133 (93.0) 231 (68.3) 
Yes 483 (31.7) 97 (49.7) 10 (7.0) 107 (31.7) 
     
Tumour Size (cm) 
    
<1.5 484 (26.1) 38 (17.0) 23 (16.1) 61 (16.6) 
 1367 (73.9) 186 (83.0) 120 (83.9) 306 (83.4) 
     
Tumour Grade 
    
1 354 (19.1) 5 (2.2) 3 (2.1) 8 (2.2) 
2 616 (33.3) 33 (14.8) 37 (25.9) 70 (19.1) 
3 880 (47.6) 186 (83.0) 103 (72.0) 289 (78.7) 
     
Lymph Node Stage 
    
1 1187 (64.1) 122 (54.8) 53 (37.3) 178 (47.9) 
2 505 (27.3) 67 (30.0) 56 (39.4) 123 (33.7) 
3 159 (8.6) 34 (15.2) 33 (23.2) 67 (18.4) 
     
Distant Metastasis 
    
No 1288 (69.7) 122 (54.5) 124 (87.9) 246 (67.4) 
Yes 559 (30.3) 102 (45.5) 17 (12.1) 119 (32.6) 
     
Mitotic Frequency 
    
1 684 (38.3) 15 (6.8) 36 (25.9) 51 (14.2) 
2 322 (18.0) 43 (19.4) 43 (30.9) 86 (23.9) 
3 781 (43.7) 163 (73.8) 60 (43.2) 223 (61.9) 
     
Pleomorphism 
    
1 51 (2.9) 0 (0.0) 0 (0.0) 0 (0.0) 
2 718 (40.3) 26 (11.9) 12 (8.6) 38 (10.6) 
3 1011 (56.8) 193 (88.1) 127 (91.4) 320 (89.4) 
     
Tubule Formation 
    
1 119 (6.7) 2 (0.9) 0 (0.0) 2 (0.6) 
2 583 (32.6) 46 (20.8) 23 (16.5) 69 (19.2) 
3 1085 (60.7) 173 (78.3) 116 (83.5) 289 (80.2) 
     
Vascular Invasion 
    
Negative 1061 (58.2) 118 (53.4) 79 (56.0) 197 (54.4) 
Positive 763 (41.8) 103 (46.6) 62 (44.0) 165 (45.6) 
     
Relapse 
    
No 1093 (60.4) 108 (48.9) 119 (83.9) 227 (62.5) 
Yes 718 (39.6) 113 (51.1) 23 (16.1) 136 (38.5) 
     
Local Recurrence 
    
Negative 1595 (88.1) 190 (86.0) 136 (95.1) 326 (89.5) 
Positive 216 (11.9) 31 (14.0) 7 (4.9) 38 (10.5) 
     
Regional Recurrence 
    
Negative 1633 (90.2) 193 (87.3) 124 (99.2) 317 (91.6) 
Positive 178 (9.8) 28 (12.7) 1 (0.8) 29 (8.4) 
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2.2   Tissue microarrays (TMAs)  
 
2.2.1 Technique 
Using TMA technology representative tissue cores acquired from formalin-
fixed paraffin embedded (FFPE) tissue block (donor block) can be transferred 
to a new paraffin block (recipient block). Firstly portrayed by Wan et al334 after 
the technology was advanced allowing the inclusion of a high number of cases 
in one single paraffin block allowing high-throughput downstream analysis 
such as immunohistochemistry335. 
 
2.2.2 TMA construction 
 
Two separate TMA collections were constructed: 
 
1) Unselected Series TMA ± consisting of peripherally sampled tumour cores, 
with one core representing each patient. Construction of this TMA has been 
previously described330,331.  
 
2) HER2+ trastuzumab adjuvant TMA ± consisting of three cores sampled 
from each tumour: two cores from peripheral regions and one from the central 
region of the tumour.  
 
From each donor FFPE block, the quality of each block was considered, 
selHFWLQJ WKRVH KROGLQJ D VDWLVIDFWRU\ WXPRXU WKLFNQHVV  3mm).  Full-face 
H&E sections were evaluated and the most representative area for each case 
were selected and marked. Each representative area marked on the H&E slide 
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was subsequently marked on the surface of the corresponding donor block 
using a permanent marker. 
 
To construct the TMAs, a semi-automatic puncher/arrayer instrument was used 
(Alphelys Minicore Tissue Arrayer, Alphelys SAS, Ferme de Ebisoires, 
France, Figure 2.1). The punching device employs the technology of coaxial 
punches where the donor punch, recipient punch and stylet are concentric 
(Figure 2.2). The TMA cores were 0.6 mm diameter and 3 mm in height. After 
each core was obtained from the donor, the respective block was removed and 
the cycle repeated with the next donor block (Figure 2.3). Each recipient block 
holds 150 TMA cores being spaced 1mm from each other. Additionally three 
cores from control kidney tissue were included in each recipient block at the 
start of each construction in order to assist on orientation. 
 
To perform the different techniques of analyses in histopathology sectioning 
had to be implemented by the use of a standard manual rotary microtome for 
routine paraffin sectioning (Shandon, Finesse 325 Microtome, Thermo 
Scientific, UK) on X-traTM adhesive micro slide (Surgipath, Leica). 
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Figure 2.1 ± Alphelys Minicore Tissue Arrayer used to construct the TMAs showing the main 
mechanisms A) Recipient block holder, B) donor block holder, C) Selector, D) Button to rotate 
E) Punching device. 
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Figure 2.2 ± MiniCore® punching device that employs the expertise of coaxial punches. A) 
donor punch, B) recipient punch and C) style. The reason for this method is to simplify and 
reduce the possibility of misalignment concerning both punches.  
 
 
 
 
 
 
 
 
 
C
A
B
Chapter 2: Methodology 
64 
 
 
 
 
 
 
 
Figure 2.3 ± Tissue Microarrays were constructed using a technique of transferring a sample 
a) IURP D SDWLHQW¶V ZKROH WXPRXU VHFWLRQ b) to a new recipient block possessing multiple 
samples from different patients. c & d) 7KHVHSDWLHQWV¶ Vamples can then be observed in the 
same slide after sectioning and respective staining process (diagram from Sauter et al 2003)336 
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2.3   Immunohistochemistry  
 
 
 
2.3.1 Technique 
 
2.3.1.1 Dewaxing and Rehydration  
Tissue or TMA seFWLRQVPWKLFNQHVVZHUHSODFHGRQWRDÛ&KRWSODWHIRU
10 minutes. Dewax and rehydration was performed automatically device 
(Leica Auto Stainer XL, Leica, Germany) consisting of immersion in 2 
sequential xylene baths for 5 minutes each, proceeded by rehydration by 
immersing in a series of three 100% alcohol baths for 2 min each. Finally the 
slides were left in running tap water for at least for 5 min.  
 
2.3.1.2 Antigen Retrieval 
Sections were submitted to an antigen-retrieval process to unmask the 
antigenic sites, either using Citrate (pH = 6.0) or EDTA (pH = 9.0) buffers. 
This was accomplished placing the respective pre-treatment buffer for 20 min 
using a microwave keeping the temperature always below boiling point 
(Whirlpool 6th sense JT356/JT359, Whirlpool, USA). Then the slides were 
cooled in tap water, for at least 5 minutes, to stop the retrieval process. 
Immunohistochemistry was performed using either Envision (Dako, Denmark) 
or Novolink (Leica, Newcastle, UK) at room temperature. 
 
2.3.1.3 Envision Kit  
Endogenous peroxidase activity was blocked using peroxidase-blocking agent 
(Dako, Denmark) for 5 minutes. Slides were washed well in Tris-Buffered 
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Saline (TBS) and Ultra V Block (Thermo Scientific, USA) was applied and 
incubated for 5 minutes. Each primary antibody, at a specific optimised 
concentration, was added to each slide and incubated for the specific time 
(Table 2.2). Envision A solution (HRP labelled polymer/secondary antibody ± 
Envision Kit) was applied for 30 minutes and then washed in TBS. Envision B 
(Buffer Substrate ± Envision Kit) and Envision C (3,3'-diaminobenzidine 
(DAB) Chromogen ± Envision Kit), mixed to a ratio of 1:50, was added for 5 
minutes. This process was repeated. Finally the slides were washed twice in 
TBS and left for 5 minutes. The slides were counterstained with freshly filtered 
0D\HU¶V KDHPDWR[\OLQ /LOOLH¶V 0RGLILFDWLRQ 'DNR 'HQPDUN IRU  PLQXWHV
and washed well in tap water for 5 minutes.  
 
2.3.1.4 Novolink Polymer Detection Systems (Novolink kit)  
Initially Peroxidase Block (Novolink Kit) was applied onto slide for 5 minutes 
and then washed twice with TBS for 5 minutes. Protein Block (Novolink Kit) 
was added for 5 minutes and again washed twice in TBS for 5 minutes. The 
respective primary antibody was applied at specific concentrations/period of 
time (Table 2.2). Slides were washed in TBS twice for 5 minutes. Subsequently 
Post Primary (Novolink kit) was added for 5 minutes, washed in TBS twice. 
Novolink Polymer (Novolink kit) was added for 30 minutes and the slides 
washed 5 minutes twice in TBS. Finally a DAB working solution, consisting of 
1:20 DAB chromogen in DAB substrate buffer (Novolink kit), was applied for 
5 minutes and the slides washed for 5 minutes twice in TBS. Haematoxylin 
(Novolink kit) was added in a volume of 100 µl for 6 minutes and the slides 
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washed in running tap water for at least 5 minutes in a rack ready to be 
submitted to dehydration in the autostainer machine.  
 
2.3.1.5 Counterstaining, Dehydration and Mounting 
Slides were placed in the Autostainer for dehydration by incubating three times 
for 2 minutes in 100% alcohol and cleared in Xylene for 5 minutes twice. 
Subsequently of a complete dehydration process, the slides were mounted in 
DPX, a viscous solution composed by distyrene, a plasticiser (tricresyl 
phosphate) and xylene.   
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Table 2.2 ± Dilution, Source and pretreatment of antibodies used on both 
immunohistochemistry and in situ proximity ligation assay and the cut-off 
used to classify each biomarker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* H-Score 
8VHGIRULQVLWX3/$ 
 
 
 
 
 
 
 
 
 
Antibody [Clone] Dilution Incubation time (min) Source Cut-off point 
Hormone receptor proteins 
 
ER [SP1] 1:50 30 Dako 0 
 
PgR [PgR 636] 1:125 30 Dako 0 
 
Human epidermal growth factor receptor proteins 
 
EGFR [31G7] 1:30 30 Invitrogen 10 
 
EGFR [EGFR-R2] 1:10 120 Santa Cruz N/A 
 
HER2 1:400 30 Dako 10 
 
HER2 1:200 120 Dako N/A 
 
HER3 [RTJ1] 1:30 30 Leica 10 
 
HER3 [2F12] 1:40 120 Neomarkers N/A 
 
HER4 [H4.77.16] 1:100 30 Neomarkers 10 
 
HER4 [HFR1] 1:50 120 Abcam N/A 
 
p95HER2 1:50 30 
 
10 
 
Luminal associated cytokeratins 
 
CK7/8 [CAM 5.2] 1:2 30 BD 50* 
 
CK18 [DC10] 1:50 30 Dako 50* 
 
Basal cytokeratins 
 
CK5/6 [D5/16 B4] 1:20 30 Dako 10 
 
CK14 [LL002] 1:100 30 Novocastra 10 
 
Cell Cycle associated proliferation and apoptosis related proteins  
 
Ki67 [MB-1] 1:100 30 Dako 10-50* 
 
PI3K  1:50 60 Sigma Aldrich 30-100* 
 
AktpS473 [14-5] 1:10 30 Dako 60* 
 
P21 [SX118] 1:100 30 Dako 0 
 
Bcl-2 [124] 1:100 30 Dako 30 
 
Tumour suppressor genes 
 
PTEN [6H2.1] 1:100 60 Dako 10-100* 
 
P53 [DO7] 1:50 30 Novocastra 5 
 
BRCA1 [MS110] 1:100 40 Calbiochem 100 
 
Apomucins 
 
MUC-1 [MA695] 1:350 30 Novocastra 20-200* 
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2.3.1.6 Microscopy observation and Immunohistochemical scoring 
All the slides were examined using a brightfield microscope (Eclipse 80i, 
Nikon, Japan) with 20x and 40x power magnification. The positive and 
negative controls were observed carefully to approve and accept the 
immunoreactivity. Specific immunoreactivity semi-quantitation was 
considered using intensity, percentage or H-Score using different cut-off (Table 
2.2)337,338. Only cancer cells localised within tissue cores were considered, and 
only those cores revealing at least 15% of the area composed by invasive breast 
cancer cells. TMAs were scored using high-resolution digital images 
(NanoZoomer; Hamamatsu Photonics, Welwyn Garden City, UK), at x20 and 
x40 magnification via a web-based interface (Distiller; Slidepath Ltd, Dublin, 
Ireland). 
 
The intensity of staining was assessed on a range of 0 ± 3: 0 for negative 
staining, 1 for weak staining, 2 for moderate staining and 3 for strong staining. 
The first considerations were accepted as negative and the two higher 
classifications as positive. H-Score was determined by adding the intensity 
score (above) with the percentage of cells stained. Using the following 
formula: 3 x (percentage of cells showing strong staining) + 2 x (percentage of 
cells showing moderate staining) + 1 x (percentage of cells showing faint 
staining) = range 0 ± 300338.  The H-Score system as well as other semi-
quantitative systems was validated for TMAs in previous studies74,339,340. For 
HER2 IHC assessment, The American Society of Clinical Oncologists (ASCO) 
established guidelines were used341. Immunohistochemistry results were 
established as 0 (negative) where a faint membranous immunoreactivity was 
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observed in <10% of the invasive breast cancer cells, 1+ (negative) where 
>10% of the cells present in the tumour showed a barely perceptible 
membranous reactivity, 2+ (equivocal) where >10% of the cells showed 
moderate but complete membranous reactivity, and 3+ (positive) where >30% 
of the cells showed strong complete membranous reactivity.  
 
 
2.4    HER2 Gene amplification 
 
2.4.1 Fluorescent in situ hybridization (FISH) 
 
2.4.1.1 Technique 
This method was carried out using the HER2 ),6+ SKDUP'[ NLW 'DNR
'HQPDUN 7KH DVVD\ ZDV SHUIRUPHG DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V
recommendations. FFPE sections were deparaffinised by xylene for 5 minutes 
twice, ethanol 96% and ethanol 70% for 2 minutes twice and finally rehydrated 
in wash (Tris/HCl) buffer for 2 minutes. The pre-treatment was performed in 
pre-treatment buffer and microwaving for 10 minutes. The slides were cooled 
at RT and rinsed in wash buffer for 3 minutes twice. After pre-treatment the 
slides were submitted to enzymatic digestion, using pepsin incubating at 37°C 
for an optimal 6 minutes followed by being immersed in wash buffer for at 
least 3 minutes twice. Dehydration was performed by immerging the slides in 
70% and 96% ethanol for 2 minutes each and left to air dry. The phase of 
denaturation and hybridisation was performed using 10 µl of probe mix applied 
onto the slide and a coverslip placed added which was sealed around the 
periphery using sealant in order to avoid any drying out during the 
Chapter 2: Methodology 
71 
hybridisation incubation period. The slides were incubated) for denaturation at 
85°C for 5 minutes and hybridisation at 45°C for 20 hours (Dako Hybridiser) 
(Dako, Denmark). Slides were washed using Stringent wash buffer (saline-
sodium citrate) twice, the first was at 65°C for 10 minutes and the second at 
RT for 3 minutes. The slides were dehydrated in 70% and 96% ethanol for 2 
minutes and mounted with fluorescence mounting medium. Slides were 
observed on a fluorescent microscope using DAPI and Texas Red filters 
Axioskop2 (Carl Zeiss, Germany) with Leitz Weltzar 100x/1.25 oil immersion 
lens (Germany). 
 
2.4.2 Chromogenic in situ hybridization (CISH)  
 
2.4.2.1 Technique 
The Dual-colour HER2 &,6+SKDUP'[.LW'DNR'HQPDUNSURWRFROXVHG
is an extension of the HER2 ),6+ SKDUP'[ SURWRFRO KRZHYHU WKH ILQDO
dehydration, air-drying and mounting steps were not performed. Instead, the 
slides were immersed in a CISH wash buffer (TBS solution with 0.05% Tween 
'$.2'HQPDUN IRUPLQXWHV7KH VHFWLRQVZHUHFRYHUHGZLWKȝO
of peroxidase block solution (3% H2O2, 15 mmol/L NaN3) for 5 minutes and 
washed twice in CISH wash buffer for 3 minutes. CISH antibody mix (HRP-
conjugated antibody to FITC and an AP-conjugated antibody to Texas Red in 
50 mmol/L Tris buffer, pH 7.5) (HER2 &,6+ SKDUP'[ .LW ZDV DSSOLHG
onto the section, incubated in a humidified chamber for 30 minutes at RT and 
the slides were rinsed twice in the wash buffer. To visualise the AP-conjugated 
DQWLERGLHV WKH VHFWLRQV ZHUH FRYHUHG ZLWKȝORI UHG FKURPRJHQVROXWLRQ
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(Fast Red KL Salt) (HER2 &,6+SKDUP'[.LWLQDKXPLGFKDPEHUIRU
minutes and washed twice for 3 minutes. Afterwards, to visualise the HRP-
conjugated antibodieVDYROXPHRIȝOEOXHFKURPRJHQVROXWLRQ-amino-2-
[3-[5-amino-1,3-dihydro-3,3-dimethyl-1-(4-sulfobutyl)-2H-indol-2-ylidene]-1-
propenyl]-3,3-dimethyl-1-(4-sulfobutyl)-3H-Indolium, ter-trifluoroacetate) 
(HER2 &,6+ SKDUP'[ .LW ZDV DGGHG WR HDFK VOLGH in a humidified 
FKDPEHUIRUPLQXWHVDQGZDVKHGWZLFHIRUPLQXWHV7KHILOWHUHG0D\HU¶V
KDHPDWR[\OLQ/LOOLH¶V0RGLILFDWLRQ'DNR'HQPDUNGLOXWHGZLWKGLVWLOOHG
or deionised water was applied for 5 minutes onto the sections, rinsed with 
wash buffer and immersed in fresh wash buffer for at least 5 minutes. Slides 
were rinsed thoroughly with distilled water and dried at 37°C for 30 minutes, 
mounted with permanent xylene-free mounting media (Tissue-0RXQW
Sakura Finetek Europe B.V.) and evaluated using as a brightfield microscope 
at Axioskop2 (Carl Zeiss, Germany) with Leitz Weltzar 100x/1.25 oil 
immersion lens (Germany). 
 
2.4.2.2 Scoring HER2 gene amplification  
The evaluation of the dual-colour FISH or CISH slides were performed 
according to the guidelines complementing the HER2 ),6+ SKDUP'[ .LW
(Dako, Denmark). For all tumour specimens the HER2 signals (red) and CEN-
17 signals (green for FISH or blue for CISH) from 20 nuclei in invasive breast 
cells were counted and the HER2/CEN-17 ratios were calculated. All signals of 
similar size detached from each other by a gap equivalent or less than the 
diameter of one signal were counted as only one signal. Furthermore those 
cells revealing only one of the colours were ignored and not included on this 
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study. The cases where the ratio result was below 2 were classified as HER2 
non-amplified. On the other hand the carcinomas showing a ratio of 2 or higher 
were accepted as HER2 amplified. However when a ratio value between 1.8 
and 2.0 was observed, the samples were submitted to a recalculation by scoring 
a further 20 nuclei to obtain an additional rate, resulting in a final mean value 
between both ratios. 
 
2.5   HER2 heterodimerisation quantification analysis  
 
2.5.1 Duolink® in situ Proximity Ligation Assay (PLA) 
 
2.5.1.1 Overview 
HER2 protein overexpression and gene amplification are the current methods 
to discriminate those breast cancer cases to trastuzumab therapy. However 
semi-quantitative methods, such as IHC, might not be adequate and/or 
sufficient to achieve high levels of therapy success for HER2 overexpressing 
breast cancers. Thus, accurate quantification of protein expression and other 
characteristics such as type 1 growth factor receptor heterodimerisation could 
be important to elucidate their roles for detailed biological outcome. The action 
of these molecules is controlled by a complex system that includes structures 
modifications or connections with other molecules such as ligands; the 
consequence heterodimer arrangements will trigger different pathways and 
consequently different outcomes30,31. Protein interaction measurements can be 
used to explore sub-cellular processes, and can serve to reveal molecular 
pathways to be targeted for pharmaceutical intervention. Currently, protein 
interactions are being investigated to understand processes at cellular 
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dimension helping to disclose both upstream and downstream pathways, which 
might be used to achieve better diagnosis and consequently successful 
therapies.  
To detect, visualise and quantify protein expression or protein interactions, it is 
used Duolink® in situ proximity ligation assay (PLA) for brightfield 
microscope (Olink, Sweden). With this technique it is feasible to identify 
distinct signals that symbolise distinct proteins, protein interactions or even 
protein alterations such as phosphorylation. In order to achieve an effective 
detection, the approach is to generate certain DNA representations with the 
assistance of specific antibodies. This method allows detection of specific 
proteins after a polymerase chain reaction is created to amplify a DNA 
molecule. This technique needs two specific primary antibodies that identify 
the protein target or protein interaction target. These detections are possible 
once a primary antibody of different species suitable for detection of each 
protein is available82. The detection is performed using primary antibodies 
from different species against each protein followed by incubation with 
species-specific secondary antibodies, which are linked to an oligonucleotide 
chain (PLA probes). Each of these probes is linked with a   short DNA strand. 
One of the secondary antibodies is linked to a minus probe and the second to a 
plus probe. The minus probe is merely a complementary DNA sequence of the 
plus probe, which will act as a template for DNA amplification. After 
incubation with the antibodies, a hybridisation reaction will occur, however 
only successfully achieved if both probes are close enough (<40 nm) revealing 
protein interaction. Within this distance both DNA strands are able to interact 
within a following addition of a circle-forming DNA oligonucleotide. To 
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visualise the discrete signals, a ligation, amplification (via rolling circle 
amplification - RCA) and detection reactions must occur. The circular 
molecule is used as an infinite template for RCA. The amplification reaction is 
primed in one of the PLA probes and by the end of the first circle  (the end of 
the second PLA probe) the polymerase dislocates the new DNA strand, 
resulting in the production of a single stranded DNA. The detection reaction is 
characterised by hybridisation of the horseradish peroxidase (HRP) labelled 
complementary oligonucleotides with the rolling-circle DNA product. Finally 
the signal is possible to visualise as a individual brown blob throughout an 
enzymatic conversion of NovaRED substrate, being possible to detect with a 
standard microscope  (Figure 2.4)83. 
 
Figure 2.4 ± Duolink® in situ proximity ligation assay (PLA). A) Double binding of PLA 
probes (secondary antibodies linked to oligonucleotide strands) to primary antibodies (not 
represented) already connected onto respective protein target. B) Hybridisation is characterised 
by addition of a connector oligonucleotide that will react with the PLA probes only in case 
they are in close proximity. C) After ligation, rolling-circle amplification (RCA) takes place 
resulting in a concatemeric repeated sequence. D) Hybridising this sequence with horseradish 
peroxidase (HRP) labelled oligonucleotides and perform an enzymatic reaction with NovaRed 
substrate the signals become visible under brightfield microscope.    
 
A 
D 
C 
B 
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2.5.1.2 Technique 
Quantification of HER2 heterodimers in primary invasive breast cancer cases 
was performed using in situ PLA for brightfield microscope (Olink, Sweden). 
FFPE sections were deparaffinised and rehydrated as above followed by heat 
induced antigen retrieval for 20 minutes using the respective buffers (Table 
2.2) followed by peroxidase quenching using 0.3% hydrogen peroxide for 5 
minutes at RT and
C 
in a humidity chamber. To detect any heterodimer, two antibodies from two 
different species were applied. For all HER2 heterodimers, the anti-HER2 
antibody (Dako, diluted at 1:200) was used. In case of HER2/HER3 
heterodimer, anti-HER3 (clone 2F12, Neomarkers, diluted at 1:40) was used, 
which was incubated for 30 min at RT. For HER2/EGFR the anti-EGFR 
antibody (clone EGFR-R2, Santa Cruz, diluted at 1:10) was used whereas for 
the HER2/HER4 heterodimer, anti-HER4 antibody (clone HFR1, abCam 
diluted at 1:50) was used. Both were incubated for 60 minutes at RT. Slides 
were rinsed with Wash Buffer A for 2 x 5 min under gentle agitat -
- C. 
Again the slides were washed with Wash Buffer A for 2 x 5 min under gentle 
agitation. Applied oligonucleotides hybridise to both PLA probes during 
Hybridisation and Ligation incubation, which took place for 30 minutes at 
Û& 6OLGHV ZHUH ZDVKHG ZLWK :DVK %XIIHU $ IRU  [  PLQ XQGHU JHQWOH
agitation and amplification, performed by appliance of nucleotides and 
SRO\PHUDVHWRRNSODFHIRUPLQXWHVDWÛ&7RGHWHFWWKHsignals, all slides 
were washed with Wash Buffer A for 2 x 2 min under gentle agitation and 
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submitted to a detection stage using Horse Radish Peroxidase (HRP) labelled 
probes incubated for 30 minutes at RT followed by substrate solution for 10 
minutes at RT. Subsequently the slides were washed with Wash Buffer A for 2 
x 2 min under gentle agitation and the nuclear staining was performed using 
Duolink nuclear staining for 2 min at RT and washing the slides under running 
tap water for 10 min. To finish slides were mounted using Duolink® in situ 
Brightfield Mounting Medium (Duolink, Sweden) after dehydration process 
already mentioned above. 
 
2.5.1.3 Image analysis 
To quantify the HER heterodimers in breast cancer cells the software Duolink 
ImageTool® (Olink, Sweden) adapted to brightfield version (Figure 2.5) was 
employed. High-resolution digital images at 40x were obtained using high 
definition digital camera (Digital Sight-DS-SM, Nikon, Japan), three images 
were obtained from each case and exported to be analysed using Duolink 
ImageTool®. Different variables, such as total number of signals in nuclei, 
total number of signals in cytoplasm, total number of signals, total number of 
cells, region of interest area (ROI), were achieved through the bioinformatics 
software (Table 2.3). An average three analysis for each case was obtained for 
the number of signals per cell and used for all statistic analysis.  
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Figure 2.5 ± Duolink Image Tool Analysis for brightfield microscopy. One of the three 
images for the case 3183 is represented showing the area of interest selected for the analysis.  
 
 
 
Table 2.3 ± Example of summary of the results exported (case number 2895) from Duolink 
Image tool including calculation performed by the researched (highlighted), obtaining final 
average number of signals per cell used on statistical studies.  
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2.5.1.4 Quantification of HER family interactions using in situ PLA 
After following the in situ PLA methods explained above we acquired 
visualisation under brightfield microscope of HER2 protein expression by 
using two PLA probes against the same primary antibody (PLA detection of 
single protein). However HER2+ cases are characterised by overexpression of 
this monomer, which turns impossible to distinguish any individual blob 
representing each protein structure. Both human eyes and the software 
available were not skilled enough to distinguish and quantify each blob (Figure 
2.6A). Therefore it was possible to understand that this innovative technique 
possesses some limitations, when concerns single protein expression 
quantification.   
 
In Figure 2.6B is possible to observe the detection of HER3 monomer, revealing 
as an example that displays distinguishable blobs possible to quantify due to 
lowers levels comparing with HER2+ cases. Therefore detection of dimers 
such HER2/HER3, will be quantifiable due to the low number of HER3 
monomer that limits the quantity of blobs possible to observe and quantify. 
Furthermore heterodimerisation is not a cellular physical structure but a 
reaction dependent on several molecules. Therefore any signal detected only 
represents reactions that were occurring at that moment, which reduces the 
number of signals and the possibility of quantification (Figure 2.6C).  
 
This technique had to be adapted and optimised to our study. Antibodies 
concentrations were submitted to several trials until individual and cancer 
specific discreet signals were observed. The background was also an issue and 
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was reduced by using double volume of wash buffer and lower antibody 
concentrations.  
 
During every PLA procedure negative controls were characterised by the 
absence of only one primary antibody. These samples were observed 
cautiously in order to find whether any false reaction occurred and accept the 
PLA reaction results. 
 
 
 
Figure 2.6 ± in situ Proximity Ligation Assay (PLA) analysis. Examples of breast 
cancer cells revealing detection of single proteins and proteins interactions by 
hybridisation of chromogenic labelled oligonucleotides; the brown/red signals represent 
the specific event for each case. A) in situ PLA using primary antibody against HER2 
only and impossible to be quantified due to signal distinguish impossibility. B) in situ 
PLA using primary antibody against HER3 only. C) in situ PLA using primary 
antibodies against both HER2 and HER3, being revealed only the dimerisation events. 
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2.6   Statistical analyses  
 
2.6.1 Correlation Analyses 
Relationship between different variables was performed using Spearman rank 
order correlation in order to understand the strength and direction of the linear 
correlation 3HDUVRQ¶V FKL-square association ( 2) test was also employed to 
verify the independency used to relate frequencies amongst the various 
parameters across the frequencies of another variable. Kappa (ț) measurement 
was employed to understand the concordance between scores of the same 
variable in order to validate the method used342.  
 
2.6.2 Survival Analyses 
The Kaplan-Meier method was used to determine the Breast Cancer Specific 
Survival (BCSS) and Disease Free Interval (DFI) analyses. The respective 
significances were determined by the log-rank test343. This type of analysis 
stipulates an evaluation of the fraction surviving to a separately period of time. 
By relating the survival curves of either two or more patient clusters, the 
statistical disparity amongst the groups replicated the probability that the 
detected variances could happen by chance. Multivariate analyses operating 
Cox proportional hazard regression model344 was applied to determine the 
influence of the HER2 monomer and HER heterodimers, adjusting to different 
variables, on BCSS and DFI. It was assessed the proportional hazard regression 
models of each covariate individually (tumour size, tumour grade and tumour 
stage). 
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All statistical analyses were performed using Statistical Package for the Social 
Sciences (SPSS 19.0 Inc. for Windows, Chicago, Illinois). Frequency 
histograms were examined to group the expression groups, which were used 
throughout the analyses. All p-values of <0.05 (two-sided) was considered 
statistically significant. 
 
2.6.3 Cut-off points 
To select the ideal cut-off it was used X-tile bio-informatics software (version 
3.4.7. Robert L Camp, 2005). The ideal cut-off point for each biomarker or 
heterodimers reaction was achieved with the p-value and relative risk against 
BCSS345. To evade the issue of achieving several cut-points, X-Tile executes 
standard Monte Carlo cross-validation in order to achieve accurate p-values345.  
The cut-off values presented in Table 2.2 for EGFR, HER3, HER4, ER, PgR, 
CK7/8, CK18, CK5/6, CK14, p21, Bcl-2, p53, BRCA1 and MUC-1 have been 
previously described346. The values of Ki67 cut-off were also previously 
determined by a different project347.     
 
2.7   Ethics 
 
Nottingham Research Ethics Committee 2 approved this research project under 
WKH WLWOH RI ³'HYHORSPHQW RI D PROHFXODU JHQHWLFV FODVVLILFDWLRQ RI EUHDVW
FDQFHU´ 
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3. CHAPTER 3: The clinical relevance of HER2 and 
p95HER2 in breast cancer 
 
3.1 Introduction 
 
 
3.1.1 HER2 in breast cancer 
HER2 overexpression and gene amplification is detected on 10%-23% of total 
breast cancer cases being described as HER2 positive breast cancers21,348,349. 
These cases reveal very poor prognosis, however can benefit from a specific 
treatment by using a monoclonal antibody, trastuzumab, which interacts 
specifically with cell overexpressing HER2 protein130.   
 
3.1.2 Clinical determination of HER2 in breast cancer  
Analysis of HER2 amplification and overexpression in patients with breast 
cancer is essential for an appropriate clinical assessment; moreover it is 
decisive in categorising patients that are suitable to receive trastuzumab 
treatment. Though some discordance is noted between immunohistochemistry 
(IHC) that evaluates protein overexpression and Fluorescent in situ 
Hybridisation (FISH) that classifies levels of gene amplification350,351. 
Guidelines have been established by the College of American Pathologists 
(CAP), American Society of Clinical Oncologists (ASCO) and by the UK NHS 
Breast Screening Programme for diagnostic laboratories to determine an 
accurate and comparable HER2 status in breast tumours86,352. 
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Immunohistochemistry 
HER2 assessment using IHC in routine FFPE tissues has several advantages in 
clinical diagnostics. With this relatively economical procedure is possible to 
preserve the tissue morphology and to identify areas with higher expression in 
situ, which is important for classification in heterogeneous samples. Even 
though this technique requires standardisation in terms of methodology as type 
of tissue fixation353, type of antibody and its concentration354, and incubation 
time amongst other variables to avoid inconsistency, it produces reliable 
results.  
 
Fluorescent in situ Hybridisation 
FISH technology evaluation is well established for identification of denatured 
specific DNA sequences using fluorescently labelled complementary probes. 
Using this technique it is possible to visualise gene amplification, 
translocations or even deletions. Determination of such gene aberrations that 
occur in cancer cells, make possible the understanding of the prognosis and 
direct the patient to a specific therapy355. FISH is utilised in routine 
laboratories to detect gene amplification in those cases with moderate HER2 
protein overexpression356. This is particularly important as only those breast 
carcinomas designated as IHC 2+ (equivocal) that also show gene 
amplification will possibly benefit from trastuzumab168. However FISH results 
are greatly affected by fixative techniques and the morphology of the cells is 
not perceptible scoring process357,358.   
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Chromogenic in situ Hybridisation  
Chromogenic in situ Hybridisation (CISH) has emerged over the last few years 
as an alternative to FISH and is based on a simple bonding reaction of a 
specific targeted probe to an enzymatic indicator for chromogenic reaction ± 
horseradish peroxidase (HRP). Peroxidase reaction only requires brightfield 
microscopy, a common instrument in all pathological laboratories unlike the 
more expensive fluorescent equipment, which also requires specific expertise 
to evaluate. CISH, in similarity to FISH, can incorporate dual-colours, which 
allows comparison to a centromeric probe (Figure 3.1). Moreover this dual-
colour method is more reliable when compared with one-colour version due to 
being able to accurately distinguish real amplification from aneuploidy. 
Additionally a chromogenic reaction is more permanent whereas fluorescent 
signals are lost within days/weeks 359 and the cells morphology is perceptible 
not being necessary an expertise to perform a plausible scoring 358. 
 
3.1.3    p95HER2 or HER2 carboxy terminal fragment 
p95HER2 or the HER2 carboxy terminal fragments (CTFs) is a HER2 active 
fragment that might become a unique biomarker identifying a subtype of HER2 
(p185HER2) positive breast cancer with exclusive biological and prognosis 
characteristics173,360. p95HER2 is related with resistance to trastuzumab treatment 
due to lack of ectodomain, which is crucial for trastuzumab to attach175. 
 
There are two mechanisms that instigate p95HER2 creation: a proteolytic 
shedding of the ectodomain of HER2 protein or by translation of mRNA 
encoding of internal codons166,361. The exclusion of the ectodomain is carried 
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out by the metalloprotease ADAM10 ( -secretase), results in a membrane 
p95HER2 molecule (648-CTF) of 95 to 100 kDa362,363 (Figure 3.1). The 
translation process results in two different types of p95HER2 fragment, the 611-
CTF and the 687-CTF, which are respectively 100 to 115 kDa and 90 to 95 
kDa. Their names are linked with the codons where the translation process 
begins. The extra 76 amino acids in 687-CTF results in the possession of a 
transmembrane domain and a small cysteine-rich ectodomain361. Additionally 
687-CTF and 611-CTF are different in their potency of reaction, 611-CTF has 
activity highly similar to the full length HER2 but is considerably more 
reactive to trigger downstream pathways179. Moreover the efficiency of driving 
cell migration is much higher by this hyperactive fragment when compared 
with the HER2 (p185) molecule364. Even though these HER2 structures are 
small and abnormal, it does not avoid holding into the cellular membrane, 687-
CTF may also be detected in the cytoplasm361. The main difference amongst 
these two small fragments resides in the presence of 5 cysteine located on the 
diminutive ectodomain of 611-CTF. These cysteines form disulphide bonds 
and therefore the activated homodimer is conserved by covalent bonds179. The 
fragment 687-CTF, is not activated in the same way due to it not possessing 
any cysteines in the ectodomain, which does not encourage dimerisation42. 
Moreover this small member, 687-CTF, also may react with HER2174.  
 
611-CTF expression has been suggested to be able to discriminate a subclass of 
HER2 amplified breast cancers, which possess a clear and particular biological 
and clinical outcome365. The frequency of ER positivity amongst 611-CTF 
positive cancer cells, compared with HER2 positive, is considerably lower 
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reaching only 30%365,366. The same p95HER2 fragment is highly associated with 
metastasis localised in lungs, moreover the relapse time and survival time were 
considerably shorter when compared with full length HER2 positive 
carcinomas366. Comparing both highly reactive forms of p95HER2, 611-CTF and 
648-CTF, the first triggers not only proliferative signalling pathways like 
Akt179  but also cell migration364 as it tends to form homodimers by disulphide 
bonds. Conversely, 648-CTF does not form homodimers and therefore its 
reactions are vey similar to those develop by HER2173.   
 
p95HER2 is a very reactive molecule166 and easily reacts with identical 
molecules forming homodimers179. All this high reactivity might be associated 
with the lack of ectodomain, which might perform as a deplete factor on 
development of heterodimers367. Therefore and as expected cases expressing 
p95HER2 molecules are associated with worse outcome and metastasis 
development when compared with those patients overexpressing HER2173. 
 
The current system of HER2 breast cancer classification has been revealing 
lack of accuracy on diagnosis and therefore selection of patients to be 
submitted to trastuzumab need an even more specific classification. This way 
in this chapter by characterising HER2 amongst both series it is hypothesised 
that some variances on HER2 classification might reveal different prognosis or 
even development of resistance under trastuzumab therapy.  In this chapter it is 
going to be analysed the correlation between IHC and CISH, and understand 
outcome among different HER2 status, paying more attention to amplified or 
not amplified cases. Moreover we will give a special attention on survival 
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RXWFRPH LQ +HUFHS7HVW  FDVHV ERWK DPSOLILHG DQG QRW DPSOLILHG. 
Additionally examining p95HER2 status amongst these series might reveal to be 
DQDGGLWLRQDOPDUNHUWKDWVLJQLILFDQWO\LPSDFWVRQ+(5SDWLHQWV¶RXWFRPH 
 
 
 
 
 
Figure 3.1 ± (From left to right) The structure of p95HER2 (611-CTF) 
originated by expression of a codon localised in position 611, the structure of 
full length HER2 or p185HER2 and the structure of p95 HER2 created by 
cleavage process of a p185hER2 molecule and does not possess any 
ectodomain substructure. Trastuzumab is not able to interact with any 
structure without the entire ectodomain. The anti-p95HER2 antibody is able to 
interact with the epitopes localised in 100-115kDa, which are masked in the 
full length HER2 molecule.  
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3.2 Methods 
 
Two breast cancer series were analysed for HER2: Unselected series (n = 
1858) and the HER2+ trastuzumab adjuvant series (n = 143). The methodology 
including immunohistochemical detection, in situ hybridisation and pre-
treatments are described in chapter 2 and it was performed in TMAs for both 
series, with exception for Ki67, which had to be performed in full sections to 
detect the hotspot of the tumour, i.e., the high proliferative regions. 
Additionally the classification method for HER2 protein expression and gene 
amplification is also described in chapter 2. The p95HER2 IHC scoring was 
performed in the same way as HER2 (p185) due to similar membrane staining. 
Therefore four groups were obtained on p95HER2 scoring, classified as weak 
staining (negative) or as strong staining (positive). 
 
3.3 Results 
3.3.1 HER2 expression in breast cancer 
In the Unselected series of breast cancers, a total of 1604 (86.3%) cases 
showed negative (0) or very weak (1+) membrane protein expression, 180 
(9.7%) cases show overexpression of HER2 (3+) protein and were classified as 
HER2 positive. The remaining 74 (4.0%) cases were classified as borderline or 
equivocal (2+) due to revealing a weak to moderate protein expression. In the 
HER2+ Trastuzumab series, 30/143 (21%) cases were scored as equivocal and 
113/143 (79%) cases were classified as positive. All the equivocal cases 
revealed HER2 gene amplification as well and therefore classified as HER2+ 
(Figure 3.2). 
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Figure 3.2 ± Immunohistochemistry analysis. Detection of HER2 protein expression in breast 
FDQFHU FRUHV E\ LPPXQRKLVWRFKHPLVWU\ +HUFHS7HVW DQG VFRUHG DFFRUGLQJ WR $PHULFDQ
Society of Clinical Oncology guidelines. The cells were labelled with a specific antibody 
against HER2 to detect the intensity of expression of this protein present in the cell membrane. 
The cells are scored in four different classes of protein expression: (A) 0 when a faint 
membranous immunoreactivity was observed in less than 10% of the cancer cells, (B) 1+ when 
more than 10% of the invasive carcinoma cells show a barely perceptible membranous 
reactivity, (C) 2+ when more than 10% of the tumour cells show moderate but incomplete 
membranous reactivity, and (D) 3+ when more than 30% of the cells show strong and complete 
membranous reactivity. 
 
 
 
 
Figure 3.3 ± Chromogenic in situ hybridization (CISH) detection of HER2 gene amplification 
in breast cancer cells. A ± Breast cancer cells revealing no HER2 amplification (HER2/CEN17 
ratio < 2). B ± Breast cancer cells revealing HER2 gene amplification (HER2&(1UDWLR
2). 
A B 
C D 
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3.3.2 HER2 amplification in breast cancer  
A total of 1115 Unselected cases were available for HER2 amplification 
analysis determined by CISH (Figure 3.3). Amongst them 163 (14.6%) cases 
VKRZHG +(5&(1   DQd were deemed cases that had HER2 
amplification and the remaining 952 (85.4%) cases were not amplified for 
HER2 (Table 3.1). 
 
 
3.3.3 HER2 status in breast cancer 
HER2 protein expression data was analysed against HER2 ratio data to define 
the HER2 status as positive or negative according to ASCO guidelines, even 
though in this project CISH was used instead of FISH. Within the borderline 
cases from the Unselected series, a total of 30/74 (40.5%) do not reveal gene 
amplification and were classified as negative. Therefore a total of 1634 cases 
(87.9%) in the Unselected Series were deemed HER2 negative whereas 224 
(12.1%) were HER2 positive (Table 3.1). These cases formed the HER2 
trastuzumab naïve series. Combining the HER2 trastuzumab naïve series and 
the HER2 trastuzumab series, it resulted in the HER2+ series consisting of 367 
tumours. 
 
3.3.4 Correlation between HER2 expression with HER2 amplification  
There was a significant correlation between HER2 protein expression and 
HER2 gene amplification determined by CISH (p < 0.001). Among the 952 
(85.4%) HER2 non-amplified carcinomas, only one case (0.1%) was associated 
with overexpression of the protein. A total of 921 (96.7%) HER2 non-
amplified samples were associated with negative HER2 protein expression (0 
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or 1+) and 30 (3.2%) cases that showed an equivocal protein expression were 
non-amplified.  In contrast, only three cases (1.8%) amongst a total of 163 
HER2 amplified cases demonstrated negative HER2 protein expression. 
Nevertheless a total of 160 (98.2%) cases exhibiting HER2 amplification were 
associated with moderate to strong HER2 protein expression (Table 3.1). 
 
 
 
 
 
Table 3.1 ± Relation between HER2 protein expression and HER2 gene amplification in 
breast cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 HER2 IHC  
 0+ 
(%) 
1+ 
(%) 
2+ 
(%) 
3+ 
(%) 
Total 
(%) 
P value 
(Chi-Square) 
HER2 CISH (Ratio)               
Non-Amplification 756 (100) 
165 
(98.2) 
30 
(40.5) 1 (0.9) 
 
952 
(85.4) 
<0.001 
(940.539) 
Amplification 0   (0.0) 
3 
(1.80) 
44 
(59.5) 
116 
(99.1) 
 
163 
(14.6) 
Total 756 (100) 
168 
(100) 
74 
(100) 
117 
(100) 
 
1115 
(100) 
HER2 Status       
Negative 1329 (100) 
275 
(100) 
30 
(40.5) 
0  
(0.0) 
 
 
1634 
(87.9) 
<0.001 
(1689.758) 
Positive 0 (0.0) 0 (0.0) 44 (59.5) 
180 
(100) 
 
224 
(12.1) 
Total 1329 (100) 
275 
(100) 
74 
(100) 
180 
(100) 
 
1858 
(12.1)  
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3.3.5 Correlation of HER2 protein, HER2 amplification and HER2 status with 
clinicopathological parameters 
Overexpression of HER2 protein in the Unselected series was associated with a 
higher tumour stage (p = 0.002), larger tumour size (p = 0.006) higher tumour 
grade, more nuclear pleomorphism, higher mitotic frequency, less tubule 
formation and presence of distant metastases (all p < 0.001). HER2 protein 
overexpression was also significantly associated with poor NPI prognostic 
groups (p < 0.001) and death due to breast cancer (p < 0.001). The age of the 
patients did not reveal significant association with HER2 overexpression (p = 
0.149) (Table 3.2). 
 
There was a highly significant association between HER2 protein 
overexpression and histological tumour type where the majority of cases were 
invasive ductal carcinoma (p < 0.001) (Table 3.4 and Table 3.5) 
 
As expected, the presence of HER2 amplification and HER2 positive status 
showed similar significant associations with the same parameters as HER2 
protein overexpression (Table 3.3).  
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Table 3.2 ± The relation between HER2 protein expression with clinicopathological 
parameters. 
 
 
Parameters 
 HER2 IHC 
 0+  (%) 1+  (%) 2+  (%) 3+  (%) p value (Chi-Square) 
Tumour Grade 
 
    
 
1 
 
280  (21.2) 65 (23.8) 4 (5.4) 5 (2.8) 
<0.001  
(139.041) 
2 
 
457 (34.5) 115 (42.1) 21 (28.4) 23 (12.8) 
3 
 
586 (44.3) 93 (34.1) 49 (66.2) 152 (84.4) 
  
    
 Tubule Formation 
 
    
 
1 
 
101 (7.9) 14 (5.5) 2  (2.8) 2 (1.1) 
<0.001   
(42.934) 
2 
 
421 (32.8) 107 (42.1) 19  (26.4) 36  (20.3) 
3 
 
762 (59.3) 133 (52.4) 51  (70.8) 139 (78.5) 
  
    
 Pleomorphism 
 
    
 
1 
 
43  (3.4) 8  (3.2) 0  (0.0) 0 (0.0) 
<0.001  
(103.870) 
2 
 
556 (43.4) 126  (49.8) 17  (23.6) 19 (10.9) 
3 
 
681 (53.2) 119  (47.0) 55  (76.4) 156 (89.1) 
  
    
 Mitotic Frequency 
 
    
 
1 
 
550 (42.8) 113 (44.5) 8  (11.1) 13  (7.3) 
<0.001  
(125.939) 
2 
 
213 (16.6) 57  (22.4) 18 (25.0) 34  (19.2) 
3 
 
521 (40.6) 84  (33.1) 46  (63.9) 130  (73.4) 
  
    
 Tumour Stage 
      
1 
 
861  (65.0) 188  (68.9) 41  (55.4) 97 (54.2) 
0.002 
(20.938) 
2 
 
363  (27.4) 62 (22.7) 26  (35.1) 54 (30.2) 
3 
 
101 (7.6) 23  (8.4) 7  (9.5) 28 (15.6) 
  
    
 Distant Metastasis 
 
    
 
Negative 
 
956  (72.4) 195  (70.9) 40  (55.6) 97 (53.9) <0.001   
(32.977) Positive 
 
364  (27.6) 80  (29.1) 32  (44.4) 83 (46.1) 
 
 
    
 Local Recurrence 
 
    
 
Negative 
 
812 (62.9) 161 (59.2) 50 (47.2) 86 (48.6) <0.001 
(21.474) Positive 
 
479 (37.1) 111 (40.8) 56 (52.8) 91 (51.4) 
 
 
     Regional Recurrence 
 
     
Negative 
 
1182 (91.6) 236 (86.8) 91 (85.8) 154 (87.0) 0.015 
(10.499) Positive 
 
109 (8.4) 36 (13.2) 
 
15 (14.2) 23 (13.0) 
 
 
     Tumour Size 
 
     
<1.5cm 
 
371 (28.0) 68 (24.9) 15  (20.3) 30  (16.7) 0.006 
 (12.326) 
 
FP 
 
953  (72.0) 205 (75.1) 59 (79.7) 150 (83.3) 
 
 
    
 Vascular Invasion 
 
    
 
Negative 
 
779 (59.9) 149 (54.6) 37 (51.4) 96 (53.9) 0.128  
(5.679) Positive 
 
522 (40.1) 124 (45.4) 35 (48.6) 82 (46.1) 
 
 
    
 NPI 
 
    
 
Good 
 
481 (36.7) 112 (41.5) 13 (18.3) 14 (7.9) 
<0.001 
(84.845) Moderate  644 (49.2) 137 (50.7) 44 (62.0) 116 (65.5) 
Poor 
 
187 (14.3) 21 (7.8) 14 (19.7) 47 (26.6) 
 
 
    
 Age 
 
    
 
<50 
 
413 (31.1) 93 (33.5) 44 (39.3) 67 (37.0) 0.149 
(5.337)   
 
915 (68.9) 185 (66.5) 68 (60.7) 114 (63.0) 
 
 
    
 Death  
 
    
 
Negative 
 
776 (72.1) 156 (67.5) 32 (50.8) 79 (50.6) <0.001  
(38.727) 
 
Positive 
 
300 (27.9) 75 (32.5) 31 (49.2) 77 (49.4) 
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Table 3.3 ± The relation between HER2 gene amplification and HER2 status in breast cancer 
with clinicopathological parameters. 
 
 
Parameters 
 HER2 CISH  HER2 Status 
 <2  (%) (%) p value  (Chi-Square)  Neg  (%) Pos (%) p value  (Chi-Square) 
Tumour Grade         
1  171  (18.0) 3    (1.9) 
<0.001  
(82.018) 
 349  (21.5) 5     (2.2) 
<0.001  
(131.835) 2  346  (36.5) 23  (14.4)  583  (35.9) 33  (14.7) 
3  432  (45.5) 134  (83.8)  694  (42.7) 186  (83.0) 
         Tubule Formation         
1  51  (5.6) 1    (0.6) 
<0.001  
(19.952) 
 117  (7.5) 2    (0.9) 
<0.001  
(36.135) 2  318  (34.8) 35  (22.2)  537  (34.2) 46  (20.8) 
3  546  (59.7) 122  (77.2)  912  (58.2) 173  (78.3) 
         Pleomorphism         
1  21  (2.3) 0    (0.0) 
<0.001  
(63.542) 
 51   (3.3) 0    (0.0) 
<0.001  
(100.475) 2  393  (43.0) 18  (11.5)  692  (44.3) 26  (11.9) 
3  499  (54.7) 138  (88.5)  818  (52.4) 193  (88.1) 
         Mitotic Frequency         
1 
 
 359  (39.2) 9    (5.7) 
<0.001  
(73.209) 
 669  (42.7) 15  (6.8) 
<0.001  
(117.730) 2  156  (17.0) 29  (18.4)  279  (17.8) 43  (19.5) 
3  400  (43.7) 120  (75.9)  618  (39.5) 163  (73.8) 
         Tumour Stage         
1  587  (61.9) 90  (56.6) 
0.037  
(6.594) 
 1065  (65.4) 122  (54.7) 
<0.001  
(17.296) 2  279  (29.4) 45  (28.3)  438  (26.9) 67  (30.0) 
3  82  (8.6) 24  (15.1)  125  (7.7) 34  (15.2) 
         Distant Metastasis         
Negative  655  (69.3) 85  (53.1) <0.001  
(16.208) 
 1166  (71.8) 122  (54.5) <0.001  
(28.165) Positive  290  (30.7) 75  (46.9)  457  (28.2) 102  (45.5) 
         Local Recurrence         
Negative  985 (61.9) 108 (48.9) <0.001 
(13.875) 
 548 (59.3) 75 (47.5) 0.005 
(7.743) Positive  605 (38.1 113 (51.1)  376 (40.7) 83 (52.5) 
         Regional Recurrence         
Negative  1440 (90.6) 193 (87.3) 0.130 
(2.292) 
 827 (89.5) 137 (86.7) 0.298 
(1.084) Positive  150 (9.4) 28 (12.7)  97 (10.5) 21 (13.3) 
         Tumour Size         
<1.5cm  231 (24.1) 27  (16.9) 0.039  
(4.276) 
 446  (27.4) 38  (17.0) 0.001  
(11.130) FP  718  (75.7) 133  (83.1)  1181  (72.6) 186  (83.0) 
         Vascular Invasion         
Negative  523 (55.8) 84 (53.2) 0.535 
(0.385) 
 943 (58.8) 118 (53.4) 0.125 
(2.357) Positive  414 (44.2) 74 (46.8)  660 (41.2) 103 (46.6) 
NPI         
Good  316 (33.7) 12 (7.7) 
<0.001 
(31.4) 
 602 (31.4) 18 (31.4) 
<0.001 
(31.4) Moderate  481 (51.2) 104 (66.7)  798 (31.4) 143 (31.4) 
Poor  142 (15.1) 40 (25.6)  211 (31.4) 58 (31.4) 
         Age         
<50  315 (32.6) 58 (35.6) 0.460 
(0.545) 
 519 (31.8) 82 (36.6) 0.148 
(2.095)   650 (67.4) 105 (64.4)  1114 (68.2) 142 (63.4) 
         Death          
Negative  536 (68.6) 69 (49.3) <0.001 
(19.711) 
 945 (71.0) 98 (50.3) <0.001 
(33.828) Positive  245 (31.4) 71 (50.7)  386 (29.0) 97 (49.7) 
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Table 3.4 ± HER2 protein expression with histological tumour type. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.5 ± HER2 gene amplification and HER2 status association with histological 
tumour type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tumour 
Histology 
 HER2 IHC 
 
0+ (%) 1+ (%) 2+ (%) 3+ (%) p Value (Chi-Square) 
Ductal 
 
687 (52.8) 135 (50.4) 85 (75.9) 155 (87.6) 
< 0.001 
(119.400) 
Lobular  
 
170 (13.1) 31 (11.6) 5 (4.5) 1 (0.6) 
Medullar  
 
33 (2.5) 4 (1.5) 2 (1.8) 7 (4.0) 
Mixed  
 
83 (6.4) 15 (5.6) 8 (7.1) 4 (2.3) 
Other  
 
38 (2.9) 5 (1.9) 1 (0.9) 0 (0.0) 
Tubular  
 
289 (22.2) 78 (29.1) 11 (9.8) 10 (5.6) 
Total  
 
1300 (100) 268 (100) 112 (100) 177 (100) 
Tumour 
Histology 
 
HER2 CISH Ratio  HER2 Status 
 < 2 (%) (%) p Value (Chi-Square) 
 
Neg (%) Pos (%) p Value (Chi-Square) 
Ductal  510 (54.1) 140 (87.0) 
< 0.001 
(68.048) 
 838 (52.5) 193 (87.7) 
< 0.001 
(106.380) 
Lobular   115 (12.2) 1 (0.6)  203 (12.7) 1 (0.5) 
Medullar   26 (2.8) 6 (3.7)  38 (2.4) 7 (3.2) 
Mixed   56 (5.9) 4 (2.5)  101 (6.3) 6 (2.7) 
Other   12 (1.3) 0 (0.0)  43 (2.7) 0 (0.0) 
Tubular   223 (23.7) 10 (6.2)  372 (23.3) 13 (5.9) 
Total   942 (100) 161 (100)  1595 (100) 220 (100) 
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3.3.6 Correlation of HER2 expression, HER2 amplification and HER2 status with 
hormone and HER family receptors 
Overexpression of HER2 protein showed a significant negative association 
with both ER and PgR positivity (p < 0.001). A positive association was 
observed between HER2 protein expression and those tumours expressing 
HER4 (p < 0.001), but not with HER3 (p = 0.505) and EGFR (p = 0.066). 
Additionally, no association was observed between HER2 protein 
overexpression and basal phenotype (p = 0.918) (Table 3.6).  
 
The results of HER2 DPSOLILFDWLRQUDWLRDQG+(5VWDWXVUHYHDOHGVLPLODU
significant associations with the respective biomarkers as protein expression 
(Table 3.7). 
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Table 3.6 ± Relationship between HER2 expression with hormone 
receptors and HER family receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.7 ± Relationship between HER2 gene amplification and HER2 status with 
hormone receptors and HER family receptors. 
 
 
Biomarker 
 HER2 IHC 
 
0+ 
(%) 
1+ 
(%) 
2+ 
(%) 
3+ 
(%) 
p value 
(Chi-Square) 
Basal       
Negative  974 (79.3) 204 (77.9) 52 (76.5) 136 (79.1) 0.918 
(0.505) Positive  255 (20.7) 58 (22.1) 16 (23.5) 36 (20.9) 
  
     EGFR  
     
Negative  932 (83.1) 176 (81.9) 40 (75.5) 112 (75.2) 0.066 
(7.203) Positive  189 (16.9) 39 (18.1) 13 (24.5) 37 (24.8) 
  
     HER3 
 
 
     
Negative  135 (12.7) 30 (14.9) 8 (15.4) 14 (9.7) 0.505 
(2.340) Positive  924 (87.3) 171 (85.1) 44 (84.6) 130 (90.3) 
  
     HER4  
     
Negative  255 (23.9) 49 (23.6) 9 (17.3) 13 (9.0) <0.001 
(17.173) Positive  813 (76.1) 159 (76.4) 43 (82.7) 131 (91.0) 
  
     ER  
     
Negative  306 (24.7) 37 (14.2) 16 (25.4) 106 (60.6) <0.001 
(125.208) Positive  935 (75.3) 224 (85.8) 47 (74.6) 69 (39.4) 
  
     PgR 
 
 
     
Negative  467 (37.9) 84 (33.3) 33 (53.2) 126 (72.8) <0.001 
(86.914) Positive  764 (62.1) 170 (66.7) 29 (46.8) 47 (27.2) 
  
    
 
  
 
    
Biomarker 
 
HER2 CISH (Ratio) 
 
HER2 Status 
 
<2 
(%) 
 
(%) 
p value 
(Chi-Square) 
 
Neg 
(%) 
Pos (%) p value 
(Chi-Square) 
Basal 
        
Negative 
 
717 (79.7) 121 (79.1) 0.869 
(0.027) 
 
1197 (79.0) 169 (78.6) 0.905 
(0.014) Positive 
 
183 (20.3) 32 (20.9) 
 
319 (21.0) 46 (21.4) 
           EGFR 
        
Negative 
 
666 (83.0) 92 (74.2) 0.017 
(3.723) 
 
1125 (82.9) 135 (74.6) 0.006 
(7.461) Positive 
 
136 (17.0) 32 (25.8) 
 
232 (17.1) 46 (25.4) 
         HER3 
 
        
Negative 
 
97 (12.6) 13 (10.7) 0.551 
(0.356) 
 
168 (13.1) 19 (10.8) 0.386 
(0.750) Positive 
 
675 (87.4) 109 (89.3) 
 
1112 (86.9) 157 (89.2) 
         HER4 
        
Negative 
 
183 (23.7) 12 (10.0) 0.001 
(11.379) 
 
308 (23.8) 18 (10.2) <0.001 
(16.472) Positive 
 
590 (76.3) 108 (90.0) 
 
988 (76.2) 158 (89.8) 
         ER 
        
Negative 
 
206 (23.0) 81 (52.6) <0.001 
(61.015) 
 
345 (22.7) 120 (56.1) <0.001 
(106.916) Positive 
 
690 (77.0) 70 (46.4) 
 
1178 (77.3) 94 (43.9) 
         PgR 
 
        
Negative 
 
321 (36.3) 107 (72.3) <0.001 
(67.817) 
 
559 (37.1) 151 (71.6) <0.001 
(90.697) Positive 
 
564 (63.7) 41 (27.7) 
 
948 (62.9) 60 (28.4) 
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3.3.7 Correlation of HER2 expression, HER2 amplification and HER2 status with 
biomarkers 
HER2 expression revealed high association with CK18, pAkt, PI3K, p53, 
PTEN and Ki67 (all cases p < 0.001). The negative association was observed 
against Bcl-2 (p < 0.001), BRCA1 (p < 0.001) and p21 (p = 0.008) (Table 3.8).  
 
The relationship of both HER2 amplification and HER2 status against the 
biomarkers is summarised in  Table 3.9. In all cases the association between 
these two variables and the biomarkers are very similar with HER2 protein 
expression.  
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Table 3.8 ± Relationship between HER2 expression with hormone receptors and 
biomarkers. 
 
 
 
 
 
 
Biomarkers 
 HER2 IHC 
 0+ (%) 1+ (%) 2+ (%) 3+ (%) p value (Chi-Square) 
CK5/6 
      
Negative  
 
1065 (84.5) 221 (84.0) 59 (85.5) 148 (85.1) 0.987 
(0.138) Positive 
 
195 (15.5) 42 (16.0) 10 (14.5) 26 (14.9) 
  
     CK 7/8 
 
     
Negative 
 
29 (2.3) 1 (0.4) 1 (1.5) 1 (0.6) 0.099 
(6.279) Positive 
 
1232 (97.7) 263 (99.6) 67 (98.5) 173 (99.4) 
  
     CK14 
 
     
Negative 
 
1109 (89.2) 228 (86.4) 62 (88.6) 149 (86.1) 0.430 
(2.762) Positive 
 
134 (10.8) 36 (13.6) 8 (11.4) 24 (13.9) 
  
     CK 18 
 
     
Negative 
 
221 (18.5) 19 (8.3) 6 (9.7) 11 (6.9) <0.001  
(28.089) Positive 
 
971 (81.5) 211 (91.7) 56 (90.3) 149 (93.1) 
  
     Bcl-2 
 
     
Negative 
 
65 (35.1) 17 (28.8) 2 (22.2) 19 (76.0) <0.001 
(19.117) Positive 
 
120 (64.9) 42 (71.2) 7 (77.8) 6 (24.0) 
  
     pAkt 
 
     
Negative 
 
222 (27.3) 28 (16.3) 6 (11.5) 28 (22.4) 0.002 
(14.788) Positive 
 
591 (72.7) 144 (83.7) 46 (88.5) 97 (77.6) 
  
     PI3K 
 
     
Negative 
 
260 (28.0) 60 (28.2) 12 (17.4) 16 (11.9) 
<0.001 
(39.497) Moderate  256 (27.6) 57 (26.8) 21 (30.4) 22 (16.3) Strong 
 
413 (44.5) 96 (45.1) 36 (52.2) 97 (71.9) 
  
     P21 
 
     
Negative 
 
114 (85.1) 28 (63.6) 10 (83.3) 15 (93.8) 0.008  
(0.008) Positive 
 
20 (14.9) 16 (36.4) 2 (16.7) 1 (6.3) 
  
     MUC-1 
 
     
Negative 
 
120 (11.1) 23 (10.8) 5 (10.0) 9 (6.3) 
0.406 
 (6.157) Moderate  432 (40.0) 84 (39.6) 26 (52.0) 62 (43.1) Strong 
 
528 (48.9) 105 (49.5) 19 (38.0) 73 (50.7) 
 
 
     BRCA1 
 
     
Negative 
 
540 (51.5) 97 (48.5) 27 (51.9) 97 (69.8) <0.001 
(18.326) Positive 
 
509 (48.5) 103 (51.5) 25 (48.1) 42 (30.2) 
 
 
     P53 
 
     
Negative 
 
936 (75.2) 193 (74.5) 45 (68.2) 90 (52.3) <0.001 
(40.798) Positive 
 
309 (24.8) 66 (25.5) 21 (31.8) 82 (47.7) 
 
 
     PTEN 
 
     
Weak 
 
104 (23.8) 16 (14.8) 4 (10.8) 5 (6.5) 
<0.001 
(24.537) Moderate  131 (30.0) 49 (45.4) 18 (48.6) 31 (40.3) Strong 
 
202 (46.2) 43 (39.8) 15 (40.5) 41 (53.2) 
 
 
     Ki67 
 
     
Weak 
 
454 (43.0) 105 (50.5) 10 (16.4) 29 (20.7) 
<0.001 
(61.399) 
Moderate 
 
315 (29.8) 75 (36.1) 28 (45.9) 61 (43.6) 
Strong 
 288 (27.2) 28 (13.5) 23 (37.7) 50 (35.7) 
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Table 3.9 ± Relationship between HER2 gene amplification and HER2 status with 
biomarkers. 
 
 
 
 
 
Biomarkers 
 
HER2 CISH (Ratio) 
 
HER2 Status 
 <2 
(%) 
 
(%) 
p value 
(Chi-Square)  
Neg 
(%) 
Pos  
(%) 
p value 
(Chi-Square) 
CK5/6 
        
Negative  
 
782 (85.4) 130 (83.9) 0.627 
(0.236) 
 1310 (84.6) 183 (84.3) 0.927 
(0.008) Positive 
 
134 (14.6) 25 (16.1)  239 (15.4) 34 (15.7) 
  
       CK 7/8 
 
       
Negative 
 
19 (2.1) 2 (1.3) 0.512 
(0.430) 
 30 (1.9) 2 (0.9) 0.294 
(1.100) Positive 
 
894 (97.9) 153 (98.7)  1520 (98.1) 215 (99.1) 
  
       CK14 
 
       
Negative 
 
817 (90.1) 137 (89.0) 0.671 
(0.181) 
 1361 (88.7) 187 (86.6) 0.355 
(0.856) Positive 
 
90 (9.9) 17 (11.0)  173 (11.3) 29 (13.4) 
  
       CK 18 
 
       
Negative 
 
142 (16.7) 13 (9.5) 0.032 
(4.601) 
 242 (16.7) 15 (7.6) 0.001 
(10.911) Positive 
 
710 (83.3) 124 (90.5)  1205 (83.3) 182 (92.4) 
  
       Bcl-2 
 
       
Negative 
 
50 (31.3) 14 (70.0) 0.001 
(11.650) 
 83 (33.3) 20 (69.0) <0.001 
(14.140) Positive 
 
110 (68.8) 6 (30.0)  166 (66.7) 9 (31.0) 
  
       pAkt 
 
       
Negative 
 
170 (24.8) 22 (18.0) <0.107  
(2.604) 
 252 (25.0) 32 (20.6) <0.238 
(1.395) Positive 
 
516 (75.3) 100 (82.0)  755 (75.0) 123 (79.4) 
  
       PI3K 
 
       
Negative 
 
212 (24.9) 17 (11.6) 
<0.001 
(29.756) 
 326 (27.9) 22 (12.5) 
<0.001 
(40.844) Moderate  246 (28.8) 26 (17.8)  325 (27.8) 31 (17.6) Strong 
 
395 (46.3) 103 (70.5)  519 (44.4) 123 (69.9) 
  
       p21 
 
       
Negative 
 
122 (78.2) 16 (88.9) 0.289 
(1.123) 
 148 (80.0) 19 (90.5) 0.246 
(1.349) Positive 
 
34 (21.8) 2 (11.1)  37 (20.0) 2 (9.5) 
  
       MUC-1 
 
       
Negative 
 
87 (11.4) 10 (8.3) 
 
0.282 
(2.529) 
 143 (10.9) 14 (8.0) 
0.357 
(2.063) Moderate  308 (39.1) 56 (46.3)  526 (40.1) 78 (78.0) Strong 
 
393 (49.5) 55 (45.4)  642 (49.0) 83 (83.0) 
 
 
       BRCA1 
 
       
Negative 
 
385 (50.1) 79 (64.8) 0.003 
(9.103) 
 646 (50.9) 115 (66.9) <0.001 
(15.393) Positive 
 
384 (49.9) 43 (35.2)  622 (49.1) 57 (33.1) 
 
 
       p53 
 
       
Negative 
 
690 (76.7) 84 (56.8) <0.001 
(26.092) 
 1150 (75.1) 114 (54.0) <0.001 
(41.411) Positive 
 
210 (23.3) 64 (43.2)  381 (24.9) 97 (46.0) 
 
 
       PTEN 
 
       
Weak 
 
92 (22.2) 4 (5.1) 
0.002 
(12.729) 
 123 (22.0) 6 (6.1) 
0.001 
(13.994) Moderate  144 (34.7) 36 (45.6)  186 (33.2) 43 (43.4) Strong 
 
179 (43.1) 39 (49.3)  251 (44.8) 50 (50.5) 
 
 
       Ki67 
 
       
Weak 
 
306 (39.9) 24 (17.6) 
<0.001 
(24.998) 
 566 (43.9) 32 (18.1) 
<0.001 
(43.395) Moderate  253 (33.0) 59 (43.4)  402 (31.2) 77 (43.5) Strong 
 
207 (27.0) 53 (39.0)  321 (24.9) 68 (38.4) 
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3.3.8 p95HER2 expression in breast cancer 
Amongst the Unselected series, p95HER2 negative cases represented 492/543 
(90.6%) cases and the positive cases 51/543 (9.4%) (Figure 3.4). Amongst the 
HER2+ series the frequency of the p95HER2 increased to 85/177 (48.1%) and 
the negative cases were identified in 92/177 (51.9%). 
 
The association of p95HER2 protein expression with HER2 expression was 
highly significant (p < 0.001) with most of the p95HER2 negative cases 325/423 
(95.0%) being associated with both HER2 negative classifications (0+ and 1+). 
Also, almost 80% of the cases showing p95HER2 overexpression were 
associated with overexpression of HER2 (3+), with only 3/51 (5.9%) 
associated with HER2 negativity. The p95HER2 analysis against both HER2 
gene amplification and HER2 classification showed very similar results with a 
strong positive association (p < 0.001).  In both cases approximately 90% of 
the p95HER2 negative cases were associated with either no HER2 amplification 
or negative HER2 status. Amongst the p95HER2 positive cases nearly 92% 
revealed an association with HER2 gene amplification and HER2 positive 
status (Table 3.10). 
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Figure 3.4 ± Detection of p95HER2 protein expression in breast cancer cores by 
immunohistochemistry and scored according to intensity. The cells were labelled with 
a specific antibody against p95HER2 to detect the intensity of expression of this protein 
present in the cell membrane. The cells are scored in four different classes of protein 
expression: Negative expression ± (A), (B) and (C). Positive expression (D) show 
strong and complete membranous reactivity. 
 
 
 
 
 
 
 
 
 
 
 
A 
C 
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Table 3.10 ± Relation between p95HER2 protein expression, and HER2 
protein expression, HER2 gene amplification and HER2 status in breast 
cancer including respective frequencies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  p95HER2 IHC status 
 
Negative (%) Positive (%) Total (%) p value (Chi-Square) 
HER2 (IHC) 
    
0+ 325 (66.1) 3 (5.9) 328 (60.4) 
<0.001  
(180.029) 
1+ 93 (18.9) 0 (0.0) 93 (17.1) 
2+ 28 (5.7) 9 (17.6) 37 (6.8) 
3+ 46 (39.3) 39 (76.5) 85 (15.7) 
Total 492 (100) 51 (100) 543 (100) 
 
    HER2 CISH     
No amplification 255 (87.0) 3 (8.6) 258 (78.7) 
<0.001 
(114.652) Amplification 38 (13.0) 32 (91.4) 70 (21.3) 
Total 293 (100) 35 (100) 328 (100) 
 
    HER2 Status     
Negative 427 (88.2) 4 (8.5) 431 (81.2) 
<0.001 
(178.079) Positive 57 (11.8) 43 (91.5) 100 (18.8) 
Total 484 (100)    47 (100) 531 (100)  
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3.3.9 Correlation of p95HER2 expression with clinicopathological parameters 
The p95HER2 protein positive expression revealed to be highly associated with 
higher tumour grade (p < 0.001), more nuclear pleomorphism (p < 0.001), 
higher mitotic frequency (p = 0.008), occurrence of metastasis (p = 0.003), 
death due to breast cancer (p = 0.017) and poor NPI (p = 0.001) (Table 3.11).  
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Table 3.11 ± The relation between p95HER2 status in breast 
cancer with clinicopathological parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameters 
 p95HER2  IHC Status 
Negative (%) Positive (%) p Value (Chi-Square) 
Tumour Grade 
 
   
1 
 
61 (12.4) 2 (3.9) 
<0.001  
(15.568) 2  156 (31.8) 6 (11.8) 
3 
 
273 (55.7) 43 (84.3) 
 
 
   Tubule Formation 
 
 
   
1 
 
14 (3.0) 1 (2.0) 
0.643   
(0.822) 2  145 (30.9) 13 (25.5) 
3 
 
311 (66.2) 37 (72.5) 
  
   Pleomorphism 
 
   
1 
 
6 (1.3) 0 (0.0) 
<0.001   
(16.850) 2  176 (37.5) 5 (9.8) 
3 
 
287 (61.2) 46 (90.2) 
  
   Mitotic Frequency 
 
   
1 
 
 
123 (26.2) 4 (7.8) 
0.008  
(9.775) 2  100 (21.3) 10 (19.6) 
3 
 
247 (52.6) 37 (72.5) 
  
   Tumour Stage 
   
 
1 
 
298 (60.8) 24 (47.1) 
0.149  
(3.802) 2  143 (29.2) 21 (41.2) 
3 
 
49 (10.0) 6 (11.8) 
  
   Distant Metastasis 
 
   
Negative 
 
323 (66.3) 23 (45.1) 0.003   
(9.063) Positive 
 
164 (33.7) 28 (54.9) 
 
 
   Local Recurrence 
 
   
Negative 
 
267 (55.7) 19 (38.0) 0.017 
(5.738) Positive 
 
212 (44.3) 31 (62.0) 
 
 
   Regional Recurrence 
 
   
Negative 
 
411 (85.8) 45 (90.0) 0.413 
(0.670) Positive 
 
68 (14.2) 5 (10.0) 
 
 
   Tumour Size 
 
   
<1.5cm 
 
96 (19.6) 10 (19.6) 0.998   
(0.00) FP 
 
394 (80.4) 41 (80.4) 
  
   Vascular Invasion 
 
   
Negative 
 
255 (52.6) 21 (42.0) 0.154   
(2.031) Positive 
 
230 (47.4) 29 (58.0) 
  
   NPI 
 
   
Good 
 
120 (24.7) 4 (8.0) 
0.001  
(8.965) Moderate  285 (58.6) 32 (64.0) 
Poor 
 
81 (16.7) 14 (28.0) 
  
   Age 
 
   
<50 
 
177 (36.0) 19 (37.3) 0.856   
(0.033)  
 
315 (64.0) 32 (62.7) 
 
 
   Death  
 
   
Negative 
 
257 (61.8) 19 (43.2) 0.017   
(5.734) Positive 
 
159 (38.2) 25 (56.8) 
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3.3.10 Correlation of p95HER2 expression with hormone and HER family receptors 
Amongst the HER family receptors, positive expression of p95HER2 was only 
highly correlated with HER4 expression (p = 0.002). Against basal-type 
tumours and expression of both ER and PgR the correlation was highly 
negative with all p values under 0.001 (Table 3.12).  
 
 
 
Table 3.12 ± Relationship between HER2 expression with 
hormone receptors and HER family receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomarker 
 
p95HER2 IHC Status 
 
Negative (%) Positive (%) p value 
(Chi-Square) 
 
Basal 
     
Negative 
 
26 (19.4) 8 (88.9) <0.001 
(22.468) 
 
Positive 
 
108 (80.6) 1 (11.1) 
 
        EGFR 
     
Negative 
 
331 (80.9) 33 (76.7) 0.510 
(0.435) 
 
Positive 
 
78 (19.1) 10 (23.3) 
 
      HER3 
 
     
Negative 
 
42 (10.7) 2 (4.9) 0.241 
(1.375) 
 
Positive 
 
351 (89.3) 39 (95.1) 
 
      HER4 
     
Negative 
 
74 (18.9) 0 (0.0) 0.002 
(9.335) 
 
Positive 
 
318 (81.1) 41 (100) 
 
      ER 
     
Negative 
 
146 (31.2) 37 (72.5) <0.001 
(34.450) 
 
Positive 
 
322 (68.8) 14 (27.5) 
 
      PgR 
 
     
Negative 
 
207 (44.2) 36 (73.5) <0.001 
(15.223) 
 
Positive 
 
261 (55.8) 13 (26.5) 
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3.3.11 Correlation of p95HER2 expression with biomarkers 
The positive expression of p95HER2 protein revealed to be highly correlated 
with CK18 (p = 0.006), p53 (p = 0.003), PTEN (p = 0.042) and Ki67 (p = 
0.007). Additionally p95HER2 expression was negatively associated with CK5/6 
(p = 0.029), Bcl-2 (p = 0.003) and BRCA1 (p = 0.016) (Table 3.13). 
 
The same analysis was performed amongst the HER2+ series, however p95HER2 
did not reveal any significant associations with either clinicopathological 
parameters or biomarkers (table not included).  
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Table 3.13 ± Relationship between p95HER2 expression with 
biomarkers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biomarkers 
 
p95HER2 IHC Status 
 Negative (%) Positive (%) p Value  (Chi-Square) 
CK5/6 
 
   
Negative  
 
388 (81.5) 46  (93.9) 0.029       
(4.740) Positive 
 
88  (18.5) 3  (6.1) 
  
   CK 7/8 
 
   
Negative 
 
10  (2.1) 0  (0.0) 0.301  
 (1.068) Positive 
 
467  (97.9) 50  (100) 
  
   CK14 
 
   
Negative 
 
405  (76.5) 44  (90.0) 0.480  
 (0.500) Positive 
 
65 (23.5) 5  (10.0) 
  
   CK 18 
 
   
Negative 
 
81  (18.4) 1  (2.2) 0.006   
(7.614) Positive 
 
359  (81.6) 44  (97.8) 
  
   Bcl-2 
 
   
Negative 
 
40  (41.7) 7  (100) 0.003  
(8.949) Positive 
 
56  (58.3) 0  (0.0) 
  
   pAkt 
 
   
Negative 
 
76  (22.8) 6  (14.3) 0.207   
(1.591) Positive 
 
257  (77.2) 36  (85.7) 
  
   PI3K 
 
   
Negative 
 
99  (24.3) 8  (19.5) 
0.553   
(1.184) Moderate  86  (23.6) 9  (19.5) Strong 
 
212  (52.1) 25  (61.0) 
  
   p21 
 
   
Negative 
 
61  (77.2) 2  (66.7) 0671   
(0.181) Positive 
 
18  (22.8) 1  (33.3) 
  
   MUC-1 
 
   
Negative 
 
44  (11.1) 1  (2.4) 
0.219 
  (3.035) Moderate  172  (43.3) 19  (46.3) Strong 
 
181  (45.6) 21  (51.2) 
  
   BRCA1 
 
   
Negative 
 
219  (56.9) 32  (76.2) 0.016   
(5.826) Positive 
 
166  (43.1) 10  (23.8) 
 
 
   p53 
 
   
Negative 
 
323  (69.0) 24  (48.0) 0.003 
(0.023) Positive 
 
145  (31.0) 26  (52.0) 
 
 
   PTEN 
 
   
Weak 
 
60  (18.1) 2  (6.1) 
0.042  
(6.321) Moderate  131  (39.6) 10  (30.3) Strong 
 
140  (42.3) 22  (63.6) 
 
 
   Ki67 
 
   
Weak 
 
128  (32.7) 6  (15.4) 
0.007   
(5.308) Moderate  156  (39.9) 18  (46.2) Strong 
 
107  (27.4) 15  (38.5) 
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3.3.12 HER2 and Patient Outcome  
Kaplan±Meier survival analysis demonstrated that tumours overexpressing 
HER2 protein (IHC score of 2+ and 3+), HER2 amplification (ratio > 2) or 
HER2 positive status showed similar significantly shorter BCSS (Figure 3.5A, 
Figures 3.6A and C) and DFI (Figure 3.5B, Figures 3.6B and D) compared 
with those showing unequivocal negative HER2 protein expression, no 
amplification or HER2 negativity (in all cases p < 0.001). Interestingly, for 
HER2 protein expression, those cases showing moderate status (2+) had 
slightly better outcome compared with those tumours with overexpression of 
the protein (3+), though those differences were not significant (BCSS p = 
0.334, DFI p = 0.657) (Figures 3.5C and D). 
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Figure 3.5  ± A) BCSS and B) DFI analysis for HER2 protein expression status amongst the 
Unselected series. C) BCSS and D) DFI analysis for HER2 equivocal (2+) protein expression 
against positive (3+) cases amongst the Unselected series. 
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Figure 3.6 ± A) BCSS and B) DFI analysis for HER2 amplification status amongst the 
Unselected series. C) BCSS and D) DFI analysis for HER2 classification amongst the 
Unselected series 
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3.3.13 Survival analysis for HER2 expression equivocal cases harbouring either HER2 
amplification or not  
Combining the HER2 expression and HER2 gene amplification data, it was 
observed a better survival outcome within the first 60 months for those patients 
classified as HER2 equivocal tumours with no gene amplification (IHC 2+ 
non-amplified), comparing against the equivocal cases harbouring gene 
amplification and the positive cases (Figure 3.7A). However after this period 
BCSS was similar between both equivocal with or without gene amplification 
and IHC 3+ tumours. Analysing only IHC 2+ cases, either with or without 
gene amplification, it was not possible to observe a significant survival 
difference between both groups (p = 0.487; Figure 3.7B).  Regarding the DFI 
both 0+ and 1+ negative group revealed a better outcome comparing with the 
positive IHC 3+ and both IHC 2+ groups (p = 0.001; Figure 3.7C). 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: HER2 and p95HER2 in breast cancer 
114 
 
 
 
 
 
Figure 3.7 ± A) BCSS and C) DFI analysis for HER2 protein expression discriminating the 
equivocal cases (IHC 2+) either with or without gene amplification. B) BCSS and D) DFI 
analysis for HER2 protein expression discriminating only the equivocal cases (2+) either with 
or without gene amplification 
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3.3.14 Survival analysis for ER amongst the HER2+ trastuzumab naïve series  
The survival analyses performed the HER2+ trastuzumab naïve either 
expressing ER or not showed a very similar outcome for both BCSS  (p = 
0.488) and DFI (p = 0.499) (Figure 3.8A and B, respectively). Interestingly 
after a period of 110 months the differences became evident with those 
overexpressing ER possessing a significant worse outcome for both BCSS (p = 
0.012) and DFI (p = 0.002) (Figure 3.8C and D, respectively).  
 
 
 
Figure 3.8 ± A) BCSS and B) DFI analyses for ER expression amongst HER2+ trastuzumab 
naïve cases. C) BCSS and D) DFI analysis for ER expression amongst HER2+ trastuzumab 
naïve cases after 110 months from first diagnosis.  
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3.3.15 Survival analysis for p95HER2 expression   
Because of such a high association of p95HER2 with HER2, survival analysis 
revealed a significant worst outcome of the p95HER2 positive cases against the 
negative cases for both BCSS (p = 0.003) and DFI (p = 0.011) amongst the 
Unselected series (Figures 3.9A and B, respectively).  
 
 
 
 
 
 
 
 
Figure 3.9 ± A) BCSS and B) DFI analysis for HER2 p95 protein expression in breast 
cancer.  
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3.3.16 Survival analysis for HER2 IHC status amongst the HER2+ trastuzumab 
adjuvant series   
For the HER2+ trastuzumab adjuvant series only HER2 IHC status survival 
analysis was performed. Both HER2 amplification and HER2 classification 
status survival analyses were not conceivable due to all patients from this 
series being HER2 amplified or HER2 positive. Therefore it was achievable to 
compare those patients revealing HER2 equivocal expression (2+) versus 
HER2 overexpression cases (3+). The Kaplan-Meier analysis did not revealed 
any significant differences for BCSS (p = 0.240) and DFI (p = 0.157) between 
equivocal and overexpressing patients (Figures 3.10A and B, respectively).     
 
 
 
Figure 3.10 ± A) BCSS and B) DFI analysis for HER2 protein expression for 
trastuzumab adjuvant series. 
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3.3.17 HER2 and patient outcome in HER2+ tumours trastuzumab naïve versus 
adjuvant 
Kaplan-Meier survival analyses were performed concerning the BCSS and DFI 
outcome of those cases submitted to adjuvant trastuzumab treatment against 
trastuzumab naïve patients.  Amongst the HER2 equivocal cases no significant 
difference was observed between for both BCSS (p = 0.198; Figure 3.11A) and 
DFI (p = 0.071; Figure 3.11B). 
 
Amongst the HER2 3+ patients BCSS and DFI analyses revealed significant 
GLIIHUHQFHVRQSDWLHQWV¶RXWFRPHSFigures 3.11C and D). 
 
 
 
Figure 3.11 ± BCSS and DFI analysis for HER2 status amongst the HER2+ trastuzumab 
adjuvant series against HER2+ trastuzumab naïve series regarding A) and B) HER2 equivocal 
status (2+ IHC) but amplified or C) and D) HER2 positive status (IHC 3+). 
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3.3.18 Survival analysis for p95HER2 expression amongst both the HER2+ trastuzumab 
naïve and trastuzumab adjuvant series   
Kaplan-Meier study was performed for p95HER2 amongst both HER2+ 
trastuzumab naïve series and trastuzumab adjuvant series. This mode it was 
possible to understand if patients revealing p95HER2 positive expression 
shown worse prognosis comparing with the other HER2+ patients. Amongst 
the HER2+ trastuzumab naïve those cases with p95HER2 positive status did 
not reveal a worse outcome for both BCSS (p = 0.681) and DFI (p = 0.409) 
(Figures 3.12A and B, respectively). Amongst the trastuzumab adjuvant series 
the p95HER2 expression did not reveal a significant worse prognosis for both 
BCSS (p  = 0.120) and DFI (p = 0.392) (Figures 3.12C and D, respectively).   
 
Figure 3.12 ± A) BCSS and B) DFI analysis for p95HER2 protein expression for trastuzumab 
naïve series and C) BCSS and D) DFI for trastuzumab adjuvant series. 
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3.4 Discussion 
 
 
The diversity amongst the different breast carcinomas is astonishingly high 
when morphology, molecular outline and effects of therapies applied. Genetics 
studies achieved the identification and distinction of classes of breast 
carcinomas17. HER2 is of great interest in breast cancer due to its 
overexpression being associated with dismal innate prognosis and as 
therapeutic target for trastuzumab51,55,368-371 and other emerging therapies219,372. 
In this chapter, HER2 protein expression and gene amplification were 
determined in a large historical cohort of primary breast cancer, prior to the 
introduction of trastuzumab treatment and also a series of HER2+ tumours 
from patients treated with adjuvant trastuzumab. Previous studies show 
concordance of 73% to 98% between IHC and FISH techniques in detection of 
overexpression of HER2373-375. This discrepancy might be due to different IHC 
techniques used by different groups, which can be influenced by different 
commercial antibodies that demonstrated diverse specificities and sensitivities 
to dissimilar epitopes present in HER2371,376-378.  
 
CISH reveals high concordance with FISH but possesses several advantages 
over FISH. CISH is relatively low cost, only requires routine equipment 
present in a regular histopathology laboratory and possible to store for long 
periods of time and is therefore a useful and more suitable alternative for high-
throughput screening of breast cancers prepared as TMAs than 
FISH355,359,371,379,380. Also CISH is suitable to be performed in TMAs because 
is not affected by the intratumoral heterogeneity of HER2 amplification. The 
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concordance between both TMAs and whole tissue sections results reveal to be 
extremely high381.  
 
In the case of this study, for detection of each biomarker, instead of performing 
a couple of thousand immunohistochemistry analyses for each biomarker 
detection, this was possible to be achieved in only 13 TMAs sections for 
unselected series and 1 TMA section for HER2+ adjuvant trastuzumab cohort. 
This way it was possible to avoid time consuming and high quantities of 
detections solutions, which would reveal to be extremely expensive and 
unfeasible to obtain a more complete characterisation of both cohorts.  
Additionally using TMAs, all specimens included into the same block were 
submitted to exactly the same physical and chemical conditions (temperature, 
solutions concentrations and the period of time for incubations), providing 
more consistent results382,383. However for each case analysed on a TMA, only 
0.3% of a 1 cm cancer tissue is represented. Therefore this method might 
reveal some limitations due to this small amount of tissue tested. Instead this 
statistical variability between whole tissue and TMA core results is eliminated 
by the large amount of cases analysed, which is able to counterbalance any 
false negative result340,384. Different studies suggested that the use of TMAs is 
enough to represent the whole tissue section from each patient382,384,385. 
However heterogeneity amongst the full tissue section might reveal to be an 
issue for such a method that only uses an insignificant percentage of each 
sample. Only one core marked for HER2 able to be scored is representative of 
more than 90% of the whole tissue section, revealing that in some cases this 
statistical analysis can achieve 95% concordance386. A unique core was 
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expressive enough in 95% for ER, up to 81% for PgR and up to 74% for p53 
against the original full sections387.  
 
HER2 gene amplification and protein overexpression was observed in 14.6% 
and 9.7% of a large unselected series of breast cancer cases, respectively. 
Utilising a combination of both techniques a final frequency of 12.1% of HER2 
positive cases being in concordance with a different study349. However is 
clearly lower when compared with another study that revealed HER2 positivity 
frequency levels of 22.8%21. Only four out of a total of 1115 cases studied with 
IHC against CISH did not show concordance, i.e., 99.6% of our samples 
revealed protein overexpression harbouring gene amplification, which shows 
an excellent concordance between these two techniques. Only one case showed 
high protein expression but no gene amplification, which might be a false 
positive where IHC was excessively sensitive to antigen retrieval process58,388, 
or this fact could be explained by polysomy on chromosome 17 that provokes 
HER2 overexpression58,389.  It was observed three cases where there was gene 
amplification but no protein overexpression, which could be explained by an 
alteration of the structure in charge of gene expression59. Therefore CISH 
revealed to be reliable technique on HER2 gene amplification detection with 
supplementary advantages when compared against FISH.  
 
HER2 positivity is associated with very poor outcome amongst the breast 
cancer patients348,390. In this study HER2 was significantly correlated with poor 
prognostic clinicopathological parameters including higher stage, larger size, 
higher grade, high nuclear pleomorphism, higher mitotic frequency, less tubule 
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formation, higher occurrence of development of distant metastases and poor 
NPI. Occurrence of death due to breast cancer is highly associated with HER2, 
ZDV QRWDVVRFLDWHG ZLWK SDWLHQW¶V DJH+(5VWDWXV ZDV REVHUYHG PRUH RIWHQ
amongst the ductal carcinomas in contrast to other pathological types that are 
more correlated with favourable outcome391.  
 
The molecule p95HER2 was previously highly related with poor prognosis 
clinicopathological parameters as development of metastases and higher 
tumour stage but not significantly associated with higher tumour size166. In this 
study p95HER2 analyses against clinicopathological parameters revealed not 
only high association with development of distant metastasis but also high 
correlation with tumour grade, high nuclear pleomorphism, high mitotic 
frequency and poor NPI but not with tumour stage. Additionally and in 
agreement with the same study, p95HER2 was not correlated with tumour size, 
which differentiates from HER2+ cases that were highly correlated with this 
parameter. Tubule formation was not correlated with p95HER2 but highly 
correlated with HER2+ cases as well. 
 
While as anticipated EGFR and HER2 expression are highly correlated392, in 
this study HER2 expression was not associated with EGFR expression, even 
though approximately close to p values under 0.05. However the gene 
amplification and HER2 status revealed to be highly associated. Again 
disagreeing with different studies70,283, HER3 expression is not correlated with 
any HER2 analyses, even though the overexpression is present in 90% of the 
HER2+ cases. The last member of HER family revealed to be highly associated 
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with HER2 positivity in concordance to a different study that also reports 
increase of sensitivity of the breast carcinomas to trastuzumab if HER4 is 
overexpressed393. The antibody used to detect the HER2 cleaved form was 
specifically designed to detect 100- to 115-kDa p95HER2 in FFPE sections and 
we could confirm that p95HER2 carcinomas comprise a subclass of HER2+ 
cases with similar biological and clinical descriptions but possible to 
differentiate. Previously it was possible to show that approximately 80% of the 
HER2- cases were ER+ and merely 50% of the HER2+ cases were ER+365,394. 
These facts concur with our results revealing the negative association between 
HER2 and the hormone receptors. The data of ER expression against p95HER2 
cases revealed an extraordinary linkage between them.  Even though the 
frequency of ER+ versus p95HER2 negativity is similar as against HER2- cases, 
the number of p95HER2+ that are also ER+ is not greater than 30% against the 
50% for HER+ cases, which is reflected in previous works395. Also becomes 
even more evident the lack of association of p95HER2 expression with EGFR 
and basal-like breast tumours, which is not in agreement with Pedersen and 
colleagues that stated a high correlation of p95HER2 with EGFR 
overexpression179.  
 
HER2 revealed strong correlation with poor prognostic biomarkers and 
negative association with biomarkers correlated with better outcome, even 
though some exceptions were observed. HER2 was not correlated with any of 
the basal cytokeratins (CK5/6 and CK14) and luminal associated cytokeratin 
CK7/8. As already documented the association of HER2 protein expression 
with PI3K and pAkt revealed to be very strong396, which is in concordance 
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with this study. Moreover incidences as high cell proliferation and 
transformation had been related with overexpression of PI3K and pAkt 
arbitrated by overexpression of HER2396. However HER2 gene amplification 
did not reveal any correlation with pAkt. Additionally HER2 was correlated 
with Ki67, a biomarker highly associated with cancer proliferation and also 
with breast carcinoma relapse and death397.  Previous studies have related Bcl-
2 and p53 describing their apoptotic role on breast cancer and consequently 
delivering different prognosis398,399. An apoptosis reaction triggered by p53 is 
inhibited by the anti-apoptotic role developed by Bcl-2. Moreover both 
biomarkers expression is inversely correlated amongst most of human breast 
cancer cell lines, suggesting downregulation of Bcl-2 by p53400. Breast cancer 
patients revealing high expression of Bcl-2 and elimination of p53 are related 
to more aggressive carcinomas401,402. Our results revealed a high association of 
HER2 with p53 and a negative association with Bcl-2. This fact is supported 
by an anticipated study revealing that the biomarker Bcl-2 is inversely 
correlated with HER2 and Ki67 and positively associated with ER and PgR 398. 
On the other hand and in agreement with this study p53 is inversely correlated 
with ER and PgR and highly associated with HER2398. HER2 also revealed 
negative association against BRCA1, which contrast with previous studies 
revealing no correlation between them even though lack of BRCA1 association 
with poor prognosis392. BRCA1 is involved on control of cell cycle and 
proliferation progression, DNA repair and recombination however absence or 
mutation drive breast cancer cell malignancy403.  
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Interestingly the results achieved for p95HER2 demonstrated to be similar to 
HER2, however not in all cases. The cleaved molecule was correlated with one 
basal biomarker ± CK5/6 ± which is related with the most aggressive class of 
breast cancers404. However and similarly to HER2 positivity, p95HER2 
demonstrated to be highly associated with CK18, which is linked to 
suppression of tumour development405.  Another remarkable difference is 
achieved against pAkt, where p95HER2 was not correlated and HER2 protein 
expression is highly associated.  
 
Expression of HER2 was highly associated with poor BCSS and DFI. Negative 
or low HER2 protein expression (IHC score of 0+ and 1+) was associated with 
a better outcome comparing it to 2+ and 3+ during the entire period analysed. 
However, discrimination of those HER2 tumours with IHC score of 2+ 
between those showing HER2 amplification or no-amplification revealed a 
differential outcome during the first 60 months. However, those cases with 
HER2 overexpression but not gene amplification had a similar overall outcome 
(post 60 months) to those with gene amplification. Hence IHC 2+ and 3+ cases 
revealed similar long-term outcome irrespective of HER2 gene amplification 
status. This suggests that despite the gene amplification, the outcome can be 
affected by the quantity of receptors available to dimerise and trigger 
downstream pathways and worse outcome is acquired in both 2+ and 3+ 
regardless gene amplification. In present clinical settings, cases exhibiting IHC 
2+ and no HER2 amplification will not be offered targeted HER2 therapy 
although they do demonstrate long-term aggressive clinical behavioural 
characteristics. Even though in trastuzumab adjuvant series all patients possess 
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HER2 gene amplification, those scored as equivocal HER2 protein expression 
(2+) for protein expression revealed a worse outcome after a period of 60 
months, suggesting development of resistance to trastuzumab therapy. 
However statistical relevant results were not possible to be achieved due to 
limitation of samples and short period of treatment of these patients. 
Concluding, HER2 equivocal patients (2+) possess bad outcome as positive 
patients (3+) amongst the trastuzumab naïve series but the equivocal patients 
that harbour gene amplification amongst the trastuzumab adjuvant series might 
possess worst outcome comparing against the positive patients. This might 
indicate the possibility that HER2 equivocal patients might not possess enough 
expression levels to react with trastuzumab. As referred before trastuzumab 
only reacts with cells expressing HER2 10-100 times above normal levels56. 
Finally amongst the trastuzumab naïve series it was possible to understand that 
ER overexpression might confer a worse outcome, however that difference is 
only significant after a period of 120 months, overall the significance is 
inexistent.  The crosstalk HER2/ER is a significant factor for development of 
resistance to breast cancer treatment105. Therefore understand the interaction 
between these two receptors and its effect on cancer treatment is crucial to 
develop new therapies that target HER2 overexpressing carcinoams. Lapatinib 
was approved by FDA to be applied against HER2+ breast carcinomas in 
combination with chemotherapy227.  
 
Amongst the trastuzumab naïve series both negative and positive p95HER2 
status showed similar outcome, though the therapy (chemotherapy adjuvant) 
was not specifically directed against this cleaved target. This statement is not in 
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concordance with previous study revealing worse outcome for those patients 
expressing high levels of p95HER2 406. Even though amongst the trastuzumab 
adjuvant series the outcome still not significantly different for both p95HER2 
statuses, it is possible to understand that those HER2+ patients expressing high 
levels of p95HER2 are starting to uncover a worse prognosis. No action of 
trastuzumab against p95HER2 form due to the lack of the ectodomain takes 
place366 and the idea of p95HER2 used as a biomarker to define an aggressive 
subtype of HER2+ breast carcinomas becomes real173,406. Therefore and in 
agreement with Scaltriti and colleagues p95HER2 positive patients develop 
resistance to trastuzumab treatment175.  However the application of lapatinib is 
effective duo to its properties of reacting with the tyrosine kinases located on 
endoplasmic domain and blocking the receptor signalling pathways179. Even 
though p95HER2 analysis revealed a high correlation of the positive cases with 
worse outcome, our study did not reveal any significant difference to turn 
p95HER2 as an alternative bioPDUNHU WREH VHOHFWHG RQ EUHDVW FDQFHU SDWLHQW¶V
differentiation. However this molecule does not possess an ectodomain to react 
with trastuzumab, which might contribute to resistance development against 
this drug 360.   
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4. CHAPTER 4: The role of EGFR in HER2+ breast 
cancer 
 
4.1 Introduction 
 
4.1.1 EGFR in breast cancer 
EGFR is a 53 amino acid polypeptide expressed by a gene located on 
chromosome 7 location 7p12.3-p12.1407 and its molecular weight is 
170KDa408. Studies using EGFR knockout mice demonstrated that EGFR is 
implicated in epithelial cell cycle and essential in mid-gestational stage where 
animals that survived several weeks after birth had skin, lungs, brain and liver 
malformation and mammary gland with reduced size and small ducts29,409-411. 
The overexpression of EGFR, similarly to the other HERs, has been highly 
associated with the development of several types of cancer with poor 
prognosis, especially amongst aggressive brain tumours, detected in 90% of 
high grade astrocytic glioma cases and up to 50% of glioblastoma 
multiforme412,413.  Also EGFR has been detected and associated with solid 
tumours progression, becoming a specific target in treatments of bladder, 
colorectal pancreatic, cervical, prostate, melanoma, lung and breast cancer414. 
The non-small-cell-lung cancer is highly affected by EGFR overexpression 
reaching up to 80% of the patients415. In a normal breast cell, EFGR is crucial 
for expansion and differentiation of different tissues throughout the last stage 
of gestation416. The frequency of this protein in a normal cell can be between 
40,000-100,000417 against a dramatic increase of this number in cancer cells 
that possibly reaches 2,000,000418. Such a dramatic increase on its expression 
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triggers a high rate of proliferation and angiogenic and metastasis 
development419 resulting in constant growth of the carcinomas420. Even though 
some studies contradict this arguments revealing an association of EGFR 
expression with reduction of the tumour progress421, supported by other studies 
revealing no association between EGFR expression and tumour size, grade or 
lymph node stage422,423. On the cytoplasmic domain if EGFR there are six 
autophosphorylation spots categorised as major, which includes Y1068, 
Y1148, Y1173424,425, and minor including Y992, Y1045, Y108631,426,427. The 
consequences of these sites being phosphorylated comprise proliferation, 
angiogenesis and anti-apoptotic improvement428,429, suggesting that EGFR 
overexpression as a biomarker revealing poor outcome in breast cancer. 
However a complete characterisation of EGFR affecting breast cancer 
development still ambiguous. A later EGFR research study by Rampaul 
showed that 20% of breast cancer was EGFR positive and possessed a 
significant association with tumour type, and grade430.  
 
EGFR overexpression has also been linked with triple negative (TN) invasive 
ductal breast carcinomas333,431 revealing a frequency between 10-54% of the 
cases432-434 suggesting this receptor as a good target for anticancer therapies435. 
Although expression of EGFR is highly associated with poor prognosis in 
breast cancer21 and expressed in about 33% of human carcinomas and 50% of 
glioblastomas, the presence of this receptor is highly expressed in only 2.7% of 
breast tumours from patients with poor prognosis21. It is being an arguable 
discussion among those that suggested an association of EGFR with poor 
prognosis and recurrence high incidence436,437 and those that revealed no 
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association438,439. It is possible to understand that the discordance between 
studies still significant and might be explained by small cohort sizes used, 
diminutive follow up, the use of different techniques to detect this protein are 
even the different adjuvant therapies applied. However, most studies have 
applied different cut-off points, which might influence significantly the 
analysis.  
 
Treatments are being targeted to obstruct EGFR activity, which will target 
within the extracellular domain by applying monoclonal antibodies like 
panitumumab or cetuximab. An alternative method is to target the intracellular 
domain or tyrosine kinase domain using gefitinib or erlotinib known as small 
molecules or tyrosine kinase inhibitors (TKI)440,441. Until now, it is not possible 
to confirm whether the patients benefit or not with this therapy due to being in 
early clinical research stage442. Reactive oxygen species (ROS), which 
regulates cellular signalling pathways by association with EGFR-associated 
tyrosine phosphatase, plays an important role in developing resistance to TKI 
treatments. Therefore the use of cell-penetrating catalase (specific anti-oxidant 
enzymes) is crucial to sensitise these carcinoma cell to gefinitib443.   
 
4.1.2 HER2/EGFR in breast cancer 
Approximately 25%-35% of the breast carcinomas revealed co-expression of 
both EGFR and HER2442,444, indicating a possible existence of the heterodimer 
HER2/EGFR, which might be associated with creation of the EGFR active 
form pEGRF-y992 located at the membrane and the cytoplasmic form 
Y1068442. Patients revealing the co-expression of these two growth factors 
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showed the worse prognosis444,445. This poor outcome might be related with 
high activity of PI3K/Akt downstream pathways implicated in cell apoptosis 
evasion, expansion, motility and angiogenesis. Akt is intrinsically associated 
with PI3K phosphorylation due to react with PIP3, a result of PI3K activity, 
which phosphorylates Akt at threonine 308. However to be completely 
activated this molecule requires an extra phosphorylation on serine 473 
initiated by mammalian target of rapamycin complex 2 (mTORC2)446. 
Furthermore phosphorylated PI3K is similarly involved on phospholipase C-Ȗ1 
(PLC-Ȗ1) instigation. PLC-Ȗ1 reacts also with PIP3 which is recruited to the 
plasma membrane and activated by reacting with the phosphorylated tyrosine 
kinases from the growth receptor when in close proximity447. It is proposed that 
EGFR/HER2/PLC-Ȗ1triggers cell motility107 and HER2/HER3/PI3K may 
undertake a communication that endorses not only cell proliferation108 but also 
motility. This data suggests there is cooperation between the heterodimers 
EGFR/HER2 and HER2/HER3 (Figure 4.1).  
 
PLA methodology permits the recognition of the heterodimers cell allocation at 
a molecular level448-450. For the first time it was possible to study the 
heterodimerisation amongst the HER family and their effect over breast 
carcinoma development. Thus, for further understanding it was decided to 
analyse the relationships between the expression of each monomer and their 
interaction with HER2, to further comprehend and predict effectiveness of 
trastuzumab. It is also hypothesise that the different heterodimers are correlated 
to other biomarkers in a different manner. With this new classification system 
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it is possible to discriminate patients and understand in a more consistent way 
if trastuzumab is the best alternative therapeutic strategy.  
 
 
 
 
 
 
Figure 4.1 ± The intercommunication between the heterodimers HER2/EGFR and 
HER2/HER3 promoting both cell survival and migration. 
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4.2 Methods 
 
EGFR is a protein receptor localised predominantly in the cell membrane as 
observed in positive control tonsil tissue. This receptor was detected using the 
respective antibody anti-EGFR (Clone 31G7, Invitrogen), pre-treatment and 
the Envision technology as described in Chapter 2.  
 
The detection of HER2/EGFR heterodimers was performed using in situ PLA 
as described in Chapter 2.  These heterodimers were detected in TMAs of both 
series using two primary antibodies from different species, which were stable 
under the same pre-treatment conditions (rabbit anti-HER2 (Dako) antibody 
and mouse anti-EGFR (clone EGFR-R2, Santa Cruz) antibody). To quantify 
the heterodimers levels Duolink ImageTool software was applied. Red signals 
representing HER2/EGFR heterodimers were localised predominantly in the 
cell membrane. The cut-off between high and low levels of heterodimerisation 
was determined by applying X-tile software.  
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4.3 Results 
 
4.3.1 EGFR 
 
4.3.1.1 Expression in breast cancer  
Regarding the EGFR expression, in the Unselected series a total of 1276/1594 
(80.1%) cases revealed negative expression and 318/1594 (19.9%) cases 
expressed positive levels. Amongst the HER2+ series a total of 188/305 
(61.6%) patients showed negative expression and 117/305 (38.4%) cases 
possessed positive levels for EGFR (Figure 4.2). 
 
 
 
 
Figure 4.2 ± Detection of EGFR protein expression in breast cancer cores by 
immunohistochemistry. The cells were labelled with a specific antibody against EGFR to 
detect the intensity of expression of this protein present in the cell membrane. The cells are 
scored in four different classes of protein expression: (A) Negative when a faint membranous 
immunoreactivity was observed in less than 10% of the cancer cells and (B) Positive when 
more than 10% of the invasive carcinoma cells show a weak/moderate perceptible 
membranous reactivity. 
 
 
 
      
A    B 
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4.3.1.2 Correlation with clinicopathological parameters 
Positive expression of EGFR protein in the Unselected series was highly 
correlated with higher tumour grade, more nuclear pleomorphism, higher 
mitotic frequency, poor NPI score and death (all p < 0.001). Also EGFR 
expression was correlated with less tubule formation (p = 0.006), presence of 
distant metastasis (p = 0.001) and higher tumour size (p = 0.037) (Table 4.1) 
 
Amongst the HER2+ series, HER3 positive expression was highly associated 
with more nuclear pleomorphism (p = 0.004), local recurrence (p = 0.031), 
vascular invasion (p = 0.023), poor NPI score (P = 0.027) and death instigated 
by breast cancer (p = 0.038) (Table 4.1) 
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Table 4.1 ± The relation between EGFR status with clinicopathological parameters in breast 
cancer. 
                                   EGFR Status 
Parameters 
 Unselected Series  HER2+ Series 
 Neg  (%) Pos (%) p value  (Chi-Square) 
 Neg  (%) Pos (%) p value  (Chi-Square) 
Tumour Grade         
1  252 (19.7) 26 (8.9) 
<0.001  
(79.908) 
 6 (3.2) 0 (0.0) 0.093  
(4.746) 2  463 (36.1) 52 (17.9)  36 (19.1) 18 (15.4) 
3  566 (44.2) 213 (73.2)  146 (77.7) 99 (84.6) 
         Tubule Formation         
1  87 (5.6) 9 (0.6) 0.006  
(10.359) 
 1 (0.5) 0 (0.0) 0.325  
(2.250) 2  420 (34.8) 83 (22.2)  38 (20.5) 17 (14.8) 
3  736 (59.7) 196 (77.2)  146 (78.9) 98 (85.2) 
         Pleomorphism         
1  33 (2.7) 2 (0.7) 
<0.001  
(69.751) 
 0 (0.0) 0 (0.0) 0.004  
(8.257) 2  542 (43.7) 54 (18.8)  25 (13.6) 4 (3.5) 
3  664 (53.6) 231 (80.5)  159 (86.4) 111 (96.5) 
         Mitotic Frequency         
1 
 
 500 (40.2) 53 (18.4) 
<0.001  
(81.246) 
 27 (14.6) 13 (11.3) 0.714  
(0.673) 2  250 (20.1) 37 (12.8)  41 (22.2) 27 (23.5) 
3  493 (39.7) 198 (68.8)  117 (63.2) 75 (65.2) 
         Tumour Stage         
1  809 (63.2) 179 (61.7) 0.715  
(0.671) 
 88 (46.8) 51 (43.6) 0.632  
(0.919) 2  366 (28.6) 83 (28.6)  68 (36.2) 41 (35.0) 
3  105 (8.2) 28 (9.7)  32 (17.0) 25 (21.4) 
         Distant Metastases         
Negative  909 (71.3) 176 (61.1) 0.001  
(11.475) 
 
 122 (71.8) 83 (54.5) 0.254  
(1.303) 
 
Positive  366 (28.7) 112 (38.9)  65 (28.2) 33 (45.5) 
                Local Recurrence         
Negative  772 (61.8) 159 (56.8) 0.123 
(2.276) 
 119 (64.0) 88 (75.9) 0.031 
(4.679) Positive  478 (38.2) 121 (43.2)  67 (36.0) 28 (24.1) 
         Regional Recurrence         
Negative  1143 (91.4) 248 (88.6) 0.131 
(2.279) 
 
 165 (91.2) 100 (95.2) 0.203 
(1.624) 
 
Positive  107 (8.6) 32 (11.4)  16 (8.8) 5 (4.8) 
                  Tumour Size     
0.037  
(4.335) 
    
0.189  
(1.727) 
<1.5cm  330 (19.9) 58 (19.9)  33 (17.6) 14 (12.0) 
FP  951 (80.1) 233 (80.1)  155 (82.4) 103 (88.0) 
         Vascular Invasion         
Negative  730 (55.8) 146 (53.2) 0.062 
(3.488) 
 
 91 (48.7) 72 (62.1) 0.023 
(5.176) 
 
Positive  544 (44.2) 139 (46.8)  96 (51.3) 44 (37.9) 
       NPI        
Good  447 (35.3) 50 (17.5) 
<0.001 
(33.735) 
 4 (2.7) 2 (2.1) 
0.027 
(7.247) Moderate  636 (50.2) 180 (63.2)  40 (27.4) 42 (44.2) 
Poor  184 (14.5) 55 (19.3)  102 (69.9) 51 (53.7) 
         Age         
<50  428 (33.4) 95 (32.6) 0.802 
(0.063) 
 519 (31.8) 82 (36.6) 0.148 
(2.095)   853 (66.6) 196 (67.4)  1114 (68.2) 142 (63.4) 
         Death          
Negative  734 (70.2) 135 (57.9) <0.001 
(13.091) 
 107 (62.9) 83 (74.8) 0.038 
(4.295) Positive  312 (29.8) 98 (42.1)  63 (37.1) 28 (25.2) 
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4.3.1.3 Association with patient outcome  
EGFR positive expression showed significant shorter BCSS when compared 
with the negative expression cases (p < 0.001; Figure 4.3A). Also high EGFR 
expression was associated with worst outcome for DFI (p = 0.001; Figure 
4.3B), revealing higher difference in the first 120 months, remaining constant 
afterwards. Amongst the HER2+ trastuzumab naïve series, EGFR expression 
did not reveal any correlation with poor outcome for both BCSS (p = 0.0515; 
Figure 4.2C) and DFI (p = 0.430; Figure 4.3D). Similar result was obtained for 
HER2+ trastuzumab adjuvant. For both BCSS (p = 0.441; Figure 4.3E) and 
DFI (p = 0.370; Figure 4.3F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4: HER2/EGFR in breast cancer 
139 
Figure 4.3 ± BCSS and DFI survival analyses of EGFR IHC status amongst the 
Unselected series A) and B) or HER2+ trastuzumab naïve series C) and D) or HER2+ 
trastuzumab adjuvant E) and F). 
 
 
 
 
 
  
 
  
 
  
 
Unselected Series 
Trastuzumab Naïve Series 
Trastuzumab Adjuvant Series 
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4.3.2 HER2/EGFR 
 
 
4.3.2.1 HER2/EGFR in breast cancer  
The breast cancer cases in general revealed a range of signals/cell for 
HER2/EGFR heterodimer, which were predominantly detected on the 
membrane of tumour cells between 0 ± 28.7 signals/cell.  
 
Because the frequency of HER2/EGFR levels did not reveal a normal 
distribution, the cut-off point to define the heterodimer levels status was 
determined using X-tile345, which dichotomised data into low and high levels 
of heterodimerisation. It was therefore considered that low levels of 
HER2/EGFR heterodimers were in those cases showing less than 1.0 
HER2/EGFR signals per cell (Figure 4.4A). Any incidence above these limits 
were accepted as high levels of heterodimerisation (Figure 4.4B).  
 
The incidence of HER2/EGFR interaction was investigated in 812 breast 
carcinomas in Unselected series and 229 breast carcinomas amongst the 
HER2+ series revealing high levels of HER2/EGFR in 104 (12.8%) and 168 
(73.4%) cases respectively.  
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Figure 4.4 ± Photomicrographs of in situ PLA detection of HER2/EGFR heterodimers 
at x40 magnification and IHC detection at x20 magnification with a scale bar 
representing 100 µm. Case 1: Primary breast cancer cells displaying A) low levels of 
HER2/EGFR, B) HER2 protein expression and C) EGFR protein expression. Case 2: 
Primary breast cancer cells displaying D) high levels of HER2/EGFR, E) HER2 protein 
expression and F) EGFR protein expression. 
 
 
 
 
 
 
 
 
 
A 
B 
C 
 
 
 
 
 
D 
F 
E 
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4.3.2.2 Correlation with HER family monomers expression 
As expected, there was a strong positive correlation between HER2/EGFR 
heterodimer and HER2 status (p < 0.001) amongst the Unselected series (Table 
4.2). A total of 81/96 (84.4%) breast cancer cases exposing HER2/EGFR 
heterodimers were HER2+. Of the remaining 15 cases that showed 
HER2/EGFR heterodimers but not HER2 overexpression, the majority (11/15, 
73.3%) had very low levels of heterodimers (<2.4 signals/cell). Two cases had 
HER2 protein expression, regarded as 2+ determined by IHC but did not show 
gene amplification by CISH. The remaining two cases had high levels of 
HER2/EGFR heterodimers but no overexpression of HER2. There were a  
proportion of HER2+ cases (27/108, 25.0%) that did not reveal high levels of 
HER2/EGFR heterodimers. Interestingly, 59/89 (66.3%) cases with 
HER2/EGFR heterodimers did not express EGFR protein (p = 0.002).  
 
Similar to that observed in the Unselected series, the levels of the HER2/EGFR 
heterodimer in the HER2+ series was independent of EGFR expression (p = 
0.455) where approximately half cases showing the heterodimer were negative 
for EGFR protein.  There was 168/229 (73.8%) HER2 overexpressing cases 
that revealing HER2/EGFR high levels against 61 (26.2%) possessing low 
levels. Amongst these 61 cases, 31/61 (50.8%) cases were EGFR negative 
cases and the remaining 30/61 (49.2%) cases revealed low levels of the 
heterodimers despite HER2 positivity. From these 30 cases 21 (70%) possessed 
EGFR expression and the remaining 9 no data was available concerning EGFR 
expression (Table 4.2).  
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Table 4.2 ± Association between HER2/EGFR heterodimer levels and expression of HER 
family and hormone receptors in breast cancer. 
                                HER2/EGFR heterodimers expression 
Biomarker 
 
Unselected Series 
 
HER2+ series 
 Low (%) High (%) p value (Chi-Square)  Low (%) High (%) 
p value 
(Chi-Square) 
EGFR         
Negative  476 (80.7) 59 (66.3) 0.002 
(9.578) 
 31 (59.6) 81 (53.6) 0.455  
(0.558) Positive  114 (19.3) 30 (33.7)  21 (40.4) 70 (46.4) 
         HER2         
Negative  655 (96.0) 15 (15.6) <0.001 
(455.221) 
 0 (0.0) 0 (0.0) N/A Positive  27 (4.0) 81 (84.4)  61 (100) 168 (100) 
         HER3         
Negative  48 (8.5) 3 (3.6) <0.119 
(2.427) 
 4 (8.3) 5 (3.6) 0.190  
(1.716) Positive  519 (91.5) 81 (96.4)  44 (91.7) 133 (96.4) 
         HER4         
Negative  97 (17.1) 6 (7.0) 0.017 
(5.743) 
 0 (0.0) 5 (3.6) 0.184  
(1.763) Positive  471 (82.9) 80 (93.0)  47 (100) 132 (96.4) 
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4.3.2.3 Correlation with HER2 and EGFR mutual expression  
Where there were high levels of HER2 monomer, determined by IHC, the 
frequency of heterodimers increased dramatically up to 80% (Figure 4.2F). 
When the HER2 expression status was negative the levels of HER2/EGFR 
changed dramatically to low status on a frequency of nearly 99% (Table 4.3). 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.3 ± Frequency of HER2/EGFR levels against HER2 
and EGFR mutual expression status. 
Expression 
Status 
 HER2/EGFR 
 Low (%)  High (%) 
HER2+/EGFR+  13 (20.3)  51 (79.7) 
HER2+/EGFR-  8 (28.6)  20 (71.4) 
HER2-/EGFR+  93 (93.9)  6 (6.1) 
HER2-/EGFR-  461 (98.5)  7 (1.5) 
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4.3.2.4 Correlation with HER2 amplification 
Figure 4.5 represents the correlation between HER2 gene amplification with 
the number of detected signals/cell of HER2/EGFR heterodimers where there 
was a positive correlation observed (r2 = 0.381, p < 0.001). Most of the cases 
representing HER2/EGFR low levels remained under the HER2/CEN17 ratio 
2. 
 
 
 
 
Figure 4.5 ± Linear regression analysis between 
HER2/EGFR and HER2 gene amplification in breast cancer 
(Unselected series).  
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4.3.2.5 Correlation with histological tumour type 
There was a very strong correlation between histological types and 
HER2/EGFR levels ( 2 = 16.297, p = 0.003, Figure 4.6). A significantly higher 
percentage (20.8%) of medullary carcinomas showed of HER2/EGFR 
heterodimers. The highest number of HER2/EGFR heterodimers occurred in 
invasive ductal with 90 cases. No expression of HER2/EGFR heterodimers was 
observed in invasive lobular or tubular carcinomas. 
 
 
 
Figure 4.6 ± Correlation of histological tumour type and HER2/EGFR dimerisation levels for 
Unselected series (p = 0.003).  
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4.3.2.6 Correlation with the clinicopathological parameters  
Correlations between HER2/EGFR heterodimers and clinicopathological 
parameters are summarised in Table 4.4. Within the Unselected series, 
HER2/EGFR heterodimers were significantly associated with higher tumour 
grade, marked pleomorphism, higher mitotic frequency and poor NPI, (all p < 
0.001) and lack of tubule formation (p = 0.010). High HER2/EGFR 
heterodimer levels were also associated with presence of distant metastasis (p = 
0.005). Both local and regional recurrence (p = 0.033 and p = 0.042, 
respectively) and death due to breast cancer (p = 0.042) were also highly 
correlated with HER2/EGFR high levels. Though, tumour stage, tumour size, 
vascular invasion and age of the patient were not correlated with HER2/EGFR 
levels. 
 
Within the HER2+ series, HER2/EGFR heterodimers were associated with 
high tumour grade (p = 0.006), less of tubule formation (p = 0.033) and poor 
NPI score (p = 0.048). 
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Table 4.4 ± Association of HER2/EGFR dimerisation levels with clinicopathological 
parameters in breast cancer 
 
HER2/EGFR heterodimers status 
Parameters 
Unselected Series 
 
HER2+ Series     
Low (%) High (%) p value 
(Chi- Square)  
Low (%) High (%) p value 
(Chi- Square) 
Tumour Grade 
       
1 94 (13.3) 4 (3.8) 
<0.001 
(37.203) 
 
1 (1.6) 6 (3.6) 
0.006  
(9.3267) 2 231 (32.7) 11 (10.6)  20 (32.8) 25 (14.9) 3 381 (54.0) 89 (85.6) 
 
40 (65.6) 137 (81.5) 
        
 
       Tubule Formation 
       
1 21 (3.1) 2 (1.9) 
0.010 
(9.115) 
 
0 (0.0) 2 (1.2) 
0.033  
(6.795) 2 226 (33.4) 20 (19.4)  17 (28.3) 23 (13.9) 3 429 (63.5) 81 (78.6) 
 
43 (71.7) 140 (84.8) 
        
 
       Pleomorphism 
       
1 8 (1.2) 0 (0.0) 
<0.001 
(21.096) 
 
0 (0.0) 0 (0.0) 
0.113  
(2.506) 2 253 (37.5) 16 (15.5)  10 (16.7) 15 (9.1) 3 414 (61.3) 87 (84.5) 
 
50 (83.3) 149 (90.1) 
 
       
 
       Mitotic Frequency 
       
1 193 (28.6) 10 (9.7) 
<0.001 
(23.796) 
 
11 (28.3) 23 (14.5) 
0.490  
(1.426) 2 132 (19.5) 14 (13.6)  18 (23.3) 42 (26.1) 3 351 (51.9) 79 (76.7) 
 
31 (48.3) 99 (59.4) 
 
       Tumour Stage 
       
1 404 (57.3) 53 (51.0) 
0.104 
(4.522) 
 
23 (39.0) 70 (41.7) 
0.926  
(0.154) 2 233 (33.0) 34 (32.7)  23 (39.0) 64 (38.1) 3 68 (9.6) 17 (16.3) 
 
13 (22.0) 34 (20.2) 
 
       Distant Metastases 
       
No 471 (67.1) 55 (52.9) 0.005 
(8.067) 
 
47 (78.3) 118 (70.7) 0.252  
(1.310) Yes 231 (32.9) 49 (47.1) 
 
13 (21.7) 49 (29.3) 
        Local Recurrence 
       
No 406 (58.8) 48 (47.5) 0.033 
(4.543) 
 
 
49 (80.3) 117 (70.1) 0.123  
(2.379) 
 
Yes 285 (41.2) 53 (52.3) 
 
12 (19.7) 50 (29.9) 
      
        Regional Recurrence 
   
     
No 616 (89.1) 83 (82.2) 0.042  
(4.128) 
 
55 (93.2) 140 (90.9) 0.587  
(0.295) Yes 75 (10.9) 18 (17.8) 
 
4 (6.8) 14 (9.1) 
        
        Tumour Size 
  
 
0.406 
(0.690) 
   
 
0.866  
(0.028) 
<1.5 cm 147 (20.8) 18 (17.3) 
 
10 (16.4) 26 (15.5) 
FP 559 (79.2) 86 (82.7) 
 
51 (83.6) 142 (84.5) 
        
        Vascular Invasion 
       
No 367 (52.3) 46 (45.1) 0.175 
(1.838) 
 
34 (56.7) 90 (54.2) 0.744  
(0.1076) Yes 335 (47.7) 56 (54.9) 
 
26 (43.3) 76 (45.8) 
        
        NPI 
       
Good 160 (24.3) 7 (6.8) <0.001 
(31.055) 
 
15 (24.6) 21 (12.5) 
0.048 
(11.152) Moderate 402 (57.5) 63 (61.2)  37 (60.7) 95 (56.2) Poor 127 (18.2) 33 (32.1) 
  
9 (14.7) 52 (30.9) 
        Age 
  
0.310  
(1.029) 
    
<50 230 (32.5) 39 (37.5)  23 (37.7) 77 (46.7) 0.229 
(1.450)  478 (67.5) 65 (62.5)  38 (62.3) 88 (53.3) 
        
        Death 
       
No 374 (63.4) 47 (52.2) 0.042  
(4.130) 
 
47 (79.7) 114 (72.2) 0.261  
(1.265) Yes 216 (36.6) 43 (47.8) 
 
12 (20.3) 44 (27.8) 
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4.3.2.7 Correlation with expression of other biomarkers  
Concerning other biomarkers that are not included in the HER family, their 
association with HER2/EGFR heterodimers in the Unselected series are 
summarised in Table 4.5. High expression of HER2/EGFR heterodimers 
revealed a very significant association with CK18 (p < 0.001), PI3K (p = 
0.002), p53 (p < 0.001), Ki67 (p = 0.004) and PTEN (p = 0.007). On the other 
hand, a significantly negative association was observed against Bcl-2 (p < 
0.001), ER (p < 0.001) and PgR (p < 0.001).  
 
Within the HER2+ series, HER2/EGFR was positively correlated with only 
CK18 (p = 0.012). There was a significant association between high 
HER2/EGFR heterodimer status with negative ER and PgR status (p = 0.002 
and p = 0.016, respectively), Bcl-2 (p = 0.014) and CK14 (p = 0.014) 
expression. Though HER2/EGFR heterodimers were not associated with PI3K 
the heterodimers possessed a strong trend with PI3K (p = 0.051). 
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Table 4.5 ± Association between HER2/EGFR heterodimer levels and expression of 
biomarkers in breast cancer. 
                      HER2/EGFR Status 
Biomarkers 
 Unselected Series  HER2+ Series 
 Low (%) High (%) p value 
(Chi- Square) 
 Low (%) High (%) p value 
(Chi- Square) 
     
    CK5/6     
    
Negative  557 (81.4) 83 (83.9) 0.563 
(0.335) 
 33 (57.9) 94 (61.0) 0.679 
(0.172) Positive  127 (18.6) 16 (16.2) 
 24 (42.1) 60 (39.0) 
 
    
    CK7/8     
    
Negative  20 (2.9) 0 (0.0) 0.084 
(2.980) 
 1 (3.7) 0 (0.0) 0.086  
(2.954) Positive  662 (97.1) 99 (100) 
 26 (96.3) 79 (100) 
     
    CK14     
    
Negative  584 (86.5) 89 (89.0) 0.493 
(0.469) 
 35 (81.4) 123 (93.9) 0.014 
(6.056) Positive  91 (13.5) 11 (11.0)  8 (18.6) 8 (6.1) 
     
    CK18     
    
Negative  124 (19.7) 5 (5.3) 0.001 
(11.734) 
 6 (15.0) 
  
5 (3.8) 0.012 
(6.367) Positive  506 (80.3) 90 (94.7) 
 34 (85.0) 126 
 
     
   
 Bcl-2     
   
 
Negative  210 (40.1) 60 (76.9) <0.001 
(37.267) 
 26 (47.3) 93 (66.4) 0.014 
(6.092) Positive  314 (59.9) 18 (23.1) 
 29 (52.7) 47 (33.6) 
     
   
 pAkt     
   
 
Negative  127 (25.2) 16 (20.0) 0.311 
(1.027) 
 8 (33.3) 13 (20.3) 0.202 
(1.629) Positive  376 (74.8) 64 (80.0) 
 16 (66.7) 51 (79.7) 
     
   
 PI3K     
   
 
Negative  126 (21.7) 8 (10.0) 
0.002 
(12.346) 
 3 (5.8) 3 (2.2) 0.051 
(0.051) Moderate  153 (26.3) 14 (17.5)  10 (19.2) 12 (8.8) Strong  302 (52.0) 58 (72.5) 
 39 (75.0) 122 
      
   
 p21     
   
 
Negative  87 (78.4) 9 (90.0) 0.385 
(0.756) 
 10 (41.7) 15 (25.4) 0.144 
(2.138) Positive  24 (21.6) 1 (10.0) 
 14 (58.3) 44 (74.6) 
     
   
 MUC-1     
   
 
Negative  72 (12.5) 6 (7.3) 
0.385 
(1.911) 
 4 (7.3) 5 (3.4) 0.466 
(1.527) Moderate  278 (48.4) 43 (52.4)  28 (50.9) 73 (50.0) Strong  224 (39.0) 33 (40.2) 
 23 (41.8) 68 (46.6) 
     
   BRCA1     
    
Negative  326 (58.3) 57 (67.9) 0.097 
(2.759) 
 35 (66.0) 101 (69.2) 0.674 
(0.177) Positive  233 (41.7) 27 (32.1) 
 18 (34.0) 45 (30.8) 
     
    p53     
    
Negative  473 (70.9) 50 (50.5) <0.001 
(16.579) 
 20 (34.5) 54 (33.3) 0.874 
(0.025) Positive  194 (29.1) 49 (49.5) 
 38 (65.5) 108 (66.7) 
PTEN     
    
Weak  98 (19.0) 4 (5.1) 
0.007 
(9.913) 
 2 (4.7) 6 (5.6) 0.946  
(0.111) Moderate  191 (37.0) 30 (38.5)  19 (44.2) 49 (45.8) Strong  227 (44.0) 44 (56.4) 
 22 (51.2) 52 (48.6) 
 
    
    Ki67     
    
Weak  173 (30.6) 12 (14.1) 
0.004  
(11.186) 
 2  (11.1) 7 (10.6) 0.216  
(3.062) Moderate  209 (37.0) 34 (40.0)  
 
 11 (61.1) 26 (39.4) 
Strong  183 (32.4) 39 (45.9) 
 5 (27.8) 33 (50.0) 
        ER     
    
Negative  197 (29.4) 64 (66.0) <0.001 
(50.658) 
 23 (39.7) 102 
 
0.002  
(9.775) Positive  474 (70.6) 33 (34.0) 
 35 (60.3) 59 (36.6) 
 
    
    PgR     
    
Negative  296 (44.6) 72 (75.8) <0.001 
(32.266) 
 
 32 (54.2) 111 (71.6) 0.016  
(5.819) 
 
Positive  367 (55.4) 23 (24.2) 
 27 (45.8) 44 (28.4) 
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4.3.2.8 Correlation with the other HER heterodimers 
There was a strong association between HER2/EGFR heterodimerisation levels 
with both HER2/HER3 and HER2/HER4 for both the Unselected and HER2+ 
series (all p < 0.001; Figure 4.6).  
 
 
 
 
 
 
 
Table 4.6 ± Association of HER2/EGFR heterodimer and HER2/HER3 or 
HER2/HER4 heterodimer levels in breast cancer. 
 
 
 
 
 
 
 
 
 
 
                          HER2/EGFR Status 
Heterodimers 
 Unselected Series  HER2+ Series 
 Low 
(%) 
High 
(%) 
p Value 
(Chi- Square) 
 Low 
(%) 
High 
(%) 
p Value 
(Chi- Square) 
HER2/HER3 
   
 
<0.001 
(306.265) 
   
 
Low  387 
(97.5) 
11 
(16.7) 
 38 
(84.4) 
18 
(13.7) <0.001 
(77.182) High  10 
(2.5) 
55 
(83.3) 
 7 
(15.6) 
113 
(86.3) 
         HER2/HER4    
 
<0.001 
(274.489) 
    
Low  432 
(98.0) 
24 
(31.6) 
 41 
(95.3) 
36 
(26.3) 
<0.001 
(63.787) 
High  9 
(2.0) 
52 
(68.4) 
 2 (4.7) 101 
(73.7) 
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4.3.2.9 Association with patient outcome  
High levels of HER2/EGFR heterodimer were significantly associated with 
poor outcome in relation to both BCSS (p = 0.006) and DFI (p = 0.014) in the 
Unselected series (Figure 4.7A and B). However HER2/EGFR heterodimers 
amongst trastuzumab naïve and trastuzumab adjuvant cohorts did not reveal 
any significant association with either BCSS (Figure 4.7C and E, respectively) 
or DFI (Figure 4.7D and F, respectively).  
 
Amongst the Unselected series the multivariate Cox regression including 
tumour size, stage and grade, high levels of HER2/EGFR heterodimers was an 
independent predictor for worse BCSS (HR = 0.64, 95% CI= 0.45-0.89, p = 
0.009, Table 4.7) and DFI (HR = 0.64, 95% CI = 0.47-0.88, p = 0.005, Table 
4.7).  
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Figure 4.7 ± BCSS and DFI analysis for HER2/EGFR status amongst the Unselected 
series (A and B), Trastuzumab Naïve Series (C and D) and Trastuzumab Adjuvant Series 
(E and F). 
 
 
 
 
 
 
 
  
 
 
Trastuzumab Naïve Series 
 
Trastuzumab Adjuvant Series 
Unselected Series 
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Table 4.7 ± Multivariate Cox regression analysis of factors associated with BCSS and DFI for 
Unselected series. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
 BCSS  DFI 
 Hazard Ratio 
(95% CI) p Value  
Hazard Ratio 
(95% CI) p Value 
Tumour Size (cm)  0.52 (0.34-0.79) 0.002  0.66 (0.48-0.91) 0.010 
Tumour Stage 
 
1.92 (1.62-2.29) <0.001  1.78 (1.53-2.09) <0.001 
Tumour Grade 
 
1.49 (1.49-1.20) <0.001  1.23 (0.95-1.34) 0.163 
HER2/EGFR 
 
0.64 (0.45-0.89) 0.009  0.64 (0.47-0.88) 0.005 
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4.3.2.10 Association with ER status and patient outcome 
Survival analysis was conducted for HER2/EGFR heterodimers amongst both 
ER negative and ER positive populations in relation to BCSS and DFI. In the 
ER negative population, there was no association with either BCSS or DFI (p = 
0.138 and p = 0.165, respectively, Figure 4.8A and B). However for those 
patients with ER positive tumours and high HER2/EGFR heterodimer levels 
were significantly associated with worse BCSS (p = 0.009; Figure 4.9A) and 
DFI (p = 0.032; Figure 4.9B). 
 
For the first 60 months the prognosis was significantly different for the 
different HER2/EGFR levels.  Amongst the ER negative population that 
outcome difference still not significant for both BCSS (p = 0.156; Figure 4.8C) 
and DFI (p = 0.183; Figure 4.8D). Though amongst the ER positive patients for 
the first 60 months the difference of survival is highly significant for both 
BCSS (p = 0.004; Figure 4.9C) and DFI (p = 0.029; Figure 4.9D). 
 
The multivariate Cox regression model including tumour size, tumour stage 
and tumour grade, revealed that high levels of HER2/EGFR amongst the ER 
positive patients was not independently associated with worse BCSS (HR = 
0.62, 95% CI = 0.36-1.04, p = 0.070, Table 4.8) and DFI (HR = 0.68, 95% CI 
= 0.42-1.12, p = 0.134, Table 4.8) 
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Figure 4.8 ± BCSS and DFI analysis for HER2/EGFR status amongst the ER negative cases in 
Unselected series for a period of 250 months A) and B) or for a period of 60 months C) and 
D).  
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Figure 4.9 ± BCSS and DFI analysis for HER2/EGFR status amongst the ER positive 
cases in Unselected series for a period of 250 months A) and B) or for a period of 60 
months C) and D).  
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Table 4.8 ± Multivariate Cox regression analysis of factors associated with BCSS and DFI for 
ER positive cases in Unselected series. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
 BCSS  DFI 
 Hazard Ratio 
(95% CI) p Value  
Hazard Ratio 
(95% CI) p Value 
Tumour Size (cm)  0.51 (0.32-0.84) 0.007  0.64 (0.44-1.12) 0.022 
Tumour Stage  1.89 (1.50-2.38) <0.001  1.70 (1.39-2.08) <0.001 
Tumour Grade  1.52 (1.19-1.94) 0.001  1.20 (0.98-1.46) 0.084 
HER2/EGFR 
 
0.62 (0.36-1.04) 0.070  0.69 (0.42-1.12) 0.134 
Chapter 4: HER2/EGFR in breast cancer 
159 
 
4.3.2.11 Association with patient outcome in HER2+ trastuzumab adjuvant versus naïve  
Survival analysis of the adjuvant trastuzumab cohort against the trastuzumab 
naïve was performed and is represented in Figure 4.10A-D. Similar stage and 
grade patients from both cohorts were selected and matched in order to obtain 
comparable patients where the significant difference would be the in the 
treatment plan, which included or not trastuzumab. There was no significant 
GLIIHUHQW RQ SDWLHQWV¶ RXWFRPH ZKHQ +(5(*)5 OHYHls are low for both 
BCSS (p = 0.099; Figure 4.10A) and DFI (p = 0.056; Figure 4.10B). Using 
+(5(*)5 KLJK OHYHOV WR XQGHUVWDQG SDWLHQWV¶ VXUYLYDO RU UHODSVH
occurrences, the Kaplan-Meier analysis revealed that those receiving 
trastuzumab had a better outcome for BCSS (p < 0.001; Figure 4.10C) and DFI 
(p < 0.001; Figure 4.10D). At the end of 60 months the probability of survival 
for those receiving trastuzumab was above 80% comparing with not even 60% 
for the naïve group. 
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Figure 4.10 ± BCSS and DFI analysis for HER2/EGFR status amongst the HER2+ 
trastuzumab adjuvant series against HER2+ trastuzumab naïve series regarding A) and B) 
HER2/EGFR low levels or C) and D) HER2/EGFR high levels. 
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4.4 Discussion 
 
EGFR is not only a very critical biomarker in molecular classification but also 
valuable as a prognostic factor in breast cancer451. Mutual expression of EGFR 
and HER2 has been commonly detected in some types of carcinomas, 
particularly in ovarian452 and breast453. Moreover constitutive HER2/EGFR 
heterodimer is determinant on migration signalling of breast cancer cells454.  
The aims of this chapter were to investigate the expression of EGFR in breast 
cancer and whether its dimerisation with HER2 was associated with patient 
outcome and response to trastuzumab treatment. 
 
EGFR positive expression detected via IHC revealed to reach 20%, concurrent 
with previous study developed by Rampaul and colleagues438. Furthermore, it 
was revealed a co-expression of EGFR and HER2 monomers in 25%-35% of 
tumours442,444, which is comparable to the results presented, showing 38.4% of 
the patients with the same condition. Different prognostic suggestions were 
anticipated regarding EGFR expression associating with high levels of 
proliferation and development of metastases419, but also been associated with 
decline of tumour progression421. In this study EGFR was highly associated 
with presence of metastases, higher tumour grade and high tumour size, which 
is supported by other studies423,430. But contradicting the same studies EGFR 
expression was not associated with tumour stage. Even though only 2.7% of 
the EGFR positive cases are associated with poor prognosis455. It was 
demonstrated that 19.3% were associated with poor NPI score and the 
correlation with death occurrence due to breast cancer was highly significant. 
Amongst the HER2+ series, EGFR expression did not reveal to be relevant 
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against clinicopathological parameters as amongst the Unselected series. 
Understandably the outcome of those patients possessing high expression of 
EGFR was worse amongst the Unselected series in concordance with previous 
studies414 but no significance was observed when co-expressed with HER2, 
also sustained by Rehim and colleagues331. Different studies have been 
revealing different results regarding EGFR expression with some suggesting a 
correlation with worse prognosis and recurrence great prevalence436,437 and 
those that discovered no association438,439. 
 
Even though, multiple studies were performed concerning EGFR and HER2 
co-expression but none have reported the prognostic values of the heterodimer. 
HER2/EGFR dimerisation frequency revealed to be present in 12.8% of the 
Unselected series against the 35% previously reported for HER2 and EGFR co-
expression444. This difference of frequency indicates that further mechanisms 
are involved in heterodimerisation such as ligand/receptor interaction249. Also 
supports the idea that PLA detects primarily protein interactions and not co-
localisation of monomers as suggested by different studies456,457.   
 
The frequency of HER2/EGFR heterodimer high levels drops dramatically 
(from 71.4% to 6.1%) when HER2 monomer scoring turns to negative. The 
reduction was almost inexistent (from 79.7% to 71.4%) when EGFR monomer 
expression becomes deficient. This dramatic difference might explain the idea 
that dimerisation occurrence may not be dependent on EGFR overexpression 
but can also materialise when its levels are not considered positive using IHC. 
Furthermore dimerisation is dependent on ligand/EGFR32 activation reaction 
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upstream and not on EGFR overexpression individually. The expression of the 
ligands EGF and TGF  is extremely correlated with EGFR expression249 
promoting cancer development and aggressiveness, though EGFR is dependent 
on these ligands to become in an activated conformation268. In contrast, HER2, 
which is unable to interact with any ligand, must be only highly expressed in a 
constant competent form to function as co-receptor63. However still some 
inconsistencies, when is observed high levels of HER2/EGFR while none of 
the monomers were positively scored, representing 8.3% of the total cases. One 
explanation might reside on the antibodies used in both techniques for the 
respective labelling. For both technologies was used the same anti-HER2 
antibody, however due to methodology restrictions each technique required a 
different anti-EGFR antibody. Therefore different antibodies react against 
different epitopes delivering different levels of sensitivity and specificity. 
Additionally pre-treatments during the procedure such as antigen-retrieval 
unmask the epitopes to make them available for interaction with the respective 
antibody458. In this study for both methods the antigen retrieval treatment 
consists in different methodologies delivering some variances in the results. 
Though, the correlation between the HER2/EGFR heterodimers levels and the 
monomers results still highly significant.  
 
The analyses of HER2/EGFR levels against HER2 amplification revealed to be 
very interesting by the observation of the significant differences on 
HER2/EGFR levels between both margins of the cut-off established for 
HER2/CEN17 ratio to define the amplification status. Most of the high levels 
of HER2/EGFR heterodimers were associated with HER2 gene amplification. 
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It was observed some cases that whilst there was HER2 amplification and 
EGFR expression, heterodimerisation did not occur, supporting the idea that 
other mechanisms are critical on dimerisation occurrence167,249,459. 
 
The very high association of HER2/EGFR with distant metastases occurrence 
and high mitotic frequency is promoted by cell proliferation and apoptosis 
evasion, which is correlated with PI3K107,460,461. Throughout the tumour 
development, a shift is required to modify the cells behaviour, resulting in 
motility competence from the main carcinoma cluster invading adjacent 
tissues. EGFR homodimers and HER2/EGFR heterodimers are assembled by 
EGF ligand stimulation, but HER2 is the critical to activate PLC-ȖVXSSRUWLQJ
the idea that the heterodimers are favoured over the homodimers462. 
HER2/EGFR trigger downstream pathways that control PLC-Ȗ VLJQDO
transduction and triggers cell motility107. Furthermore PLC-Ȗ VLJQDO
transduction is not only triggered directly by HER2/EGFR heterodimer but 
also indirectly by PI3K447. This indirectly triggering of PI3K is regulated by 
HER2/HER3 heterodimerisation signalling transduction108, suggesting a 
possible crosstalk between HER2/EGFR and HER2/HER3461. In this study it 
was revealed a strong association between HER2/EGFR with PI3K expression 
and also between both HER heterodimers supporting the idea of a possible 
crosstalk between them. As anticipated Bcl-2 has an important role in breast 
carcinomas being highly associated with ER positivity however its lost is 
associated with other poor prognostic markers such as p53, EGFR and HER2 
expressions463. It was even suggested that EGFR ligands had an important role 
on downregulation of Bcl-2463. In this study HER2/EGFR high levels 
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demonstrated a negative association with both Bcl-2 and ER for both series, 
but highly associated with strong expression of p53 in only the Unselected 
series. This supports the idea that Bcl-2 anti-apoptotic role might be regulated 
by the hormone receptors previously defended463. However does not necessary 
supports the idea that cell harbouring high levels of HER2/EGFR are directed 
to apoptosis. Two studies revealed that the levels of CK18 degrades with 
apoptosis occurrence464,465, which confirm the idea that HER2/EGFR is 
involved in apoptosis evasion processes by being associated with CK18 
expression in both cohorts. Also the HER2/EGFR high levels were highly 
correlated with Ki67, which is involved in high levels of cell proliferation397.   
 
Although the monomers EGFR and HER2 overexpression amongst breast 
cancer have been previously correlated with worse outcome466,467, 
HER2/EGFR heterodimerisation has not been well documented in breast 
cancer. In this chapter, it is shown for the first time that HER2/EGFR 
heterodimers were highly prevalent in HER2+ breast cancer and were 
correlated with poor outcome. This is in contrast to a previous study which 
showed that EGFR and HER2 co-expression had no significant association 
with survival331. Moreover the HER2/EGFR high levels were identified as an 
independent prognostic factor in multivariate analysis. Amongst the HER2+ 
trastuzumab naïve cohort the prognostic analysis did not reveal to be 
significant, though nearly significant for DFI outcome. For the first 80 months 
of trastuzumab adjuvant treatment, HER2/EGFR levels did not demonstrate 
any worse outcome or development of resistance to this target therapy.  
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Because of a negative association of HER2/EGFR heterodimer against ER 
OHYHOV LW ZDV UHOHYDQW WR XQGHUVWDQG WKH LPSOLFDWLRQ RQ SDWLHQWV¶ VXUYLYDO
Indeed if ER status is negative, the patients with high levels of HER2/EGFR 
heterodimerisation did not possess a worse outcome. When ER positivity is 
present, those cases possessing high levels of HER2/EGFR demonstrated a 
worse outcome, especially significant for BCSS. However HER2/EGFR was 
not identified as an independent prognostic factor in multivariate analysis. The 
reason for this fact is probably because of the negative correlation with ER, 
which is recognised as a prognostic factor in breast cancer468. This poor 
prognosis is developed throughout the first 60 months after diagnosis, 
suggesting that a even though negatively associated, if both classes of receptors 
are expressed in breast carcinomas, a signalling crosstalk between them takes 
place contributing for development of aggressiveness. The association of 
HER2/EGFR with PI3K might explain this poor outcome, due to PI3K also be 
connected with activation of ER and its co-regulators. This cycle of HER2/ER 
crosstalk is involved in carcinomas development and resistant to 
therapies105,109.  
 
Finally it was possible to demonstrate the significant role of HER2/EGFR 
amongst breast carcinomas and moreover the effectiveness of trastuzumab by 
revealing the similar outcome between both HER2+ series in case the dimer is 
not present in high levels. Though the prognostic data for those submitted to 
trastuzumab revealed to be considerable improved comparing with trastuzumab 
naïve patients.  
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In conclusion, PLA demonstrated to be a reliable, reproducible and able to 
quantify HER2/EGFR heterodimers in FFPE clinical cores. The high levels of 
HER2/EGFR seem to associate with poor outcome confirming the hypothesis 
proposed. However the results demonstrated no development of resistant to 
trastuzumab by patients possessing high levels of HER2/EGFR. Possibly the 
series did not involve enough number of cases to turn the results expressively 
different. Nonetheless the significance of multiple protein interactions and 
identification of both upstream and downstream protein interactions, such as 
ligand/receptor, might still relevant on selection of patients to be submitted to 
new developed therapies as lapatinib or other monoclonal therapeutic 
antibodies. Therefore the present results sustain the idea of further 
investigations to characterise in more detail the biochemistry of HER2/EGFR.  
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5. CHAPTER 5: The role of HER3 in HER2+ breast 
cancer 
 
 
5.1 Introduction 
 
5.1.1 HER3 in breast cancer  
The third member of HER proto-oncogene family, HER3, is located on 
chromosome 12 location 12q13 with a protein molecular weight of 145 kDa469. 
By itself HER3 does not comprise an activated tyrosine kinase due to a storing 
of extra inactive residues (histidine and asparagine) in its structure that 
substitute the active residues (glutamate and asparate)469. Therefore HER3 
requires contact with another HER member to trigger a signalling cascade64, 
which makes this monomer as an obligate partner for heterodimerisation43. A 
study using mouse mutants deficient in HER3 expression showed that only 
20% survived to embryonic stage; however remaining pups died shortly after 
birth, showing several imperfections on development and differentiation of 
Schwann cells. They also did not respond to tactile stimulus and showed 
abnormal development of the lung. Nevertheless, mammary epithelial cells 
were not affected by lack of HER3 expression, as expression of HER4 
compensated for this loss as it possesses similar roles470.  
 
In breast tumour tissues, HER3 possesses a high affinity to bind with PI3K 
promoting anti-apoptotic reaction471. The SH2 domains acts as a PI3K linkage 
to the receptor with reasonable to elevated attraction472. Levels of HER3 in 
breast tumour cells can raise considerably compared with their normal 
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counterparts as a result of either higher protein expression caused by either 
protein translation or increased half-life of the receptor470. When HER2 is 
inactivated by antagonist antibodies, a decrease of HER3 signalling activity 
occurs, due to overexpression of HER3 and HER2 being greatly 
associated70,283. Indeed HER3 might have a role with HER2 on promotion of 
cell transformation and breast cancer progression470 and is the preferred 
heterodimer arrangement with proliferative downstream pathways43. Lack of 
HER3 in breast cancer cells are strongly antiproliferative, although still 
expressing EGFR and HER4 suggesting that EGFR or HER4 are not competent 
to substitute for the absence of HER360. The heterodimer HER2/HER3 is 
imperative in cell proliferation by keeping constitutive action of PI3K/PKB 
downstream signalling473.    
 
Overexpression of HER3 is associated with poor prognosis in different types of 
cancer such as breast, lung and ovarian474. It was reported that 17.5% of breast 
cancer patients show high expression of HER3 associated with poor 
prognosis21, including association with high grade475 and recurrence476. 
However its prognostic value still not coherent when other studies reveal an 
absence of correlation between HER3 overexpression and poor survival in 
breast carcinomas476. 
 
The HER3 endoplasmic domain is unique since EGFR and HER2 do not 
comprise the same kinase domain molecular structure and HER4 only 
possesses a single PI3K link spot included in one of its isoforms477. However 
another important characteristic of HER3 is in its ectodomain, which is able to 
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link with numerous ligands contributing to homodimerisation creation 
avoidance478. This increases the limitation on HER3 activation and 
downstream pathways being triggered. However this feature might be a mode 
to control PI3K premature activation197. Being a very important regulator of 
cellular processes as cell proliferation, PI3K precipitate triggering has to be 
avoided. Therefore HER3 activation is limited by the lack of a kinase domain 
on its structure which is compulsory on the other members of the HER family 
and their respective ligands203. Moreover if ligand activation does not occur, 
the c-terminal tail is in trans conformation making allosteric activation 
impossible479. HER3 C-terminal possesses 14 tyrosines, which can harbour 
several SH2 or PTB binding molecules responsible for the trigger of 
downstream pathways480,481. After PI3K is activated by phosphorylated HER3, 
it is able to activate phosphoinositides present on the cell membrane, which 
through a subsequent chain of activations will trigger Akt. Akt is able to 
regulate a cascade of molecules responsible for survival, proliferation and 
differentiation of the cell482, including the mTor pathway, which coordinates 
cell growth and important metabolic reactions depending on the nutrients and 
energy accessible483. Therefore HER3 expression can be extremely significant 
in making accessible the other members of the same family for the regulation 
of Akt482. 
 
HER3 is not itself considered as an oncogene; however it is classified as a 
compulsory assistant of HER family oncogenesis. HER3 when is 
overexpressed is not associated with cancer development by itself484. Moreover 
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it has not been reported that any activating mutations or gene transformations 
of HER3 present oncogenic action93,485. 
 
In HER2 amplified breast cancer cell lines, a decline of transformed growth 
occurs when HER3 is knocked down, whereas no alterations are seen with loss 
of EGFR expression. Thus, it was possible to suggest that HER3 is critical on 
the growth of HER2 amplified breast carcinomas486. Coherently, HER3 is 
consistently coexpressed in the majority of HER2 amplified breast cancers, 
however EGFR does not follow the same tendency475.  
 
HER3 is expressed in different types of cancer, e.g. melanoma, where it is not 
associated with HER2 expression suggesting HER3 might serve as an allosteric 
activator of EGFR or HER4487. Even though it is not implicated in prostate 
cancer pathogenesis, HER3 overexpression is critical in most of the 
transformed phenotypes of prostate carcinomas488. In the same way HER3 is 
detected in a high number of colorectal carcinomas489 where HER3 is 
associated with HER4490. Within lung carcinomas, HER3 overexpression 
frequency ranges between 18% and 100% and is linked with poor 
outcome491,492.  Similarly, HER3 overexpression in ovarian cancers may vary 
from 3% to 90%493-495, although it is not associated with poor survival 
outcome474. 
 
5.1.2 HER2/HER3 in breast cancer 
The HER2/HER3 heterodimer effectively triggers downstream signalling 
responsible for proliferation and survival496, reacting as an oncogenic element 
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driving breast carcinomas to high levels of propagation108. Additionally 
chemotaxis is indirectly stimulated by this heterodimer creating distant 
metastasis497.   
 
HER3 presence in breast carcinomas is highly associated with anti-apoptosis 
development by promotion of PI3K pathway471. Cell transformation and breast 
carcinoma progression might be triggered by HER2 and HER3 interaction498 
being narrated as the most common heterodimer associated with proliferative 
downstream pathways43. Therefore the heterodimer HER2/HER3 could be 
essential to sustain a constitutive role of the PI3K downstream pathway473.  
 
Even though HER2 and HER3 are not able to form homodimers and promote 
any downstream pathways, the heterodimerisation between these two 
monomers creates a highly functional triggering intracellular domain43. The 
HER2/HER3 dimer is the combination of HERs with superior effectiveness 
when compared with any homodimer or heterodimer amongst this receptor 
tyrosine kinase family. This oncogenic combination promotes phosphorylation 
of the downstream pathways Erk1/2 (MAPK) and PI3k/Akt promoting cells 
proliferation (Figure 5.1)499,500. 
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Figure 5.1 ± The main downstream pathways triggered by HER family dimers activated by the 
ligands, with the example of HER2/HER3 dimerisation.  
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5.2 Methods 
 
Immunohistochemical detection of HER3 was achieved by using the anti-
HER3 (clone RTJ1, Leica) antibody and appliance of Novolink Polymer 
Detection Systems method following the antigen retrieval pre-treatment. In 
positive control tonsil tissue, HER3 was distributed mostly in the cells 
membrane. Detection of the heterodimer HER2/HER3 was performed by 
applying the PLA technology as described in chapter 2 using two antibodies 
from different species reacting under the same pre-treatment conditions (rabbit 
anti-HER2 (Dako) and mouse anti-HER3 (clone 2F12, Neomarkers)). The red 
signals present mostly in the cancer cells membrane were quantified and the 
cut-off achieved using the same methodology applied for HER2/EGFR 
heterodimerisation.  
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5.3 Results 
 
 
5.3.1 HER3 
5.3.1.1 Expression in breast cancer  
Amongst the Unselected series HER3 negative expression was detected in 
170/1509 (11.3%) cases and the positive expression in 1339/1509 (88.7%) 
cases. The HER2+ series revealed only 21/278 (7.6%) cases with negative 
expression for HER3 and 257/278 (92.4%) patients possessed positive 
expression (Figure 5.2). 
 
 
 
 
Figure 5.2 ± Detection of HER3 protein expression in breast cancer cores by 
immunohistochemistry. The cells were labelled with a specific antibody against HER3 to 
detect the intensity of expression of this protein present mostly in the cell membrane. The cells 
are scored in four different classes of protein expression: (A) Negative when a faint 
membranous immunoreactivity was observed in less than 10% of the cancer cells and (B) 
Positive when more than 10% of the invasive carcinoma cells show a weak/moderate 
perceptible membranous reactivity. 
 
 
 
      
A    B 
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5.3.1.2 Correlation with clinicopathological parameters 
Overexpression of HER3 protein amongst the Unselected series was highly 
associated with higher tumour grade, more nuclear pleomorphism, higher 
mitotic frequency and poor NPI (all p < 0.001). Additionally HER3 expression 
was correlated with less tubule formation (p = 0.003), higher tumour stage (p = 
0.010) and higher vascular invasion (p = 0.007) (Table 5.1).  
 
For the HER2+ series, the HER3 expression was not significantly associated 
with any of the clinicopathological parameters (Table 5.1).  
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Table 5.1 ± The relation between HER3 status with clinicopathological parameters in 
breast cancer. 
                                   HER3 Status 
Parameters 
 Unselected Series  HER2+ Series 
 Neg  (%) Pos (%) p value  (Chi-Square) 
 Neg  (%) Pos (%) p value  (Chi-Square) 
Tumour Grade         
1  60 (31.4) 208 (15.8) 
<0.001  
(45.141) 
 1 (4.8) 5 (1.9) 
0.211  
(3.113) 2  70 (39.8) 417 (31.7) 
 6 (28.6) 41 (16.0) 
3  55 (28.8) 691 (52.5)  14 (66.7) 211 (82.1) 
         Tubule Formation         
1  18 (9.7) 71 (5.5) 0.003  
(11.509) 
 0 (0.0) 1 (0.4) 
0.386  
(1.905) 2  76 (40.9) 422 (32.9) 
 6 (30.0) 45 (17.7) 
3  92 (49.5) 788 (61.5)  14 (70.0) 208 (81.9) 
Pleomorphism         
1  10 (5.4) 19 (1.5) 
<0.001  
(54.580) 
 0 (0.0) 0 (0.0) 
0.116  
(2.475) 2  110 (59.1) 460 (36.1) 
 4 (20.0) 23 (9.1) 
3  66 (35.5) 797 (62.5)  16 (80.0) 230 (90.9) 
         Mitotic Frequency         
1 
 
 95 (51.1) 439 (34.3) 
<0.001  
(21.713) 
 3 (15.0) 30 (11.8) 
0.354  
(2.075) 2  33 (17.7) 240 (18.7) 
 2 (10.0) 61 (24.0) 
3  58 (31.2) 602 (47.0)  15 (75.0) 163 (64.2) 
         Tumour Stage         
1  138 (72.3) 804 (61.2) 0.010  
(9.224) 
 13 (61.9) 113 (44.0) 
0.184  
(3.391) 2  39 (20.4) 400 (30.4) 
 4 (19.0) 99 (38.5) 
3  14 (7.3) 110 (8.4)  4 (19.0) 45 (17.5) 
         Distant Metastases         
Negative  130 (68.4) 913 (69.7) 0.722  
(0.127) 
 14 (66.7) 171 (67.1) 0.971  
(0.001) Positive  60 (31.6) 397 (30.3)  7 (33.3) 84 (32.9) 
         Local Recurrence         
Negative  105 (55.9) 800 (62.3) 0.089 
(2.885) 
 
 13 (61.9) 171 (67.3) 0.612 
(0.257) 
 
Positive  83 (44.1) 484 (37.7)  8 (38.1) 83 (32.7) 
       Regional Recurrence         
Negative  175 (93.1) 1165 (90.7) 0.292 
(1.112) 
 19 (90.5) 228 (93.1) 0.659 
(0.195) 
 
 
Positive  13 (6.9) 119 (9.3)  2 (9.5) 17 (6.9) 
         Tumour Size         
<1.5cm  48 (25.1) 326 (24.8) 0.915 
(0.012) 
 3 (14.3) 37 (14.4) 0.989 
(0.001) 
 
FP  143 (74.9) 990 (75.2)  18 (85.7) 220 (85.6) 
         Vascular Invasion         
Negative  125 (65.4) 718 (55.1) 0.007 
(7.304) 
 13 (61.9) 133 (52.2) 0.390 
(0.740) Positive  66 (34.6) 586 (44.9)  8 (38.1) 122 (47.8) 
         NPI         
Good  91 (47.9) 384 (29.5) 
<0.001 
(28.449) 
 1 (6.3) 4 (2.0) 
0.460 
(1.553) Moderate  84 (44.2) 702 (54.0) 
 4 (25.0) 68 (33.3) 
Poor  15 (7.9) 214 (16.5)  11 (68.8) 132 (64.7) 
Age         
<50  66 (34.6) 435 (33.0) 0.676 
(0.175) 
 11 (55.0) 112 (43.9) 0.337 
(0.921)   125 (65.4) 882 (67.0)  9 (45.0) 143 (56.1) 
         Death          
Negative  91 (63.6) 756 (69.0) 0.191 
(1.710) 
 8 (50.0) 164 (68.0) 0.137 
(2.208) Positive  52 (36.4) 339 (31.0)  8 (50.0) 77 (32.0) 
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5.3.1.3 Association with patient outcome  
The survival analyses for HER3 monomer amongst the Unselecteed series 
revealed no significant worse prognosis between those patients that express 
high levels of HER receptor and those not revealing any expression, for both 
BCSS (p = 0.762; Figure 5.3A) and DFI (p = 0.286; Figure 5.3B).  
 
Kaplan-Meier test was not performed for both trastuzumab adjuvant and naïve 
series because over 90% of the cases were HER3 positive, which would not 
reveal any significant results.  
 
 
 
 
Figure 5.3 ± A) BCSS and B) DFI analysis for HER3 status amongst the Unselected 
series. 
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5.3.2 HER2/HER3 
5.3.2.1 HER2/HER3 in breast cancer  
In breast carcinoma cells the HER2/HER3 heterodimers signals were mostly 
detected in the cell membrane on a range of 0 to 34.6 signals per cell. The cut-
off defined as low levels those cases revealing less than 4.5 HER2/HER3 
signals per cell (Figure 5.4A) and high levels were considered for any 
occurrence above that value (Figure 5.4D).  
 
The frequency of HER2/HER3 heterodimers high levels was detected in 
97/743 (13.1%) for the Unselected series and 149/226 (65.9%) amongst the 
HER2+ series.  
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Figure 5.4 ± Photomicrographs of in situ PLA detection at HER2/HER3 heterodimers 
at x40 magnification and IHC detection at x20 magnification with a scale bar 
representing 100 µm. Case 1: Primary breast cancer cells displaying A) low levels of 
HER2/HER3, B) HER2 protein expression and C) HER3 protein expression. Case 2: 
Primary breast cancer cells displaying D) high levels of HER2/HER3, E) HER2 
protein expression and F) HER3 protein expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
 
B 
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F 
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5.3.2.2 Correlation with HER family monomers expression 
The correlation between HER2/HER3 and the HER family monomers is 
summarised in Table 5.2 A significant proportion (p < 0.001) of cases showing 
HER2/HER3 heterodimers were HER2+ (79/89, 88.8%). Of those remaining, 
7/10 (70.0%) cases had relatively low levels of heterodimers as detected by 
PLA (<6.9 signals/cell) and 3/10 (30.0%) cases had increased HER2 protein 
expression (2+) but showed no gene amplification by CISH analysis. There 
were a number of HER2+ cases, 33/112 (29.5%) that did not show dimerisation 
of HER2/HER3. There was no significant association (p = 0.999) between 
HER2/HER3 heterodimer and HER3+ tumours although the majority of cases 
with high HER3 displayed high levels of HER2/HER3 heterodimers 71/78 
(91.0%). However, 477/548 (87.1%) of HER3+ cases were correlated with low 
levels of HER2/HER3 heterodimers, which means that amongst a total of 548 
HER3+ cases only 71 (12.9%) were associated with high levels of 
HER2/HER3 heterodimers.  
 
Within the HER2+ series, the majority of the patients (149/226, 65.9%) were 
associated with HER2/HER3 dimerisation. There was no correlation between 
HER2/HER3 heterodimers and HER3 expression (p = 0.450), with 117/123 
(95.1%) of cases with high heterodimer levels and 61/66 (92.4%) of low-level 
cases being HER3 positive. A total of 6/123 (4.9%) revealing high levels of the 
HER2/HER3 heterodimers showed negative expression of HER3 despite 
showing strong HER2 protein expression (IHC score of 3+).    
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Table 5.2 ± Association between HER2/HER3 levels and expression of HER family monomers 
in breast cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          HER2/HER3 Status 
Biomarker 
 
 
Unselected Series 
  
HER2+ Series 
 Low (%) High (%) p value (Chi-Square)  Low (%) High (%) 
p value 
(Chi-Square) 
EGFR         
Negative  430 (79.2) 60 (74.1) 0.296 
(1.094) 
 45 (66.2) 73 (55.3) 0.139 
(2.194) Positive  113 (20.8) 21 (25.9)  23 (33.8) 59 (44.7) 
         HER2         
Negative  599 (94.8) 10 (11.2) <0.001 
(414.975) 
 0 (0.0) 0 (0.0) 
N/A Positive  33 (5.2) 79 (88.8)  77 (100) 149 (100) 
         HER3         
Negative  47 (9.0) 7 (9.0) 0.999 
(0.0) 
 5 (7.6) 6 (4.9) 0.450 
(0.570) Positive  477 (91.0) 71 (91.0)  61 (92.4) 117 (95.1) 
         HER4         
Negative  82 (15.4) 5 (6.8) 0.048 
(3.919) 
 1 (1.8) 3 (2.1) 0.618 
(0.249) Positive  452 (84.6) 69 (93.2)  68 (98.2) 118 (97.5) 
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5.3.2.3 Correlation with HER2 and HER3 mutual expression 
While the expression of both monomers was positive the levels of 
HER2/HER3 heterodimers was significantly high (70.7%). However if only 
HER2 expression becomes negative or even both monomers the levels of 
dimerisation drops considerably to 1.3% (Table 5.3).  
 
 
 
Table 5.3 ± Frequency of HER2/HER3 levels against HER2 
and EGFR mutual expression status. 
Expression 
Status 
 HER2/HER3 
 Low (%)  High (%) 
HER2+/HER3+  24 (29.3)  58 (70.7) 
HER2+/HER3-  2 (25.0)  6 (75.0) 
HER2-/HER3+  439 (98.7)  6 (1.3) 
HER2-/HER3-  51 (98.1)  1 (1.9) 
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5.3.2.4 Correlation with HER2 amplification 
The relation between HER2/HER3 heterodimer levels with HER2 gene 
amplification is shown in Figure 5.5 where HER2/HER3 dimerisation levels 
were significantly associated with gene HER2 amplification (r2 = 0.429, p < 
0.001). The majority of the HER2 non-amplified cases were showed low levels 
of HER2/HER3 heterodimers. 
 
 
 
 
Figure 5.5 ± Linear regression analysis between 
HER2/HER3 and HER2 gene amplification in the breast 
cancer (Unselected series). 
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5.3.2.5 Correlation with clinicopathological parameters  
Table 5.4 summarises the correlations between HER2/HER3 heterodimers 
levels and clinicopathological variables. Within the Unselected series, 
HER2/HER3 heterodimers were significantly correlated with higher tumour 
grade (p = 0.001), tumour stage (p < 0.001), marked nuclear pleomorphism (p 
< 0.001), higher mitotic frequency (p = 0.001), lack of tubule formation (p = 
0.017), development of metastases (p = 0.004), poor NPI (p < 0.001) and death 
(p = 0.004).  
 
Within the HER2+ series, the association with the clinicopathological 
parameters was restricted only to tumour grade (p = 0.017) but not any of its 
specific components. Additionally there was no correlation between 
HER2/HER3 heterodimerisation levels and any histological tumour type (p = 
0.379). 
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Table 5.4 ± Association of HER2/HER3 levels with clinicopathological parameters in breast 
cancer. 
     HER2/HER3 Status 
Parameter 
Unselected Series  HER2+ Series     
 Low (%) High (%) p value 
(Chi-Square)  Low (%) High (%) 
p value 
(Chi-Square) 
        Tumour Grade        
1 84 (13.0) 5 (5.2) 
<0.001 
(21.591) 
 1 (1.3) 6 (4.0) 0.017 
(8.159) 2 196 (30.3) 13 (13.4)  21 (27.3) 19 (12.8) 3 366 (56.7) 79 (81.4)  55 (71.4) 124 (83.2) 
        Tubule Formation        
1 23 (3.7) 1 (1.1) 
0.017 
(8.143) 
 0 (0.0) 1 (0.7) 0.455 
(1.576) 2 213 (34.1) 21 (22.1)  16 (21.3) 23 (15.6) 3 388 (62.2) 73 (76.8)  59 (78.7) 123 (83.7) 
        Pleomorphism        
1 6 (1.0) 0 (0.0) 
<0.001 
(18.532) 
 0 (0.0) 0 (0.0) 0.137 
(2.209) 2 219 (35.2) 13 (13.8)  11 (14.7) 12 (8.2) 3 397 (63.8) 81 (86.2)  64 (85.3) 134 (91.8) 
        Mitotic Frequency        
1 173 (27.7) 11 (11.6) 
0.001 
(13.126) 
 13 (17.3) 21 (14.3) 0.355 
(2.069) 2 115 (18.4) 16 (16.8)  22 (29.3) 33 (22.4) 3 336 (53.8) 68 (71.6)  40 (53.3) 93 (63.3) 
        Tumour Stage        
1 386 (59.8) 49 (50.5) 
0.001 
(13.086) 
 35 (46.7) 66 (44.3) 0.334 
(2.191) 2 207 (32.1) 29 (29.9)  29 (38.7) 49 (32.9) 3 52 (8.1) 19 (19.6)  11 (14.7) 34 (22.8) 
        Distant Metastases        
No 432 (67.5) 51 (52.6) 0.004 
(8.305) 
 60 (77.9) 100 (68.0) 0.119 
(2.424) Yes 208 (32.5) 46 (47.4)  17 (20.1) 47 (32.0) 
        Local Recurrence        
No 363 (57.6) 46 (47.9) 0.074 
(3.188) 
 59 (76.6) 100 (67.6) 0.157 
(2.004) Yes 267 (42.4) 50 (52.1)  18 (23.4) 48 (32.4) 
        Regional Recurrence 
       
No 557 (88.4) 84 (87.5) 0.796 
(0.067) 
 71 (95.9) 127 (91.4) 0.214 
(1.547) Yes 73 (11.6) 12 (12.5)  3 (4.1) 12 (8.6) 
        Tumour Size        
<1.5 cm 142 (22.0) 14 (14.4) 0.089 
(2.897) 
 10 (13.0) 24 (16.1) 0.534 
(0.387) FP 504 (78.0) 83 (85.6)  67 (87.0) 125 (83.9) 
        
        Vascular Invasion        
No 357 (55.7) 45 (46.9) 0.106 
(2.619) 
 36 (47.4) 81 (54.7) 0.296 
(1.091) Yes 284 (44.3) 51 (53.1)  40 (52.6) 67 (45.3) 
        
        NPI        
Good 166 (27.8) 7 (7.4) 
<0.001     
(30.329) 
 12 (15.6) 17 (11.5) 0.200     
(7.295) Moderate 363 (56.5) 59 (62.1)  51 (66.3) 84 (56.4) Poor 113 (17.6) 29 (30.5)  14 (18.2) 48 (32.2) 
        Age        
<50 235 (36.4) 33 (34.0) 0.652 
(0.203) 
 33 (43.4) 67 (45.6) 0.759 
(0.094)  411 (63.6) 64 (66.0)  43 (56.6) 80 (54.4) 
                Death        
No 350 (65.1) 41 (48.8) 0.004 
(8.214) 
 58 (79.5) 97 (69.8) 0.131 
(2.276) Yes 188 (34.9) 43 (51.2)  15 (20.5) 42 (30.2) 
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5.3.2.6 Correlation with expression of other biomarkers  
Table 5.5 summarised the correlation between HER2/HER3 levels and 
additional biomarkers of importance in breast cancer. A significant correlation 
was observed between high levels of HER2/HER3 heterodimer expression with 
CK18 (p < 0.001), pAkt (p = 0.044), PI3K (P < 0.001), BRCA1 (p = 0.005), 
p53 (p < 0.001) and PTEN (p = 0.006). There was a negative association 
between HER2/HER3 heterodimer expression and Bcl-2, ER, PgR (all p < 
0.001) and MUC-1 (P = 0.020). 
 
Within the HER2+ series there was a significant association between high 
expression of HER2/HER3 heterodimers with negative ER (P < 0.001), PgR (P 
= 0.001) and Bcl-2 (p = 0.010) status. A positive correlation was observed 
between HER2/HER3 heterodimers with CK18 (P = 0.001), p21 (p = 0.027) 
and pAkt (p = 0.013).  
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Table 5.5 ± Association of HER2/HER3 dimerisation levels with biomarkers expression in 
breast cancer. 
                                      HER2/HER3 Status 
Biomarker 
 Unselected Series  HER2+ Series 
 Low (%) High (%) p Value (Chi- Square)  Low (%) High (%) 
p Value 
(Chi- Square) 
CK 5/6         
Negative  517 (82.7) 83 (88.3) 0.175 
(1.841) 
 47 (61.0) 92 (63.9) 0.676 
(0.175) Positive  108 (17.3) 11 (11.7)  30 (39.0) 52 (36.1) 
CK7/8         
Negative  22 (3.5) 0 (0.0) 0.064 
(3.419) 
 1 (3.0) 0 (0.0) 0.122 
(2.385) Positive  602 (96.5) 94 (100)  32 (97.0) 78 (100) 
CK14         
Negative  531 (87.7) 86 (91.5) 0.223 
(1.483) 
 48 (88.9) 114 (94.2) 0.215 
(1.540) Positive  79 (13.0) 8 (8.5)  6 (11.1) 7 (5.8) 
CK18         
Negative  124 (21.4) 4 (4.4) <0.001 
(14.698) 
 
9 (17.0) 3 (2.5) 0.001 
(11.943) Positive  456 (78.6) 87 (95.6) 
 
44 (83.0) 117 (97.5) 
Bcl-2     
    
Negative  207 (41.0) 53 (75.7) <0.001 
(29.925) 
 
32 (47.1) 80 (66.1) 0.010 
(6.549) Positive  298 (59.0) 17 (24.3) 
 
36 (52.9) 41 (33.9) 
pAkt     
    
Negative  121 (25.4) 11 (15.5) 0.044 
(3.295) 
 
11 (29.7) 11 (19.6) 0.263 
(1.255) Positive  356 (74.6) 60 (84.5) 
 26 (70.3) 45 (80.4) 
     
    PI3K     
    
Negative  122 (122) 7 (8.6) 
<0.001 
(15.942) 
 
4 (5.8) 5 (3.7) 
0.105 
(4.512) 
Moderate  143 (143) 13 (16.0) 
 
12 (17.4) 11 (8.2) 
Strong  288 (288) 61 (75.3) 
 
53 (76.8) 118 (88.1) 
p21     
    
Negative  99 (79.2) 10 (90.9) 0.351 
(0.871) 
 
17 (45.9) 
 
12 (23.5) 0.027 
(4.877)  Positive  26 (20.8) 1 (9.1) 
 
20 (54.1) 39 (76.5) 
MUC-1     
    
Negative  69 (12.9) 2 (2.6) 
0.020 
(7.834) 
 
4 (5.6) 4 (3.1) 
0.581 
(0.581) Moderate  243 (45.3) 43 (56.6)  39 (54.9) 66 (52.0) Strong  224 (41.8) 31 (40.8) 
 
28 (39.4) 57 (44.9) 
     
    BRCA1     
    
Negative  317 (61.0) 59 (77.6) 0.005 
(7.913) 
 
48 (72.7) 85 (69.1) 0.603 
(0.270) Positive  203 (39.0) 17 (22.4) 
 
18 (27.3) 38 (30.9) 
     
    p53     
    
Negative  435 (71.7) 46 (48.9) <0.001 
(19.524) 
 
27 (36.0) 45 (31.5) 0.499 
(0.457) Positive  172 (28.3) 48 (51.1) 
 
48 (64.0) 98 (68.5) 
     
    
     
    PTEN     
    
Weak  79 (22.8) 3 (5.5)  
0.006 
(10.092) 
 
0 (0.0) 5 (5.7) 
0.265 
(2.653) 
Moderate  130 (37.5) 21 (38.2) 
 
21 (53.8) 40 (45.5) 
Strong  138 (39.8) 31  (56.4) 
 
18 (46.2) 43 (48.9) 
Ki67     
    
Weak   172 (33.8) 21 (25.3) 
0.062 
(5.573) 
 4 (19.0) 14 (21.2) 0.400 
(1.831) Moderate  176 (34.6) 25 (30.1)  10 (47.6) 21 (31.8) Strong  161 (31.6) 37 (44.6) 
 7 (33.4) 31 (47.0) 
 
    
    ER     
    
Negative  169 (28.3) 56 (60.2) <0.001 
(37.424) 
 
23 (31.1) 91 (62.8) <0.001 
(19.699) Positive  429 (71.7) 37 (39.8) 
 
51 (68.9) 54 (37.2) 
 
    
    PgR     
    
Negative  264 (44.2) 65 (70.7) <0.001 
(22.321) 
 
36 (48.6) 100 (71.4) 0.001 
(10.845) Positive  333 (55.8) 27 (29.3) 
 
38 (51.4) 40 (28.6) 
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5.3.2.7 Correlation with HER2/HER4 
As stated in Chapter 4, HER2/HER3 dimerisation was significantly correlated 
with HER2/EGFR in both tumour series. There was likewise a positive 
correlation between HER2/HER3 and HER2/HER4 heterodimer expression (p 
< 0.001; Table 5.6).  
 
 
 
 
 
 
 
 
Table 5.6 ± Association of HER2/HER3 and HER2/HER4 heterodimer levels in breast 
cancer. 
                                       HER2/HER3 Status 
Heterodimer 
 Unselected Series  HER2+ Series 
 Low (%) High (%) p Value (Chi-Square) 
 Low (%) High (%) p Value (Chi-Square) 
HER2/HER4     
 
<0.001  
(187.288) 
   
 
<0.001 
(28.793) 
Low  364 (96.6) 26 (37.1)  46 (74.2) 38 (32.2) 
High  13 (3.4) 44 (62.9)  16 (25.8) 80 (67.8) 
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5.3.2.8 Association with patient outcome  
HER2/HER3 high levels showed a significantly worst outcome for both BCSS 
(p < 0.001; Figure 5.6A) and DFI (p = 0.001; Figure 5.6B) in the Unselected 
series. This association with patient outcome was not significant between 
HER2/HER3 dimer levels in patients with HER2+ breast cancer trastuzumab 
naïve: BCSS (p = 0.235; Figure 5.6C) and DFI (p = 0.241; Figure 5.6D). 
Similarly, high HER2/HER3 heterodimer levels were not associated with 
patient outcome in the patients with HER2+ breast cancer receiving adjuvant 
trastuzumab (Figure 5.6E and F). 
 
The multivariate Cox regression including tumour size, stage and grade, high 
levels of HER2/HER3 heterodimers was an independent predictor for worse 
BCSS (HR = 0.62, 95% CI= 0.45-0.62, p = 0.006, Table 5.7) and DFI (HR = 
0.72, 95% CI = 0.53-0.98, p = 0.037, Table 5.7).  
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Figure 5.6 ± BCSS and DFI analysis for HER2/HER3 status amongst the Unselected 
series (A and B), Trastuzumab Naïve Series (C and D) and Trastuzumab Adjuvant Series 
(E and F). 
 
 
 
 
 
 
 
 
 
 
Unselected Series 
Trastuzumab Naïve Series 
 
Trastuzumab Adjuvant Series 
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Table 5.7 ± Multivariate Cox regression analysis of factors associated with BCSS and DFI for 
Unselected series. 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
 BCSS  DFI 
 Hazard Ratio 
(95% CI) p Value  
Hazard Ratio 
(95% CI) p Value 
Tumour Size (cm)  0.55 (0.35-0.85) 0.007  0.60 (0.43-0.83) 0.002 
Tumour Stage 
 
1.87 (1.56-2.24) <0.001  1.74 (1.49-2.04) <0.001 
Tumour Grade 
 
1.64 (1.31-2.05) 0.001  1.12 (0.95-1.33) 0.179 
HER2/HER3 
 
0.62 (0.45-0.62) 0.006  0.72 (0.53-0.98) 0.037 
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5.3.2.9 Association with ER status and patient outcome 
There was no correlation between HER2/HER3 heterodimer and patient 
outcome in the ER negative population for both BCSS (p = 0.169; Figure 
5.7A) and DFI (p = 0.141; Figure 5.7B). The same analysis was performed for 
the first 60 months to understand if patients survival showed any significant 
difference between HER2/HER3 levels, however the outcome was not 
significant for both BCSS (p = 0.174; Figure 5.7C) and DFI (p = 0.079; Figure 
5.7D).  
 
Amongst the ER positive population, high HER2/HER3 dimerisation was 
significantly associated with shorter BCSS (p < 0.001; Figure 5.8A) and DFI (p 
= 0.028; Figure 5.8B). The same type of analysis performed for the first 60 
months revealed that the outcome was already significant worse for both BCSS 
(p < 0.001; Figure 5.8C) and DFI (p = 0.025; Figure 5.8D) amongst those cases 
possessing high levels of HER2/HER3.  
 
The multivariate Cox regression model including tumour size, tumour stage 
and tumour grade, revealed that high levels of HER2/HER3 amongst the ER 
positive patients was independently associated with worse BCSS (HR = 0.46, 
95% CI = 0.29-0.74, p = 0.001, Table 5.8) but not with DFI (HR = 0.67, 95% 
CI = 0.43-1.06, p = 0.087, Table 5.8). 
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Figure 5.7 ± BCSS and DFI analysis for HER2/HER3 status amongst the ER negative 
cases in Unselected series for a period of 250 months A) and B) or for a period of 60 
months C) and D).  
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Figure 5.8 ± BCSS and DFI analysis for HER2/HER3 status amongst the ER positive 
cases in Unselected series for a period of 250 months A) and B) or for a period of 60 
months C) and D).  
 
 
 
 
 
Table 5.8 ± Multivariate Cox regression analysis of factors associated with BCSS and DFI for 
ER positive cases in Unselected series. 
 
Variable 
 BCSS  DFI 
 Hazard Ratio 
(95% CI) p Value  
Hazard Ratio 
(95% CI) p Value 
Tumour Size (cm)  0.48 (0.28-0.85) 0.011  0.57 (0.38-0.85) 0.007 
Tumour Stage  1.69 (1.33-2.16) <0.001  1.61 (1.30-1.99) <0.001 
Tumour Grade  1.77 (1.37-2.30) <0.001  1.22 (0.99-1.49) 0.059 
HER2/HER3 
 
0.46 (0.29-0.74) 0.001  0.67 (0.43-1.06) 0.087 
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5.3.2.10 Association with patient outcome in HER2+ tumours trastuzumab naïve versus 
adjuvant 
7KH VXUYLYDO DQDO\VHV UHJDUGLQJ WKH SDWLHQWV¶ RXWFRPH UHFHLYLQJ RU QRW
trastuzumab adjuvant were performed for both low and high HER2/HER3 
heterodimers levels. The trastuzumab naïve patients possessing low levels of 
heterodimers reveal a significant worse outcome for both BCSS (p = 0.009; 
Figure 5.9A) and DFI (p = 0.007; Figure 5.9B).  
 
Amongst the HER2/HER3 heterodimer high levels BCSS and DFI analyses 
VKRZHGVLJQLILFDQW GLIIHUHQFHVRQSDWLHQWV¶ RXWFRPH S Figure 5.9C 
and D).  
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Figure 5.9 ± BCSS and DFI analysis for HER2/HER3 status for HER2+ trastuzumab adjuvant 
series against HER2+ trastuzumab naïve series regarding low levels A) and B) or high levels 
C) and D) of HER2/HER3. 
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5.4 Discussion 
 
HER3 is distinguished from its family members by the lack of an activated 
tyrosine kinase domain, which turns impossible the formation of 
homodimers43. Though its ectodomain is extremely reactive with a high range 
of ligands478, which classifies this member of HER family as an essential 
supporter of HER family oncogenesis484.  The co-expression with HER2 is 
strictly connected70 and if HER3 levels decline also cell transformation is 
restricted486. HER2/HER3 heterodimers has been described to be the major 
interaction amongst the HER2 amplified breast carcinomas460. In case HER3 
interacts with HER2, downstream pathways responsible for proliferation and 
survival are triggered496, also stimulating creation of metastases497. Therefore 
in this chapter it was assessed the expression of HER3 in breast cancer and 
whether its HER2/HER3 heterodimers were correlated with poor prognosis as 
already documented501 but with special attention for the development or not of 
resistance to trastuzumab therapy. HER3 has been revealed to possess an 
important and essential role in the development of HER family mediated 
carcinomas and is overexpressed in a high number of HER2+ breast cancer 
cases475. This is in concordance with the results described within this chapter 
where an incidence of up to 92% of all HER2+ cases was observed. 
Additionally HER3 is related with 17.5% of the total breast carcinomas with 
poor prognosis455, which in this study it was associated with 16.5%.  
 
Overexpression of HER3 has been inversely correlated with tumour grade502, 
which is contradicted by this study showing a strongly positive correlation not 
only with higher tumour grade but to all its criteria such as reduced tubule 
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formation, more nuclear pleomorphism and high mitotic frequency. 
Additionally HER3 monomer high expression was highly correlated with 
higher tumour stage as anticipated460,503, however no association with 
development of metastases in disagreement with Tsai and colleagues504. In this 
study HER3 as been associated with other of the poor prognostic parameters 
such a poor NPI and vascular invasion, even though not associate with deat 
occurrence due to breast cancer or local and regional recurrence. Interestingly 
HER3 monomer was not associated with any of the clinicopathological 
parameters amongst the HER2 amplified breast carcinomas, revealing no 
distinctive feature within this group of patients as a monomer.  
 
Regarding survival analysis it was demonstrated no significant association of 
HER3 as a monomer with worse outcome amongst the unselected series. A 
prognostic value regarding HER3 overexpression was not proven yet, with 
some studies associating with worse prognosis92,455,505, but also correlated with 
JRRG SDWLHQWV¶ RXWFRPH95,506. Some theories were hypothesising to try to 
explain the differences of prognostic results amongst the different groups. The 
high affinity of a soluble isoforms of HER3 to the ligands NRGs blocks the 
interaction with the membranous HER3 receptors, suggesting that subcellular 
distribution of the receptors might affect cells development507.  Therefore 
considering not only the levels of expression but also the localisation and the 
ligands presence might enhance the clinical outcome.  
 
Although HER2 and HER3 monomers overexpression has previously been 
reported has the most frequent in breast cancer455,501, it was found that all three 
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HER heterodimers were expressed at a similar frequency. HER2/HER3 
heterodimers frequency amongst the Unselected series revealed to be 
significantly lower when compared to a different study documented presence 
of high levels three times more frequent501. However definition of high levels 
might not correspond to the same criteria and moreover technique procedure 
still not standardised.  
 
As illustrated in this study dimerisation is highly but not entirely dependent on 
HER family monomers expression only. Amongst the HER2+ series, 34% of 
the cases did not reveal high levels of HER2/HER3 heterodimerisation, 
confirming the influence of supplementary factors, which are involved in 
dimerisation of these receptors. Interaction with specific ligands incites 
dimerisation occurrence130, moreover in case HER3 does not interact with one 
of its specific ligands, the competent conformation is not accomplished being 
impossible to dimerise with any receptor32. Therefore a characterisation of the 
ligands class must be performed to understand in more detail all the factors 
involved in dimerisation multifaceted foundation. An example was presented 
in subchapter 5.3.2.1 where the photomicrographs suggest that dimerisation is 
highly but not entirely dependent on HER family monomers expression only, 
when is observed moderate/high expression of both monomers but residual 
dimerisation was detected for the same case. Arguing again that PLA detected 
protein-protein interaction and not monomers co-localisation contradicting a 
different study456. Supporting this idea the analysis of HER2/HER3 
dimerisation against the monomers mutual expression status showed that when 
both monomers were highly expressed, only 70.7% of those cases possessed 
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high levels of HER2/HER3. Additionally the mutual expression analysis 
demonstrated that in case HER2 expression is absent the frequency of 
HER2/HER3 heterodimerisation drops dramatically. HER2 phosphorylation 
and activation is extremely correlated with high levels of dimerization508. 
Dimers including HER2 are more stable and with elongated active downstream 
pathways comparing with other dimers106 making HER2 the preferred growth 
factor for dimerisation509. High levels of HER2/HER3 heterodimers has been 
associated with poor prognostic parameter such as higher tumour grade and 
stage, HER2 gene amplification and ER negativity501; this is consistent with the 
results presented in this study. Additionally HER2/HER3 heterodimerisation 
revealed to be associated with poor NPI, death occurrence due to breast cancer 
and development of distant metastases in agreement with previous studies455.  
 
This heterodimer develops an important role in promotion of cell proliferation 
and apoptosis avoidance28. Even though HER2/HER3 heterodimers are not 
associated with Ki67, a biomarker involved in cell proliferation397 and 
negatively associated with Bcl-2, which is highly correlated with apoptosis 
avoidance463, this HER heterodimerisation is related with poor prognostic 
features. As a monomer, HER2 is not competent of interacting with PI3K 
subsequently activating the PI3K/Akt pathway. However the HER2/HER3 
heterodimer is favourably efficient performing it, which was confirmed by the 
strong association with both Akt and PI3K expression. This role is stimulated 
by HER3 that contains six tyrosine-binding points with the highest affinity for 
PI3K amongst the HER family471,472,510. Therefore instigation of HER3 results 
in a durable and strong trigger of the downstream PI3K/Akt cascade511. 
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Furthermore the high association with HER2/EGFR dimer and their crosstalk 
also contributes for development of metastases107 as observed in this study. 
Additionally the high association of HER2/HER3 heterodimers with CK18 
supports the idea that apoptosis does not take place amongst these cells due to 
CK18 high levels of degradation being associated with apoptosis464,465.  
 
Interestingly it was observed a high association of HER2/HER3 heterodimers 
with p21 but only amongst HER2+ breast carcinomas, which might help to 
explain the development of resistance from patients harbouring high levels of 
HER2/HER3, because the loss of p21 expression is associated with sensitivity 
to chemotherapy512. Therefore those cases expressing high levels of p21 would 
reveal resistance to chemotherapy and trastuzumab alone reveal low levels of 
success513. p53, which induces p21514, is a biomarker that its immunopositivity 
is correlated with worse survival outcome amongst the breast carcinoma 
patients512,515. This supports the idea that the association of HER2/HER3 
protein-protein interaction with p21 and p53 contributes for worse outcome. 
Additionally lack of BRCA1 is associated with poor prognosis392 and in this 
study it was confirmed the negative association of HER2/HER3 with this 
biomarker.  
 
As anticipated Bcl-2 has an important role in breast carcinomas being highly 
associated with ER positivity however its lost is associated with other poor 
prognostic markers such as p53, EGFR and HER2 expressions463. It was even 
suggested that EGFR ligands had an important role on downregulation of Bcl-
2463. In this study HER2/EGFR high levels demonstrated a negative association 
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with both Bcl-2 and ER for both series, but highly associated with strong 
expression of p53 in only the Unselected series. This supports the idea that 
Bcl-2 anti-apoptotic role might be regulated by the hormone receptors 
previously defended463. However does not necessary supports the idea that cell 
harbouring high levels of HER2/EGFR are directed to apoptosis. Two studies 
revealed that the levels of CK18 degrades with apoptosis occurrence464,465, 
which confirm the idea that HER2/EGFR is involved in apoptosis evasion 
processes by being associated with CK18 expression in both cohorts. Also the 
HER/EGFR high levels were highly correlated with Ki67, which is involved in 
high levels of cell proliferation397.  HER2/HER3 was the only heterodimer to 
be associated with strong levels of MUC-1, which is associated with poor 
prognosis amongst the breast cancer patients being described to be connected 
with the metastases progression process516,517.  
 
The Unselected series revealed to possess a robust number of cases, the 
prognostic value revealed by HER2/HER3 heterodimerisation amongst the 
trastuzumab adjuvant series should be discussed with caution due to its reduced 
number of patients. Unsurprisingly the results for Unselected series, which 
included 1858 cases with primary invasive breast cancer, revealed that high 
levels of HER2/HER3 protein interaction predicted worse outcome for both 
BCSS and DFI autonomously of pathological and treatments considerations. 
This idea is supported by the fact that HER2/HER3 dimerisation occurrence is 
directly dependent on HER2 overexpression, which is associated with poor 
prognosis17,501. HER2/HER3 high levels was an independent prognostic factor 
in multivariate analysis, in concordance with previous findings501. The high 
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association between ER and BCL-2 already documented463 and observed in 
this study (data not presented) might explain the poor outcome observed 
amongst those patients revealing high levels of HER2/HER3 and ER+ status. 
Moreover the multivariate analysis revealed HER2/HER3 high levels as an 
independent prognostic factor for both BCSS and DFI. This finding is in 
concordance to a previous study501, supporting the idea that this protein-protein 
interaction may deliver additional prognostic information to the obtained by 
HER2 gene amplification status. Moreover this worse prognostic eminence was 
observed within the first 60 months. For those patients with negative ER status 
no significant difference was observed regarding HER2/HER3. 
 
The results generated specifically within HER2+ tumours revealed that 
HER2/HER3 dimerisation levels did not discriminate between different 
outcomes. Even though the survival analysis for HER2+ trastuzumab adjuvant 
did not reveal a significant prognostic difference regarding the HER2/HER3 
heterodimers levels, it was possible to observe that after 60 months the 
probability of survival drops dramatically. This observation was not observed 
for any of the other HER heterodimers in study. Cautiously speculating it 
might indicate the development of resistance to trastuzumab by those showing 
high levels of HER2/HER3 heterodimerisation. HER2/HER3 is highly 
correlated with amplified proliferation and development of resistance to 
treatments518-520 that can be achieved in up to 32.2 months169. Even though, it 
was observed that trastuzumab still effective comparing with chemotherapy 
alone. On a period of 60 months the probability to survive amongst the patients  
treated with trastuzumab was 90 % comparing with only 55% of those not 
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receiving the monoclonal antibody. Very similar results were obtained for 
relapsing analysis.   
 
In conclusion it was possible to confirm that PLA delivers a reliable and 
reproducible assessment of HER2/HER3 heterodimers quantification in situ in 
clinical samples. High levels of HER2/HER3 heterodimers emerge to be 
associated with worse outcome and the hypothesis that this protein-protein is a 
poor prognostic factor that requires supplementary research. HER2/HER3 high 
levels contribute to trastuzumab resistance even though further analysis in a 
larger series must be performed to validate these results. Additionally 
characterisation of the ligands amongst the HER amplified breast carcinoma is 
urgently required to create a more robust classification method in order to 
avoid high levels of unsuccessfully therapy. PLA technology will permit 
researchers to investigate the clinical value of various interactions between 
molecules highly involved in breast cancer development.  
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6. CHAPTER 6: The role of HER4 in HER2+ breast 
cancer 
 
6.1 Introduction 
 
6.1.1 HER4 in breast cancer 
The last member from HER family to be characterised was HER4 in 1993 
using a breast cancer cell line (MDA-MB-453). HER4 is located on 
chromosome 2q33521 resulting in a protein of 180kDa522. This transmembrane 
protein is composed of 625 amino acid ECD, 26 amino acid transmembrane 
domain and a cytoplasmic domain composed of 633 amino acids, which 
reveals a normal RTK structure521.  The cytoplasmic domain in EGFR and 
HER2 is highly conserved in HER4 (79% and 77% respectively)521, indicating 
capacity of autophosphorylation251. Also four domains ± juxtamembrane 
region, tyrosine kinase domain, helical domain and a domain including 18 
tyrosine residues responsible for autophosphorylation ± compose this internal 
substructure521. Therefore HER4 does not require dimerisation with any other 
HER family member to trigger downstream pathways. HER4 is critical not 
only in heart development but also in the nervous system and mammary 
glands523. HER4 expression is found in carcinomas of colon, prostate, breast, 
lung, ovarian, cervix, stomach, thyroid251.  In breast, HER4 is ubiquitously 
expressed96, in both normal and malignant cells but is not as highly expressed 
in breast tumours as either EGFR or HER2524. During pregnancy, HER4 is 
overexpressed, though its phosphorylation and consequent signalling activation 
was only highly detected in later stages where breast epithelial cells were 
guided through the processes of differentiation and lactation, instead of over 
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proliferation525,526,527. In breast tumour cells, contrary to the other HERs which 
are not associated with ER overexpression, HER4 expression is related21. 
Moreover HER4 expression is related with reduced cell proliferation369.  
 
The interaction of HER4 with its respective ligands triggers several 
downstream pathways by interaction with p85 subdomain of PI3K, Shc 
molecules528 and PLC-Ȗ529. However this monomer has been correlated with 
good prognostic results in breast cancer and is present in 70% of tumours21. 
This is partly due to its action in reducing HER2 activity and consequently 
enhancing apoptosis530. In a further study performed by Suo et al320 HER4 
correlates with longer breast cancer specific survival (BCSS) and DFI. On the 
other hand, HER4 gene overexpression is correlated with poor prognosis in 
breast cancer92. Furthermore, using differential-display PCR, linked HER4 and 
HER3 gene expression results in tumour progression97. In breast cancer, it is 
infrequent to observe overexpression of HER4 with any of others of the same 
family (1.4%). However more and more studies reveal that HER4 develops a 
critical role in antiproliferation and promotion of apoptosis233,531.  
 
6.1.2 HER2/HER4 in breast cancer 
The biological characterisation knowledge of HER4 and its interaction with 
other members of the same family remain unclear. HER3/HER4 heterodimers 
were detected in some breast cancer cases, revealing a better outcome 
comparing with other dimers, even though a justification for this fact was not 
possible to be understood. Cells expressing these two monomers showed a high 
mitotic frequency but low levels of cell transformation331. On the other hand in 
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case of co-expression of HER3 and HER4 with either EGFR or HER2 
increases the levels of cell transformation dramatically484.  
 
HER4 homodimers are highly correlated with better outcome233. This idea is 
supported by in vitro observations, using HER2 positive cell lines, 
demonstrating a reduction in cell proliferation and increase of apoptosis when 
transfected with HER4 gene233,527. 
 
A particularity of HER4 dimerisation is that its downstream pathways usually 
are complemented by a cleavage and discharge of HER4 endoplasmic domain 
(4ICD), which is then transferred to the nucleus or mitochondria526. The 
accumulation of this complex in the subcellular compartments results in 
cellular proliferation532, differentiation533 and lactation534. Also it can activate 
gene expression534, promote cell cycle arrest535 but also apoptosis531.  
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6.2 Methods 
 
HER4 monomer in breast cancer TMAs was detected using ani-HER4 antibody 
(clone H4.77.16, Neomarkers) and the antigen retrieval preceding the 
immunohistochemistry technique based on the Envision kit methodology as 
described in chapter 2. In tonsil positive control HER4 was mainly detected in 
cells membrane. For detection of HER2/HER4 heterodimers the mouse anti-
HER4 antibody (clone HFR1, Abcam) was utilised. This antibody detects the 
antigen in both membrane and nucleus; however detection of HER2/HER4 was 
predominantly in the cytoplasmic membrane. To obtain any signal representing 
HER2/HER4 heterodimers, HER2 and HER4 receptors need to be in close 
proximity. Therefore the antibody anti-HER2 (Dako), which reacts only 
against the cell membrane antigens, worked as a control for detection using in 
situ PLA. 
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6.3 Results 
 
6.3.1 HER4 
 
6.3.1.1 Expression in breast cancer  
In the Unselected series HER4 negative expression was observed in 327/1525 
(21.4%) patients and overexpression in 1198/1525 (78.6%) cases. Amongst 
HER2+ series it was revealed only 21/276 (6.5%) cases with negative 
expression for HER4 and 258/276 (93.5%) patients possessed positive 
expression (Figure 6.1). 
 
 
 
 
Figure 6.1 ± Detection of HER4 protein expression in breast cancer cores by 
immunohistochemistry. The cells were labelled with a specific antibody against HER4 to 
detect the intensity of expression of this protein present in both the cell membrane and 
cytoplasm. The cells are scored in four different classes of protein expression: (A) Negative 
when a faint immunoreactivity was observed in less than 10% of the cancer cells and (B) 
Positive when more than 10% of the invasive carcinoma cells show a weak/moderate 
perceptible reactivity. 
 
 
      
A    B 
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6.3.1.2 Correlation with clinicopathological parameters 
HER4 protein overexpression amongst the Unselected series was highly 
correlated against higher tumour grade, more nuclear pleomorphism, higher 
mitotic frequency and poor NPI (all p < 0.001). Additionally HER4 expression 
was correlated with less tubule formation (p = 0.016) and higher vascular 
invasion (p = 0.030) (Table 6.1). 
 
HER4 positive expression was not significantly associated with any of the 
clinicopathological parameters amongst the HER2+ series (Table 6.1) 
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Table 6.1 ± The relation between HER4 status with clinicopathological parameters in 
breast cancer. 
 
 
 
 
 
                                   HER4 IHC Status 
Parameters 
 Unselected Series  HER2+ Series 
 Neg  (%) Pos (%) p value  (Chi-Square) 
 Neg  (%) Pos (%) p value  (Chi-Square) 
Tumour Grade         
1  85 (25.8) 177 (15.1) 
<0.001  
(61.320) 
 0 (0.0) 6 (2.3) 0.649  
(0.865) 2  143 (43.5) 354 (30.1)  2 (11.1) 43 (16.7) 
3  101 (30.7) 645 (54.8)  16 (88.9) 209 (81.0) 
         Tubule Formation         
1  30 (9.4) 59 (5.2) 0.016  
(8.275) 
 0 (0.0) 1 (0.4) 0.967  
(0.067) 2  106 (33.2) 377 (32.9)  3 (17.6) 45 (17.6) 
3  183 (57.4) 709 (61.9)  14 (82.4) 209 (82.0) 
Pleomorphism         
1  16 (5.0) 15 (1.3) 
<0.001  
(54.580) 
 0 (0.0) 0 (0.0) 0.562  
(0.337) 
2  181 (56.9) 387 (33.9)  1 (20.0) 26 (9.1) 
3  121 (38.1) 739 (64.9)  16 (80.0) 228 (90.9) 
         Mitotic Frequency         
1 
 
 166 (52.0) 364 (31.8) 
<0.001  
(52.974) 
 0 (0.0) 31 (12.2) 0.099  
(4.628) 
2  62 (19.4) 213 (18.6)  2 (11.8) 62 (24.3) 
3  91 (28.5) 568 (49.6)  15 (88.2) 162 (63.5) 
         Tumour Stage         
1  224 (68.1) 719 (61.2) 0.076  
(5.146) 
 13 (72.2) 112 (43.4) 0.053  
(5.888) 
2  82 (24.9) 356 (30.3)  4 (22.2) 95 (36.8) 
3  23 (7.0) 99 (8.4)  1 (5.6) 51 (19.8) 
         Distant Metastases         
Negative  225 (68.8) 814 (69.5) 0.807  
(0.060) 
 10 (55.6) 171 (66.8) 0.948  
(0.948) Positive  102 (31.2) 357 (30.5)  8 (44.4) 85 (33.2) 
         Local Recurrence         
Negative  188 (58.6) 709 (61.8) 0.292 
(1.112) 
 10 (55.6) 169 (66.3) 0.355 
(0.856) Positive  133 (41.4) 438 (38.2)  8 (44.4) 86 (33.7) 
       Regional Recurrence         
Negative  296 (92.2) 1036 (90.3) 0.302 
(1.065) 
 17 (94.4) 224 (91.8) 0.690 
(0.159) Positive  25 (7.8) 111 (9.7)  1 (5.6) 20 (8.2) 
         Tumour Size         
<1.5cm  81 (24.6) 289 (24.6) 0.987 
(0.001) 
 2 (11.1) 36 (14.0) 0.735 
(0.114) FP  248 (75.4) 887 (75.4)  36 (88.9) 222 (86.0) 
         Vascular Invasion         
Negative  198 (61.3) 638 (54.5) 0.030 
(4.709) 
 6 (33.3) 138 (53.9) 0.091 
(2.855) Positive  125 (38.7) 532 (45.5)  12 (66.7) 118 (46.1) 
         NPI         
Good  141 (47.9) 328 (29.5) 
<0.001 
(27.829) 
 0 (0.0) 5 (2.5) 
0.082 
(4.991) Moderate  153 (44.2) 638 (54.0)  1 (7.1) 69 (34.0) 
Poor  34 (7.9) 195 (16.5)  13 (92.9) 129 (63.5) 
Age         
<50  109 (33.2) 385 (32.7) 0.851 
(0.035) 
 8 (44.4) 113 (44.3) 0.991 
(0.001)   219 (66.8) 793 (67.3)  10 (55.6) 142 (55.7) 
         Death          
Negative  172 (67.7) 663 (68.0) <0.931 
(0.007) 
 8 (53.3) 159 (66.3) 0.307 
(1.042) Positive  82 (32.3) 312 (32.0)  7 (46.7) 81 (33.8) 
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6.3.1.3 Association with patient outcome  
HER4 overexpression did not reveal significant worse BCSS (p = 0.580; 
Figure 6.2A) and DFI (p = 0.834; Figure 6.2B) amongst the Unselected series. 
 
For both trastuzumab naïve and trastuzumab adjuvant cohorts the survival 
analysis was not possible to be performed due to nearly the total number of 
cases be characterised as HER4 positive.  
 
 
 
 
Figure 6.2 ± A) BCSS and B) DFI analysis for HER4 status amongst the Unselected 
series. 
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6.3.2 HER2/HER4 
6.3.2.1 HER2/HER4 in breast cancer 
As expected, the HER2/HER4 heterodimerisation signals were detected 
predominantly on the cell membrane of breast tumour cells on a frequency 
number of signals per cell that varied from 0 to 17.2. The cut-off determined 
using X-tile was obtained defining as low levels of HER2/HER4 heterodimers 
when less than 3.4 signals per cell was observed (Figure 6.3A). Any value 
equal or above 3.4 signals per cell was accepted as high level of 
heterodimerisation (Figure 6.3D).  
 
Amongst the Unselected series the frequency of cases revealing high levels of 
HER2/HER4 heterodimers was 96/891 (10.8%) and amongst the HER2+ series 
that incidence was observed in approximately half of the cases with 131/243 
(53.9%). 
 
Amongst a total of 149 HER2+ cases that were scored for the three 
heterodimers, 73 (49.0%) expressed high levels of all heterodimers, whereas 32 
(21.5%) cases did not show expression of any of the heterodimers investigated. 
On behalf of two heterodimers high levels presence, the detection was 
observed in only 24 (16.1%) cases for HER2/EGFR and HER2/HER3, 11 
(7.38%) cases with both HER2/EGFR and HER2/HER4, and only 1 (0.67%) 
case with both HER2/HER3 and HER2/HER4.  
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Figure 6.3 ± Photomicrographs of in situ PLA detection of HER2/HER4 heterodimers 
at x40 magnification and IHC detection at x20 magnification with a scale bar 
representing 100 µm. Case 1: Primary breast cancer cells displaying A) low levels of 
HER2/HER4, B) HER2 protein expression and C) HER4 protein expression. Case 2: 
Primary breast cancer cells displaying D) high levels of HER2/HER4, E) HER2 protein 
expression and F) HER4 protein expression. 
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6.3.2.2 Correlation with HER family monomers expression 
Table 6.2 summarised the correlation between HER2/HER4 and the HER 
family monomers. There was a strong positive correlation between 
HER2/HER4 and HER2 status (p < 0.001). However some HER2/HER4 high-
level cases were associated with HER2 negativity (10/86, 11.6%). The majority 
of these cases had nearly low levels of HER2/HER4 heterodimers (6/10 cases; 
<4.7 signals/cell) or showed overexpression of HER2 protein but not 
amplification of the gene (4/10 cases). A total of 62/138 (44.9%) HER2+ cases 
did not show high levels of HER2/HER4 heterodimers. Likewise, all but 5/74 
(6.3%) cases that possessed high levels of HER2/HER4 were positive for the 
HER4 protein (p = 0.004). Amongst the HER2+ cohort, 131/243 (53.9%) cases 
revealed high levels of the HER2/HER4 heterodimer. There was no association 
between HER2/HER4 heterodimer expression HER4 protein (p = 0.936). 
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Table 6.2 ± Association between HER2/HER4 heterodimer levels and expression of hormone 
and HER family and hormone receptors in breast cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                            HER2/HER4 Status 
Biomarker 
 Unselected Series 
 
HER2+ Series 
 Low (%) High (%) p value (Chi-Square)  Low (%) High (%) 
p value 
(Chi-Square) 
EGFR         
Negative  527 (78.5) 57 (69.5) 0.064 
(3.421) 
 64 (66.0) 64 (54.7) 0.094 
(2.807) Positive  144 (21.5) 25 (30.5)  33 (34.0) 53 (45.3) 
         HER2         
Negative  709 (92.0) 10 (11.6) <0.001 
(369.562) 
 0 (0.0) 0 (0.0) N/A 
Positive  62 (8.0) 76 (88.4)  112 (100) 131 (100) 
         HER3    
 
   
 
Negative  74 (11.7) 1 (1.3) 0.006 
(7.704) 
 6 (6.8) 2 (1.9) 0.080 
(3.055) Positive  560 (88.3) 75 (98.7)  82 (93.2) 106 (98.1) 
         HER4         
Negative  125 (19.5) 5 (6.3) 0.004 
(8.219) 
 3 (3.5) 4 (3.7) 0.936 
(0.006) Positive  517 (80.5) 74 (93.7)  83 (96.5) 104 (96.3) 
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6.3.2.3 Correlation with HER2 and HER4 mutual expression  
The high levels of HER2/HER4 revealed to be nearly to 60% when was 
observed overexpression of both monomers. It was noticed that when one of 
the HER family receptors is not expressed the frequency of HER2/HER4 low 
levels reach a minimum of 98.5% (Table 6.3).   
 
 
 
 
 
Table 6.3 ± Frequency of HER2/HER4 levels against HER2 
and HER4 mutual expression status. 
Expression 
Status 
 HER2/HER4 
 Low (%)  High (%) 
HER2+/HER4+  43 (42.2)  59 (57.8) 
HER2+/HER4-  3 (42.9)  4 (57.1) 
HER2-/HER4+  461 (98.5)  7 (1.5) 
HER2-/HER4-  121 (100)  0 (0.0) 
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6.3.2.4 Correlation with HER2 amplification 
The presence of HER2 gene amplification and HER2/HER4 heterodimers were 
significantly associated with each other (r2 = 0.377, p < 0.001), revealing that 
the majority of those cases with low levels of HER2/HER4 (n < 3.4 
signals/cell) did not have HER2 gene amplification (Figure 6.4).  
 
 
 
 
 
Figure 6.4 ± Linear regression analysis between HER2/HER4 
and HER2 gene amplification in the breast cancer (Unselected 
series).  
 
 
 
 
 
Chapter 6: HER2/HER4 in Breast Cancer 
220 
6.3.2.5 Correlation with clinicopathological parameters  
Within the Unselected series, high HER2/HER4 dimerisation levels were 
significantly associated with higher tumour grade (p < 0.001), less tubule 
formation (p = 0.007), marked pleomorphism (p < 0.001), higher mitotic 
frequency (p<0.001), higher tumour stage (p = 0.037), presence of distant 
metastasis (p = 0.002), local recurrence (p = 0.036) poor NPI score (p < 0.001), 
poor NPI score (p < 0.001),  and death (p = 0.005).  There was no association 
between HER2/HER4 heterodimers with regional recurrence (p = 0.681), 
tumour size (p = 0.419), vascular invasion (p = 0.526) and age at diagnosis (p = 
0.297). 
 
High HER2/HER4 heterodimers was not associated with any of the 
clinicopathological parameters investigated within the HER2+ cohort. 
Similarly to HER2/HER3 this protein interaction did not reveal any significant 
correlation with this pathological parameter (p = 0.483) (Table 6.4).  
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Table 6.4 ± Association of HER2/HER4 dimerisation levels with clinicopathological 
parameters in breast cancer. 
                               HER2/HER4 status 
Parameters 
Unselected Series  HER2+ Series   
 Low (%) High (%) p value 
(Chi- Square)  Low (%) High (%) 
p value 
(Chi- Square) 
Tumour Grade        
1 101 (12.7) 4 (4.2) 
<0.001 
(33.835) 
 0 (0.0) 4 (3.1) 0.075 
(5.187) 2 243 (30.6) 8 (8.3)  22 (19.6) 17 (13.0) 3 451 (56.7) 84 (87.5)  90 (80.4) 110 
 
        Tubule Formation        
1 29 (3.8) 2 (2.1) 
0.007 
(9.855) 
 0 (0.0) 2 (1.6) 0.207 
(3.147) 2 238 (31.2) 16 (16.8)  21 (19.1) 17 (13.2) 3 495 (65.0) 77 (81.1)  89 (80.9) 111 
 
        Pleomorphism        
1 12 (1.6) 1 (1.1) 
<0.001 
(26.714) 
 0 (0.0) 0 (0.0) 0.265 
(1.244) 2 259 (34.2) 8 (8.4)  12 (12.0) 9 (7.0) 3 487 (64.2) 86 (90.5)  96 (88.9) 120 
 
        Mitotic Frequency        
1 208 (27.3) 10 (10.5) 
<0.001 
(21.085) 
 10 (9.1) 18 (14.0) 0.281 
(2.538) 2 147 (19.3) 11 (11.6)  31 (28.2) 27 (20.9) 3 407 (53.4) 74 (77.9)  69 (62.7) 84 (65.1) 
        Tumour Stage        
1 485 (61.1) 48 (50.0) 
0.037 
(6.601) 
 52 (47.3) 60 (45.8) 0.866 
(0.289) 2 240 (30.2) 33 (34.4)  36 (32.7) 47 (35.9) 3 69 (8.7) 15 (15.6)  22 (20.0) 24 (18.3) 
        Distant Metastases        
No 530 (67.0) 
 
49 (51.0) 0.002 
(9.623) 
 81 (72.3) 86 (66.7) 0.343 
(0.901) Yes 261 (33.0) 47 (49.0)  31 (27.7) 43 (33.3) 
        
        Local Recurrence        
No 455 (58.6) 45 (47.4) 0.036 
(4.393) 
 83 (74.8) 85 (65.4) 0.114 
(2.500) Yes 321 (41.4) 50 (52.6)  28 (25.2) 45 (34.6) 
        Regional Recurrence 
       
No 689 (88.8) 83 (87.4) 0.681 
(0.169) 
 103 (94.5) 111 
 
0.411 
(0.675) Yes 87 (11.2) 12 (12.6)  4 (5.5) 10 (8.3) 
        Tumour Size        
<1.5 cm 169 (21.3) 17 (17.7) 0.419 
(0.653) 
 17 (15.2) 21 (16.0) 0.855 
(0.033) FP 626 (78.7) 79 (82.3)  95 (84.8) 110 
         Vascular Invasion        
No 429 (54.5) 48 (51.1) 0.526 
(0.402) 
 58 (54.5) 73 (56.3) 0.501 
(0.453) Yes 358 (45.5) 46 (48.9)  53 (45.5) 56 (43.4) 
        NPI        
Good 200 (25.5) 8 (8.4) 
<0.001      
(28.617) 
 14 (12.5) 21 (16.1) 0.259        
(6.516) Moderate 448 (57.2) 58 (60.4)  73 (65.2) 67 (51.1) Strong 136 (17.4) 30 (31.2)  25 (22.3) 43 (32.9) 
        Age        
<50 280 (35.2) 39 (40.6) 0.297  
(1.089) 
 21 (33.9) 29 (38.2) 0.602 
(0.272)  515 (64.8) 57 (59.4)  41 (66.1) 47 (61.8) 
        Death        
No 421 (64.1) 40 (48.2) 0.005 
(7.918) 
 78 (73.6) 81 (67.5) 0.318 
(0.999) Yes 236 (35.9) 43 (51.8)  28 (26.4) 39 (32.5) 
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6.3.2.6 Correlation with expression of other biomarkers 
Table 6.5 summarises the association of HER2/HER4 heterodimerisation levels 
with other biomarkers. Within the Unselected series, there was a significant 
association between HER2/HER4 and CK18 positivity (p < 0.001), PI3K (p < 
0.001), p53 (p < 0.001), PTEN (p = 0.020) and Ki67 (p = 0.004). There was a 
negative association between HER2/HER4 heterodimers with Bcl-2 (p < 
0.001), BRCA1 (p = 0.014) and both hormone receptors, ER and PR (both p < 
0.001).  
 
Within the HER2+ cohort, there was a significant association of HER2/HER4 
heterodimers with negative Bcl-2 (p < 0.001), ER (p < 0.001) and PgR status 
(p = 0.001).  
 
In both cohorts the association of HER2/HER4 heterodimers with both 
HER2/EGFR and HER2/HER3 was highly significant (Table 4.6 all p < 
0.001).  
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Table 6.5 ± Association between HER2/HER4 heterodimer levels and expression of 
biomarkers in breast cancer. 
                                 HER2/HER4 Status 
Biomarkers 
 Unselected Series  HER2+ Series 
 Low (%) High (%) p value 
(Chi- Square) 
 Low (%) High (%) p value 
(Chi- Square) 
     
    CK5/6     
    
Negative  623 (80.7) 76 (85.4) 0.283  
(1.151) 
 
69 (64.5) 78 (65.5) 0.867 
(0.028) Positive  149 (19.3) 13 (14.6) 
 
38 (35.5) 41 (34.5) 
 
    
    CK7/8     
    
Negative  21 (2.7) 0 (0.0) 0.118 
(2.447) 
 
1 (1.6) 0 (0) 0.286  
(1.138) Positive  753 (97.3) 88 (100) 
 
61 (98.4) 70 (100) 
     
    CK14     
    
Negative  652 (85.3) 81 (92.0) 0.086 
(2.952) 
 82 (85.4) 97 (93.3) 0.070 
(3.276) Positive  112 (14.7) 7 (8.0)  14 (14.6) 7 (6.7) 
     
    CK18     
    
Negative  145 (20.2) 3 (3.7) <0.001 
(13.348) 
 
8 (9.1) 4 (4.0) 0.149 
(2.082) Positive  573 (79.8) 79 (96.3) 
 
80 (90.9) 97 (96.0) 
     
   
 Bcl-2     
   
 
Negative  254 (41.7) 57 (86.4) <0.001 
(47.793) 
 
51 (51.0) 78 (75.7) <0.001 
(13.394) Positive  355 (58.3) 9 (13.6) 
 
49 (49.0) 25 (24.3) 
     
   
 pAkt     
   
 
Negative  151 (25.2) 14 (20.0) 0.348 
(0.882) 
 
11 (28.9) 8 (20.0) 0.357 
(0.847) Positive  409 (74.8) 51 (80.0) 
 
27 (71.1) 32 (80.0) 
     
   
 PI3K     
   
 
Negative  137 (22.5) 9 (11.4) 
<0.001 
(20.158) 
 
8 (8.7) 6 (5.4) 
0.063 
(5.545) Moderate  165 (27.0) 9 (11.4)  15 (16.3) 8 (7.1) Strong  308 (50.5) 61 (77.2) 
 
69 (75.0) 98 (87.5) 
     
   
 p21     
   
 
Negative  94 (81.0) 5 (100) 0.282 
(1.159) 
 
13 (34.2) 11 (28.2) 0.569 
(0.324) Positive  22 (19.0) 0 (0.0) 
 
25 (65.8) 28 (71.8) 
     
   
 MUC-1     
   
 
Negative  89 (13.6) 7 (9.2) 
0.559 
(1.162) 
 
5 (5.1) 9 (8.1) 
0.375 
(1.963) 
Moderate  290 (44.3) 35 (46.1) 
 
41 (41.8) 53 (47.7) 
Strong  275 (42.0) 34 (44.7) 
 
52 (53.1) 49 (44.1) 
     
   BRCA1     
    
Negative  371 (58.7) 55 (73.3) 0.014 
(5.993) 
 
61 (67.8) 80 (73.4) 0.386 
(0.753) Positive  261 (41.3) 20 (26.7) 
 
29 (32.2) 29 (26.6) 
     
    p53     
    
Negative  544 (72.3) 46 (52.3) <0.001 
(15.177) 
 
41 (38.3) 44 (36.1) 0.725 
(0.124) Positive  208 (27.7) 42 (47.7) 
 
66 (61.7) 78 (63.9) 
PTEN     
    
Weak  79  (20.4) 1 (2.4) 
0.020 
(7.869) 
 
4 (6.9) 3 (4.4) 
0.687  
(0.751) Moderate  150 (38.7) 19 (46.3)  26 (44.8) 35 (51.5) Strong  159 (41.0) 21 (51.2) 
 
28 (48.3) 30 (44.1) 
 
    
    Ki67     
    
Weak  197 (31.7) 12 (15.4) 
0.004  
(11.186) 
 
7 (15.9) 9 (14.3) 
0.404 
(1.811) Moderate  211 (34.0) 27 (34.6)  21 (47.7) 23 (36.5) Strong  213 (34.2) 39 (50.0) 
 
16 (36.4) 31 (49.2) 
        ER     
    
Negative  234 (30.9) 57 (64.8) <0.001 
(40.035) 
 
47 (42.7) 81 (65.9) <0.001 
(12.545) Positive  523 (69.1) 31 (35.2) 
 
63 (57.3) 42 (34.1) 
 
    
    PgR     
    
Negative  335 (44.5) 66 (75.9) <0.001 
(30.769) 
 
62 (56.9) 92 (76.7) 0.001 
(10.153) Positive  418 (55.5) 21 (24.1) 
 
47 (43.1) 28 (23.3) 
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6.3.2.7 Association with patient outcome  
Prognostic analysis were realised with HER2/HER4 levels relating to BCSS 
and DFI. Within the Unselected series, HER2/HER4 heterodimer levels were 
significantly correlated with worse outcome for both BCSS and DFI (both p < 
0.001; Figures 6.5A and B, respectively). Within the trastuzumab naïve series, 
those cases revealing high levels of HER2/HER4 dimerisation were not 
associated with either BCSS (p = 0.249; Figure 6.5C) or DFI (p = 0.151; 
Figure 6.5D). Likewise, in the HER2+ adjuvant trastuzumab there was no 
significant association between HER2/HER4 levels and BCSS (p = 0.890; 
Figure 6.5E) or DFI (p = 0.647; Figure 6.5F). 
 
The multivariate Cox regression including tumour size, stage and grade, high 
levels of HER2/HER4 heterodimers was an independent predictor for worse 
BCSS (HR = 0.66, 95% CI= 0.48-0.92, p = 0.014) and DFI (HR = 0.69, 95% 
CI = 0.51-0.94, p = 0.017, Table 6.6).  
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Figure 6.5 ± BCSS and DFI analysis for HER2/HER4 status amongst the Unselected 
series (A and B), Trastuzumab Naïve Series (C and D) and Trastuzumab Adjuvant Series 
(E and F). 
 
 
 
 
 
 
 
 
Unselected Series 
 
Trastuzumab Naïve Series 
 
Trastuzumab Adjuvant Series 
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Table 6.6 ± Multivariate Cox regression analysis of factors associated with BCSS and DFI for 
Unselected series. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 BCSS  DFI 
Variable  Hazard Ratio (95% CI) p Value  
Hazard Ratio 
(95% CI) p Value 
Tumour Size (cm)  0.59 (0.40-0.85) 0.005  0.73 (0.55-0.97) 0.032 
Tumour Stage  2.16 (1.83-2.54) <0.001  1.93 (1.66-2.25) <0.001 
Tumour Grade 
 
1.74 (1.41-2.15) <0.001  1.18 (1.01-1.39) 0.032 
HER2/EGFR  0.66 (0.48-0.92) 0.014  0.69 (0.51-0.94) 0.017 
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6.3.2.8 Association with ER status and patient outcome 
For the Unselected series, Kaplan-Meier survival analyses practically did not 
revealed a significant worse outcome amongst those patients possessing high 
levels of HER2/HER4 and negative ER status for both BCSS (p = 0.049; 
Figure 6.6A) and DFI (p = 0.046, Figure 6.6B). The same analysis, however 
paying attention to only the first 60 months, revealed no association with both 
BCSS (p = 0.061; Figure 6.6C) and DFI (p = 0.059; Figure 6.6D). 
 
For those patients expressing the hormone receptor the significance was 
incredibly high for both BCSS (p < 0.001; Figure 6.7A) and DFI (p < 0.001; 
Figure 6.7B). Moreover during the first 60 months those patients revealing 
high levels of dimerisation already possessed a significant worse outcome for 
both BCSS (p < 0.001; Figure 6.7C) and DFI (p = 0.010; Figure 6.7D). 
 
The multivariate Cox regression model including tumour size, tumour stage 
and tumour grade, revealed that high levels of HER2/HER4 amongst the ER 
positive patients was independently associated with worse BCSS (HR = 0.51, 
95% CI = 0.30-0.86, p = 0.012, Table 6.7) and with DFI (HR = 0.62, 95% CI = 
0.37-1.02, p = 0.017, Table 6.7). 
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Figure 6.6 ± BCSS and DFI analysis for HER2/HER4 status amongst the ER negative 
cases in Unselected series for a period of 250 months A) and B) or for a period of 60 
months C) and D).  
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Figure 6.7 ± BCSS and DFI analysis for HER2/HER4 status amongst the ER positive cases 
in Unselected series for a period of 250 months A) and B) or for a period of 60 months C) 
and D).  
 
 
 
Table 6.7 ± Multivariate Cox regression analysis of factors associated with BCSS and DFI for 
ER positive cases in Unselected series. 
 
Variable 
 BCSS  DFI 
 Hazard Ratio 
(95% CI) p Value  
Hazard Ratio 
(95% CI) p Value 
Tumour Size (cm)  0.62 (0.39-0.99) 0.046  0.73 (0.52-1.03) 0.072 
Tumour Stage 
 
2.02 (1.62-2.53) <0.001  1.73 (1.41-2.10) <0.001 
Tumour Grade 
 
1.84 (1.43-2.37) <0.001  1.18 (0.98-1.43) 0.085 
HER2/EGFR 
 
0.51 (0.30-0.86) 0.012  0.62 (0.37-1.02) 0.017 
  
   
Chapter 6: HER2/HER4 in Breast Cancer 
230 
 
6.3.2.9 Association with patient outcome in HER2+ trastuzumab adjuvant versus naïve 
Survival analysis for only those patients possessing low levels of HER2/HER4 
revealed that there was a significant worse outcome amongst the cases that 
were not submitted to trastuzumab adjuvant therapy for both BCSS (p = 0.015; 
Figure 6.8A) and DFI (p= 0.041; Figure 6.8B).  
 
High HER2/HER4 levels revealed a highly significant difference in patient 
outcome between both adjuvant trastuzumab and trastuzumab naïve series, 
where those receiving trastuzumab did significantly better (p < 0.001, Figures 
6.8C and D).  
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Figure 6.8 ± BCSS and DFI analysis for HER2/HER4 status amongst the HER2+ 
trastuzumab adjuvant series against HER2+ trastuzumab naïve series regarding A) and B) 
HER2/HER4 low levels or C) and D) HER2/HER4 high levels. 
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6.3.2.10 HER heterodimer frequency in HER2+ breast cancer  
A total of 73/142 (51.4%) HER2+ tumours expressed all three heterodimers 
(Table 6.8) whereas only 32/142 (22.5%) cases did not show expression of any 
of the heterodimers investigated. Expressions of only one heterodimer or two 
heterodimers were less common. Though HER2/HER3 plus HER2/EGFR are 
present in 24/142 (16.9%), being the dual combination more frequent. Also 
HER2/HER4 heterodimer alone was not observed in any case.  
 
 
 
 
 
 
 
 
                           Table 6.8 ± Frequency of HER heterodimers in HER2+ breast cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HER2/EGFR HER2/HER3 HER2/HER4 Frequency 
+ - - 4 
- + - 4 
- - + 0 
+ + - 24 
+ - + 11 
- + + 1 
+ + + 73 
- - - 32 
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6.4 Discussion 
 
While becomes more evident that overexpression of EGFR, HER2 and HER3 
are associated with poor outcome and lead to possible resistance to 
treatments187,455,501,536, HER4 is the only monomer from HER family connected 
with a good prognosis in breast cancer. However, HER4 biology in breast 
cancer remains unclear. This potentially could be related the pro-apoptotic role 
of the HER4 intracellular domain531.  
 
In this chapter, the expression and role of the HER2/HER4 heterodimer was 
determined to understand whether HER2/HER4 is related with poor prognosis 
status and if those patients carrying high levels of this heterodimer develop 
resistance to trastuzumab therapy.  
 
HER4 monomer expression was present in the majority of breast tumours 
(75%), irrespective of HER2 status, in agreement with previous studies455. The 
prognostic significance of HER4 is controversial. Even though overexpression 
of HER4 in breast cancer has been reported by different studies, revealing a 
range 11% to 45% of cases331,518,537-539. HER4 is highly correlated with lower 
tumour grade, good NPI and longer DFI455,518,537,538. However, these results are 
contradicted by others suggesting that HER4 positive expression is correlated 
with poor prognostic variables540,541 such as higher tumour grade542, high 
tumour stage, poor NPI and vascular invasion but inversely correlated with 
local recurrence331. The results presented in this chapter, confirm that HER4 
expression is associated with poor prognostic factors. This discrepancy 
between studies might be explained by the presence of different HER4 
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isoforms543. Data presented here are in agreement that HER4 positive 
expression did not distLQFWO\ DVVRFLDWH ZLWK SDWLHQWV¶ VXUYLYDO UDWH518,540. This 
suggests that agreement on HER4 scoring still not achieved and standardisation 
is required. 
 
HER2/HER4 protein-protein interactions have not been previously studied in 
breast cancer. Though the reliance of the dimerisation between HER2 and 
HER4 is dependent on the expression of the monomer it was not unique. The 
frequency HER2/HER4 was significantly lower than other heterodimers. This 
suggests that amongst breast carcinomas, the affinity of dimerisation between 
HER2 and HER4 might be weaker than comparing with EGFR or HER3. This 
idea was already anticipated where it was showed that distinct receptors 
amongst the HER family noticeably diverge in their preferred interaction 
partners481.  
 
As with the previous heterodimers, HER2/HER4 heterodimers were primarily 
dependent on high levels of HER2 amplification/protein overexpression and 
not HER4. However, it is possible that the dimerisation of HER2 and HER4 
only occurs when interacting with specific ligands rather than HER4 
expression levels. In order to dimerise, HER4 has to interact with one of the 
ligands including HB-EGF, BTC, EPR251, NRG3 or NRG4229. Several studies 
have revealed that HER4 is associated with good prognosis and even reduced 
HER2 activity537,544. However, HER2/HER4 heterodimers were tightly 
associated poor prognostic factors in the Unselected series of breast tumours, 
with exception for only high tumour size and vascular invasion.  
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HER2/HER4 was not associated with any basal biomarkers, including as 
CK5/6 and CK14, which contradicts some studies537,544, but was strongly 
associated with luminal CK18 positivity. This association reveals the lack of 
apoptosis occurrence associated with high expression of CK18464 in breast 
carcinomas expressing high levels of HER2/HER4. Also there was high 
correlation between HER2/HER4 and PI3K revealing apoptosis avoidance and 
high proliferation. Similar to other members of the HER family, a 
ligand/receptor interaction promotes dimerisation and subsequently a kinase 
activation, which in turn will trigger cell-proliferation signalling cascades such 
as PI3K477,545. Even though PI3K interacts with six tyrosines of HER3 against 
only one in HER4546. BRCA1 is expressed in normal breast cells helping to 
repair the DNA or promoting apoptosis on those cells where damaged DNA is 
not repairable547, being related with poor prognosis when not expressed392. In 
this study HER2/HER4 high levels were highly associated with the lack of 
BRCA1. Finally and supporting the idea that HER2/HER4 high levels is not an 
indication of good prognosis, this heterodimer was highly associated with p53, 
which it is related with poor prognosis when highly expressed512,548,549. Several 
studies revealed that p53 IHC is not only prognostic factor for breast 
carcinoma but also defines the sensitivity to certain treatments550-552 but also as 
a predictor for chemotherapy resistance development553,554. Patients with worse 
prognosis were associated with anomalous expression of p53, which is highly 
associated with the absence of Bcl-2555.  When Bcl-2 expression is retained, 
cell survival is extended but does not promote cell proliferation556. The main 
observation was HER2/HER4 was associated with Bcl-2 negative status. Low 
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Bcl-2 expression has been correlated with development of resistance to certain 
types of chemotherapy such as paclitaxel557. Reason to regard HER2/HER4 
heterodimers as a poor prognostic parameter despite some studies associating 
HER4 (monomer) with good prognosis455,538. 
 
Survival analysis demonstrated HER2/HER4 predicts worse outcome in the 
Unselected series although not the HER2+ positive series, suggesting that 
HER2 prognostic value is not manipulated by HER4. In HER2+ breast cancer, 
factors such as different heterodimerisations contribute a worse prognosis, 
showing that HER2/HER4 heterodimers do not develop an independent value 
for prediction of poor outcome. High levels of HER2/HER4 heterodimer were 
associated with worse outcome independent of ER status, being the only 
heterodimer showing this. Though, the poor prognostic value is much stronger 
amongst ER positive cases. One reason might due to the high expression of 
HER4 in these cases and therefore on localisation of HER4 intracellular 
domain (4ICD) in the nucleus, which trigger proliferation reactions by acting 
as a co-activator of ER558. Four different isoforms of HER4, JMa, JMb, Cyt1 or 
Cyt2, as a result of alternate RNA splicing477, although this does not influence 
ligand linkage site or structure of tyrosine kinase. However it affects sensitivity 
of the HER4 ECD to be released from the cell membrane251. Additionally, 
other HER4 isoforms with sequence mutation on tyrosine kinase domain can 
influence affinity to PI3K251. The JMa isoform possesses an ectodomain that 
can be cleaved by metalloproteinase559. A second intracellular cleavage can 
also occur resulting in the discharge in the cytoplasm of a soluble form of 
4ICD560, which can be localised in the cytoplasm or nucleus. Depending on the 
Chapter 6: HER2/HER4 in Breast Cancer 
237 
localisation of 4ICD, the roles of this small molecule include differentiation of 
the mammary cell, pro-apoptotic reactions, cell cycle arrestor cell 
proliferation526.  If 4ICD is localised in the mitochondria, apoptosis reactions 
are promoted in tumours cell, mediated by the cell-killing BH3 domain531.  
 
Survival analysis between those HER2+ patients not receiving trastuzumab 
against those that received trastuzumab revealed that the trastuzumab naïve 
patients possessed a worse prognosis independent of HER2/HER4 levels. 
Though, the significance was much higher amongst those patients possessing 
high levels of HER2/HER4. This supports the idea that HER2/HER4 might be 
the least influential heterodimer currently studied.  
 
In conclusion, HER2/HER4 heterodimers were associated with poor 
clinicopathological parameters and poor survival outcome. The data presented 
within this chapter suggests that the stated hypothesis of HER2/HER4 high 
levels contribution to trastuzumab therapy resistance is not supported. 
However expansion of the number of samples and studying the influence of 
HER4 specific ligands and isoforms might increase a further understanding on 
these structures and the signalling cascades triggered.  
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7. CHAPTER 7: General discussion 
 
7.1 Importance of HER2 in breast cancer  
 
The HER family has been showing a considerable importance on breast 
carcinoma development. HER2 acts as a dimerisation partner with the other 
members of the same family561. All except HER2 become activated upon 
contact with ligands following a dimerisation occurrence and signalling 
cascade activation135, promoting cell proliferation, survival and development of 
metastases. Because HER2 does not need interaction with any ligand, this fact 
allows HER2 to join in a number of signal transduction cascades even if a 
specific ligand is lacking135. Therefore when HER2 is overexpressed this may 
drive cells to uncontrolled proliferation and avoid apoptosis. HER2 
overexpression and gene amplification in breast cancer has been studied over 
20 years562. HER2+ breast carcinomas are present at a frequency of 12.1% and 
its expression is highly associated with the HER2 gene amplification. HER2 
status offers both prognostic and predictive value. Recent findings have led to 
development of novel drugs that exclusively target this receptor, changing 
dramatically the panorama of breast cancer therapy349.  
 
Immunohistochemistry technology permits the detection of different proteins 
in tissues and is the first approach for HER2 status assessment in patients 
identified with invasive breast tumours563. However IHC has some 
disadvantages such as issues with tissue fixation and methodologies. Variation 
in antigen retrieval and use of different antibodies can influence IHC results54. 
Additionally IHC interpretation is subjective and can vary depending on the 
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scorer. Those cases in borderline classification for HER2, gene amplification 
will be assessed by using FISH to determine status564. However as already 
documented a percentage of HER2+ patients develop resistance to trastuzumab 
and almost all patients experience disease progression while on this 
treatment565. HER2 status assessed using IHC and FISH cannot identify the 
resistance to trastuzumab. Better characterisation of the variations HER family 
interactions, downstream pathways, regulators of the cell cycle and apoptosis 
offers opportunities to understand the mechanisms of HER2 therapy sensitivity 
and resistance.  
 
Of the other HER family monomers, high expression of EGFR is the only 
alteration shown to be associated with poor outcome249,467,566,567. EGFR 
expression has been associated with triple-negative breast tumours, which is 
characterised by a very aggressive phenotype with distinctive patterns of 
metastasis435,568,569. Therefore EGFR might be an important target in breast 
cancer treatment in this molecular phenotype group. Both HER3 and HER4 
when detected as monomers do not reveal any significant association with poor 
outcome. HER3¶V prognostic value is still not well documented due to non-
conclusive data95,476,570. HER3 has been correlated with poor survival outcome 
by some groups455,571 but other group have identified a significant association 
with good prognosis95. Several groups have shown HER4 expression to be a 
good prognostic factor revealing better survival outcome95,455,544. Though 
HER4 has been correlated as well with poor outcome in a different study92. 
Additionally, the truncated form of HER2 p95HER2, when assessed in this study 
did not reveal any additional prognostic outcome when compared with HER2 
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status analyses alone. Suggesting that more complex reactions involving all 
HER family members and the respective ligands or key downstream pathways 
may be important.  
 
7.2 Dimerisation assays 
 
Previously IHC techniques have been used in a semi-quantitative approach to 
detect the presence of individual proteins. A multifaceted coordination of a 
complex system of crosstalk is thought to exist with the HER family, including 
heterodimerisation, resulting in activation of various downstream pathways 
potentially contributing to the sensitivity or resistance to treatments247,572. 
Conventional IHC is limited in its ability to detect her family dimers.  
 
In this thesis, the technique in situ PLA (brightfield version) was used as a 
novel approach for the high-throughput detection of HER heterodimerisation 
levels in FFPE primary breast carcinomas prepared as tissue microarrays. Early 
studies established the successful use of fluorescence-linked PLA in order to 
detect protein-protein interactions501,573 and this was further developed for 
chromogenic detection. PLA has been extensively applied to studying protein 
interactions amongst a high range of different cell-lines. In this project this 
technique was successfully applied in fixed primary invasive breast cancer 
samples. As performed in the past501 it was confirmed that this technique works 
efficaciously on FFPE tissues, and moreover using TMAs it can provide 
evidence of prognostic and predictive significance of the various heterodimers. 
A study on protein-protein interactions had been SHUIRUPHGXVLQJ9HUD7DJ
technology574, however this technique possesses a major limitation of requiring 
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detection in liquid phase. Thus, it cannot be performed on fixed clinical 
samples or TMAs of large patient cohorts.  
 
The use of specific primary antibodies in this technique allowed detection of 
different HER heterodimerisations partners. This study has shown high 
sensitivity and specificity of this method to detect of the HER heterodimers in 
a large series of cases. This technique have revealed in clinical arena, although 
further validation studies are vital. Use of brightfield in situ PLA identification 
of different morphological structures present in each sample, which is not 
possible amongst fluorescent techniques as Förster (Fluorescence) resonance 
energy transfer (FRET) that has been used in a different study to identify HER 
family dimerisation457. Because PLA allows identification of heterodimers at 
subcellular level and permits investigation and identification of any cellular 
subsection involved in the HER family downstream pathways, which are 
significantly associated with development of resistant to treatments575. Also the 
possibility to detect the signal allocation at both intracellular and intercellular 
levels makes possible detection of molecules with critical role at different 
downstream pathways such as proliferation, survival and motility575. However 
this study was more focussed on quantity of signals and the implications on 
prognosis and resistance to treatments.  
 
For all three HER heterodimers investigated, it was evident that whilst HER2 
overexpression is the dependent factor in dimerisation, the presence of other 
receptors did not necessarily result in heterodimerisation. HER2 has previously 
been suggested as the dominant monomer for heterodimerisation comparing 
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with any others from the same family500. It does not include an ectodomain 
where a ligand can attach, however is competent to undertake as a co-receptor 
with an extraordinary affinity to interact with the same family members 
forming heterodimers25,63. The lack occurrence of heterodimers in some 
HER2+ cases, despite both receptors being expressed, could be due to 
alternative splicing, modification of the transcription mechanism or the lack of 
ligands576. 
 
Heterodimerisation is not a cellular physical structure but characterised as a 
dynamic reaction dependent on several molecules interactions. The detection 
of HER heterodimers in FFPE breast tumours reflects status at a snapshot of 
time. Therefore any signal detected only represents reactions that were 
occurring at a specific moment during formalin fixation. This might reflect that 
the number of signals detected is low, maximum of 35 heterodimer signals per 
cell; it is known that the number of HER2 molecules per cell is able to reach 
2,000,00046. Therefore several questions emerge. Are the dimers stable and 
preserved during the Formalin fixation process? The heterodimers half-life 
might be significantly shorter compared with the period of paraffin fixation. 
Therefore further research studies should be performed in frozen fixed samples 
and cell-lines to examine this observation. Additionally different primary 
antibodies could be examined to understand if the technique is primary 
antibody dependent.  
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7.3 HER family heterodimerisation and other biomarkers 
 
It was observed that the incidence of all three heterodimers was present in 50% 
of the cases, whereas a single heterodimer was a rare occurrence. HER2/HER4 
heterodimerisation alone was not observed in these series. Additionally 
HER2/EGFR and HER2/HER3 heterodimerisations were 70% off all cases 
regardless HER2/HER4 occurrence. These two heterodimers were significantly 
correlated with PI3K expression and development of metastases. It has been 
shown that HER2/EGFR triggers cell motility107 and that HER2/HER3 
interacts to enhances cell proliferation and motility indicating that a 
³WHDPZRUN´ of two heterodimers could enhance some behaviour 
characteristics460. It can therefore be suggested that HER heterodimerisation 
may not be a single event but a complex interconnected system. A previous 
study has suggested that synergistic heterodimer signalling occurs leading to 
cell migration461. This observation could be influential to understand the 
response in combination of HER family members on therapy using Lapatinib 
in combination with trastuzumab and chemotherapy. Lapatinib is the second 
agent to be approved by FDA (2007) for the use in HER2+ breast cancer 
patients. This reversible inhibitor interacts with both HER2 and EGFR tyrosine 
kinases and specifically used in the treatment of metastatic breast tumours. 
Because it acts in a different manner from trastuzumab, it might become useful 
in those patients with development of resistance to trastuzumab199,577. 
Essentially lapatinib revealed clinical benefit in patients that experienced 
disease progression after being treated with trastuzumab199.  
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Beside ER and PgR, Bcl-2 was the only biomarker with significant negative 
association with high expression of all three heterodimers in both series of 
patients. The lack of expression of this apoptosis regulator has previously been 
associated with poor prognosis401. Results obtained in vitro by previous studies 
revealed Bcl-2 as an anti-apoptotic biomarker, contributing to malignant cell 
accumulation. Thus overexpression of this biomarker would be expected to be 
correlated with aggressive tumour cell behaviour578. In breast cancer 
specimens, the expression of this biomarker is correlated with factors related to 
better prognosis such as lower grade, ER positivity and lower proliferation579. 
Also, Bcl-2 low expression is associated with poor prognosis even when 
patients are treated with modern regimes such as paclitaxel557. Its lack of 
expression is associated with different poor prognostic biomarkers as p53, 
EGFR and HER2463. The same ligands that trigger EGFR to a competent 
conformation, also downregulate Bcl-2463. In this study heterodimers were 
negatively associated with Bcl-2 and the hormone receptors, which is in 
concordance with previous observations and in agreement with a previous 
study reflecting the regulation of Bcl-2 by the hormone receptors463. Even 
though still not understood why the lack of expression of Bcl-2 is associated 
with poor prognosis, when its main role is promotion of cell survival. The 
explanation might reside in the fact that Bcl-2 expression status by itself is not 
adequate to determine the aptitude of this biomarker in apoptosis pathway. 
Therefore it might be interesting to study the levels of other members of this 
biomarkers family. Another reason to believe that the HER heterodimers are 
associated with poor prognostic factors is their association with p53 
expression. As documenWHG E\ %RWWLQL DQG FROOHDJXHV ³p53 but not Bcl-2 
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Immunostaining is predictive of poor clinical complete response to primary 
FKHPRWKHUDS\ LQ EUHDVW FDQFHU SDWLHQWV´398. Additionally the frequency of 
mutated p53 gene is present in a high percentage of breast carcinomas and was 
proposed not only as a prognostic biomarker but also to predict cytotoxicity to 
anthracyclines398.   
 
CK18 is the last biomarker identified in this project that was associated with 
expression of all heterodimers in both series with exception for HER2/HER4. 
As stated before this biomarker is associated with apoptosis occurrence 
through apoptosis related degradation via caspase cleavage464,465,580. Those 
cases expressing high levels of HER heterodimers suggest an influence on cell 
survival. However some differences between the heterodimers was observed. 
Interestingly HER2/EGFR was the only heterodimer associated with the basal 
biomarker CK14. Different studies have already associated basal-like tumours 
with EGFR expression, even though these tumours are characterised by non-
amplification of the HER2 gene567,581. CK14 has also reported to be associated 
with a subpopulation of luminal cells582,583. Recently it was reported that the 
Luminal B subgroup is characterised by the presence of HER2 expression at a 
frequency of 30%584. Additionally HER2/EGFR heterodimerisation not 
associated with BRAC1 protein loss, which is associated with poor 
prognosis392. BRCA1 is expressed in normal breast cells and is included in 
DNA homologous recombination repair or promotion of apoptosis in those 
cells where DNA is not repairable547,392,585. Loss of BRCA1 protein is a 
fundamental factor in disruption of the error free DNA repair pathway586,587. 
The expression of BRCA1 has been critical in prevention of not only breast but 
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also ovarian cancer547, but has less impact in other types of cancer588,589. 
Functional lost of BRCA1 results in a lower reliability of DNA repair, growing 
significantly the risks of cancer development mediated by increase frequency 
of DNA repair errors547. 
 
HER2/HER3 heterodimerisation has been shown to be associated with more 
adverse tumour characteristics when compared with HER2/EGFR and 
HER2/HER4 dimers. HER2/HER3 was the only heterodimer to be associated 
with high levels of MUC-1, which is associated with poor prognosis in breast 
cancer patients as it is connected with the metastases progression process516,517. 
MUC-1 is a protein aberrantly expressed in breast carcinomas and that works 
as an oncoprotein. This biomarker has been described as a possible drug target, 
inducing cell death by blocking it, which was already achieved in vitro590. It 
interacts with HER2 contributing for PI3K/Akt pathways activation590. 
Additionally HER2/HER3 was the only heterodimerisation to be highly 
correlated with Akt positive status. This biomarker is not only involved in anti-
apoptotic pathways but also on induction of protein synthesis essential on 
general tissue growth591. Beside cell survival Akt has been highly correlated 
with proliferation and cell motility. Its uncontrolled phosphorylation is one of 
the most common modifications in human carcinomas. This fact contributes to 
the high dependency of the cancer cells on this biomarker, becoming a 
candidate to be targeted on cancer therapy592,593. Akt has a protein domain, the 
PH domain, which binds with high affinity to PIP3446,594, an activated product 
resulting in PIP2 phosphorylation by PI3K triggered by HER2/HER3108 and 
other receptors such IGF594. Intensification of the PI3K/Akt signalling cascade 
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is associate with development of resistance to trastuzumab, though not to 
lapatinib595. Therefore a drug directed to this downstream pathway might 
benefit a significant number of patients. Finally HER2/HER3 was revealed to 
be the only heterodimerisation highly correlated with p21 expression amongst 
the HER2+ series. High expression of p21 is highly associated with resistance 
to chemotherapy512. Additionally the HER2/HER3 was the only 
heterodimerisation not highly correlated with Ki67 expression, nevertheless 
near to high significance. Ki67 is a nuclear protein severely correlated with 
ribosomal RNA transcription and is expressed mostly in proliferative 
cells397,596. This suggests that HER2/HER3 promotes high rates of cell 
proliferation, though not related with Ki67 pathway, but clearly triggering 
PI3K/Akt signalling cascade including the encouragement generated by 
interaction with MUC-1590. These suggestions are in concordance with 
previous studies recommended PI3K/Akt as the most important tumorigenic 
signalling pathway promoted by HER3 amongst HER2 amplified breast 
carcinomas496, with HER3 being accepted has the main member of HER family 
with the ability to trigger this pathway202. 
 
HER2/HER4 high levels had no significant correlation with any biomarker in 
this study. It was the only heterodimerisation occurrence that was not 
correlated with CK18 protein expression amongst the HER2+ series. In 
comparison to other HER heterodimerisation occurrence HER2/HER4 is the 
protein-protein interaction that promotes the lowest anti-apoptotic signalling 
activity. HER4 has been correlated with better prognosis and the only member 
that antagonises the HER2 highly reactive anti-apoptotic nature530,544.  
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PTEN is a tumour suppressor gene that encodes its protein with the function of 
antagonising PI3K and therefore inhibits Akt phosphorylation and 
consequently tumour progression. Lack of PTEN has been shown by some to 
drive HER2+ breast carcinomas to develop trastuzumab resistance178,597.  
Although others did not observe development of resistance to trastuzumab to 
be associated with the lack of PTEN439. In this study PTEN was significantly 
associated with the three HER heterodimers in the Unselected series but not in 
the HER2+ series. Therefore the results obtained with PTEN expression 
against the heterodimers did not appear to concur with any literature. Therefore 
it is recommended that IHC analysis should be preformed once again using a 
different antibody in order to validate the present results.   
 
7.4 Heterodimerisation and the clinicopathological 
parameters 
 
In this study it was identified that within HER2+ series HER2/HER4 was the 
only dimer that was not associated with any of the clinicopathological 
parameters correlated with worse prognosis. Other studies have already 
revealed HER4 to be associated with better outcome544, which supports this 
observation. 
 
There were limited isolated associations between HER heterodimers and 
clinicopathological parameters being more difficult to characterise subgroups. 
HER2/HER3 and HER2/EGFR were correlated with higher tumour grade but 
not HER2/HER4, supporting the ideas of a crosstalk between these two 
heterodimers already suggested460.  
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HER2/EGFR heterodimerisation was the only occurrence associated with lack 
of tubule formation and poor NPI. This last association might be linked to 
EGFR being the only monomer associated with poor prognosis in this study 
and contributing for a worse NPI score when involved in heterodimerisation.   
 
This lack of distinguishable associations amongst the heterodimers within the 
HER2+ series suggests a high correlation between them. As already proposed 
crosstalk between the different heterodimers occurs108,461 and therefore the 
correlation between them is too strong, as revealed in this study. Further 
studies to target the key clinicopathological parameters or/and biomarkers is 
very important to understand in more detail the nature of these heterodimers 
and utilise them as a therapeutic target more efficiently. 
 
7.5 HER heterodimerisation crosstalk with hormone 
receptors 
 
High levels of HER heterodimerisations are associated with lack of ER and 
PgR, though not amongst all cases. This fact is in concordance with those 
studies showing an inverse correlation between HER2 and hormone receptors 
expressions598,599. In cases with high HER2/EGFR and HER2/HER3 
heterodimers, when ER was expressed, a significant worse outcome for both 
BCSS and DFI was observed. However when ER was not expressed the 
survival curves were not significantly different. Furthermore the worse 
outcome was achieved for all heterodimerisations in the first 60 months. These 
data imply that crosstalk occurring in ER+/HER2+ breast cancers could 
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enhancing each other through a genomic and non-genomic manner resulting in 
endocrine therapy resistance121. However, the interaction between these two 
receptors is still not well understood. This thesis demonstrates for the first time 
that potential crosstalk between ER/HER2 and HER2 dimers status can 
influence outcome and may be relevant to respond to treatment. Data presented 
in this thesis suggests that alternative mechanisms might be present depending 
on which heterodimer is present; supporting that HER2 monotherapy is 
perhaps not the optimal solution for treating patients with HER2+ breast 
cancer. It is already well documented that there is crosstalk between HER2 and 
ER600,601. HER2 positive tumours develop resistance to hormone 
therapies105,602-605. On the other hand ER becomes up regulated after 
trastuzumab therapy606,607. Treatments with lapatinib also demonstrated that it 
is more effective with HER2+, ER and PgR negative tumours608. Cell line 
experiments revealed an up regulation of ER with exposure to lapatinib600,536. 
These data support the view that anti-HER2 therapy could result in incomplete 
blockage of the HER family signalling cascades, if conditional HER homo or 
heterodimers are present and which could be responsible for treatment 
failure167,421,536. The combination of both lapatinib and trastuzumab has been 
shown to be more effective603,609 but relapse still occurs536. Trastuzumab is 
known to disrupt HER2/HER3 heterodimers136. Trastuzumab exposure in cell 
line exhibiting EGFR plus HER2 expression, maintain the level of these 
proteins, although phosphorylated-HER3 levels decrease significantly536. 
However some investigation have suggested that both EGFR and HER3 
contribute to trastuzumab resistance167,486. Others have identified that HER2 is 
influential in trastuzumab resistant536.  
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7.6 HER family heterodimerisation and prognostic value 
 
In this thesis has been used PLA technology to identify HER2/EGFR, 
HER2/HER3 and HER2/HER4 heterodimers. HER2+ carcinomas can show 
increased expression of the three dimers, which is in concordance with a 
previous study501. 
 
Unsurprisingly the three heterodimerisations revealed to be associated with 
poor outcome for both BCSS and DFI amongst the Unselected series, which 
had been demonstrated before for HER2/HER3455,460,501,610 and 
HER2/EGFR457,461 dimers. However this association was not observed amongst 
HER2+ cohort. Although, the results for the trastuzumab adjuvant series 
should be analysed carefully due to the limited number of cases in study, high 
levels of the HER heterodimers revealed no significant association with worse 
outcome when patients received trastuzumab. However HER2/HER3 high 
levels demonstrated a propensity for poor survival after 60 months of 
treatment. The possibility that these patients might be developing resistance is 
supported by observations that PI3K/Akt as one of the major downstream 
pathways for this heterodimers198,229,461,595, also revealed in this study. Plus, 
aggressive phenotypes are associated with PI3K/Akt downstream pathway611-
613
 that contributes significantly to resistance to chemotherapy, trastuzumab 
and tamoxifen in breast cell lines614. These ideas indicate that PI3K/Akt 
phosphorylation could be a candidate prognostic indicator and target that could 
contribute to enhance the success of breast cancer therapy. Some drugs are 
already in early stage of clinical development such as NVP-BEZ235, which has 
shown promising results through their antagoniser of PI3K signalling, inducing 
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cell cycle arrest615. Promising results has been observed in phase I/II clinical 
trial where patients were treated with the drug in combination with 
trastuzumab616.  
 
7.7 Research methodology assessment  
 
PLA technology was developed to reveal interaction between proteins where 
the targets are recognised by antibodies probes attached to DNA strands. This 
strategy has the potential to allow the detection of multiple protein and/or 
protein-protein interactions represented by a single DNA motif. 
 
PLA can support exploration of different proteins interactions and their 
downstream pathway processes. Therefore this advanced technology has the 
potential to improvement on discrimination of different cases to be submitted 
to more specific treatments that target not only HER2 but further elements of 
the same family or key upstream or downstream proteins involved in 
trastuzumab blockage avoidance and contributing to tumour progression.   
 
However different groups will use different procedures to perform PLA, which 
might be a critical factor of the PLA technique, such as the use of different 
antibodies, different cut-off points and/or the designation of the monomers 
overexpression status. The results of brightfield versus fluorescent could be a 
reason for evident discrepancies, however these two techniques produce 
similar results in both cell culture or tissue samples. Brightfield version reveals 
to be as specific and sensitive on quantification analysis as the fluorescent 
version617. Therefore standardisation of this technology is necessary. 
Chapter 7: General Discussion 
253 
7.8 Future Perspectives 
 
All studies in this thesis are based on FFPE TMAs, which due to fixation 
process might affect some protein structures and protein-protein interaction 
could be disrupted. Therefore it is recommended that the use of fresh frozen 
breast tumours must be used to further validate the method. With this 
methodology the tissue is frozen immediately after extraction and is not 
exposed to organic solvents or fixations keeping almost all native properties. 
Therefore it would be possible to detect and quantify the native levels of 
heterodimerisation in order to validate the results presented using this novel 
method. 
 
More detailed determination of the relevance of ER control, interactions of 
different dimers, the functional effects of the observed dimer patterns and the 
potential relevance of such patterns to various forms of targeted anti HER 
therapy could be studied using in vitro cell-line methods. For example a series 
of 8 breast cell lines could be used - HCC1954 and SKBR3 cell lines (HER2 
positive, ER and PgR negative), BT-474 and MDA-MB-361 cell lines (HER2 
positive, ER and PgR positive), MCF7 and T47D cell lines (HER2 negative, 
ER and PgR positive), MDA-MB-231 cell line (HER2, ER, and PgR negative) 
and normal mammary epithelial cell line MCF-10A (HER2, ER, and PgR 
negative). HER family expression characteristics of each cell line could be 
examined using western blotting and q-pcr. Behavioural characteristics could 
be investigated using functional studies. For example cell proliferation and 
viability could be assessed using standard methods, Wound Healing Assay 
used for a more complete characterisation of cellular migration behaviour. 
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Additional characterisation of the cell lines must be performed by a fixation 
method, using 10% neutral buffered formalin and paraffin embedding.  
 
It is expected that cell line manipulation might be required to mimic the 
identified clinical situations. In order to control cell lines expression and/or 
dimerisation occurrence should be use shRNA transfection for gene 
knockdown and target specific receptors making sure only one dimer is 
affecting the results or being affected by ER expression or its absence. The 
robustness and basic functionality of single and double knockout could be 
assessed using the above methods. Cell lines not expressing any heterodimer or 
respective ligands could be transfected with plasmid constructs for each 
respective situation.  
 
7.9 Conclusion 
 
With this research project it was possible to observe that HER2 heterodimers 
were significantly correlated with poor outcome features and also to identify 
that HER2 overexpression encourages heterodimerisation, which may 
stimulate growth, malignant development618 and migration619.  
 
The use of PLA through its ability to provide protein-protein interaction 
quantification might become more important in the future in respect not only to 
medical research but also clinical analysis and drug response prediction. Using 
this technique it is possible to recognise, quantify and localise molecular and 
cellular events.  
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HER2 has previously been proposed as the dominant monomer for 
heterodimerisation comparing with other family members500. HER2 does not 
include an ectodomain where a ligand can attach, however is competent to 
behave as a co-receptor with an extraordinary affinity to interact with the same 
family members forming heterodimers25. Additionally HER2 has not the ability 
to interact with any ligand and therefore its conformation arm is constantly 
predisposed to exist in a competent form and ready to connect with any of the 
other monomers from the same family63. It was found that all three HER 
heterodimers are expressed at a similar frequency501.  
 
Additionally the hypothesis that different heterodimers had different 
associations with breast cancer related biomarkers and consequently different 
clinicopathological parameters was confirmed. High levels of the three HER 
heterodimers was revealed to be associated with worse DFI and BCSS, and the 
hypothesis that they are a poor prognostic factors was also confirmed, although 
in patients receiving adjuvant trastuzumab the heterodimers patterns were not 
associated with a significantly worse outcome. High levels of HER2/HER3 
were observed to be associated with a significantly worse prognosis after 60 
months of treatment and this observation requires further investigation.  
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